<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Amphetamine - Wikipedia, the free encyclopedia</title>
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />
<meta name="generator" content="MediaWiki 1.23wmf19" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Amphetamine" />
<link rel="apple-touch-icon" href="//bits.wikimedia.org/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="//bits.wikimedia.org/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="http://en.wikipedia.org/wiki/Amphetamine" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=ext.gadget.DRN-wizard%2CReferenceTooltips%2Ccharinsert%2Cteahouse%7Cext.rtlcite%2Cwikihiero%7Cext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.ui.button%7Cskins.common.interface%7Cskins.vector.styles&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: enwiki:resourceloader:filter:minify-css:7:3904d24a08aa08f6a68dc338f9be277e */</style>

<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Amphetamine","wgTitle":"Amphetamine","wgCurRevisionId":601362017,"wgRevisionId":601362017,"wgArticleId":2504,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Good articles","Wikipedia indefinitely semi-protected pages","Use dmy dates from March 2014","Articles including recorded pronunciations","Articles containing potentially dated statements from March 2014","All articles containing potentially dated statements","Articles using fixed number of columns in reflist","Amphetamine","Amphetamines","Anorectics","Attention deficit hyperactivity disorder","Drugs acting on the cardiovascular system","Drugs acting on the nervous system","Drugs in sport","Euphoriants","German inventions","Monoamine reuptake inhibitors","Nootropics","Phenethylamines","Serotonin-norepinephrine-dopamine reuptake inhibitors","Stimulants","TAAR1 agonists"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Amphetamine","wgIsProbablyEditable":false,"wgRestrictionEdit":["autoconfirmed"],"wgRestrictionMove":[],"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"templateEditor":false,"templates":false,"preview":false,"previewDialog":false,"publish":false,"toc":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"isPageWatched":false,"magnifyClipIconURL":"//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png","pageLanguageCode":"en","pageLanguageDir":"ltr","svgMaxSize":2048},"wikilove-recipient":"","wikilove-anon":0,"wgGuidedTourHelpGuiderUrl":"Help:Guided tours/guider","wgFlowTermsOfUseEdit":"By saving changes, you agree to our \u003Ca class=\"external text\" href=\"//wikimediafoundation.org/wiki/Terms_of_use\"\u003ETerms of Use\u003C/a\u003E and agree to irrevocably release your text under the \u003Ca rel=\"nofollow\" class=\"external text\" href=\"//creativecommons.org/licenses/by-sa/3.0\"\u003ECC BY-SA 3.0 License\u003C/a\u003E and \u003Ca class=\"external text\" href=\"//en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License\"\u003EGFDL\u003C/a\u003E","wgULSAcceptLanguageList":["en-us","en"],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgWikibaseItemId":"Q179452"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function(){mw.user.options.set({"ccmeonemails":0,"cols":80,"date":"default","diffonly":0,"disablemail":0,"editfont":"default","editondblclick":0,"editsectiononrightclick":0,"enotifminoredits":0,"enotifrevealaddr":0,"enotifusertalkpages":1,"enotifwatchlistpages":0,"extendwatchlist":0,"fancysig":0,"forceeditsummary":0,"gender":"unknown","hideminor":0,"hidepatrolled":0,"imagesize":2,"math":0,"minordefault":0,"newpageshidepatrolled":0,"nickname":"","norollbackdiff":0,"numberheadings":0,"previewonfirst":0,"previewontop":1,"rcdays":7,"rclimit":50,"rememberpassword":0,"rows":25,"showhiddencats":false,"shownumberswatching":1,"showtoolbar":1,"skin":"vector","stubthreshold":0,"thumbsize":4,"underline":2,"uselivepreview":0,"usenewrc":0,"watchcreations":1,"watchdefault":0,"watchdeletion":0,"watchlistdays":3,"watchlisthideanons":0,"watchlisthidebots":0,"watchlisthideliu":0,"watchlisthideminor":0,"watchlisthideown":0,"watchlisthidepatrolled":0,"watchmoves":0,
"wllimit":250,"useeditwarning":1,"prefershttps":1,"flaggedrevssimpleui":1,"flaggedrevsstable":0,"flaggedrevseditdiffs":true,"flaggedrevsviewdiffs":false,"usebetatoolbar":1,"usebetatoolbar-cgd":1,"visualeditor-enable":0,"visualeditor-enable-experimental":0,"visualeditor-betatempdisable":0,"wikilove-enabled":1,"echo-subscriptions-web-page-review":true,"echo-subscriptions-email-page-review":false,"ep_showtoplink":false,"ep_bulkdelorgs":false,"ep_bulkdelcourses":true,"ep_showdyk":true,"echo-subscriptions-web-education-program":true,"echo-subscriptions-email-education-program":false,"echo-notify-show-link":true,"echo-show-alert":true,"echo-email-frequency":0,"echo-email-format":"html","echo-subscriptions-email-system":true,"echo-subscriptions-web-system":true,"echo-subscriptions-email-other":false,"echo-subscriptions-web-other":true,"echo-subscriptions-email-edit-user-talk":false,"echo-subscriptions-web-edit-user-talk":true,"echo-subscriptions-email-reverted":false,
"echo-subscriptions-web-reverted":true,"echo-subscriptions-email-article-linked":false,"echo-subscriptions-web-article-linked":false,"echo-subscriptions-email-mention":false,"echo-subscriptions-web-mention":true,"echo-subscriptions-web-edit-thank":true,"echo-subscriptions-email-edit-thank":false,"echo-subscriptions-web-flow-discussion":true,"echo-subscriptions-email-flow-discussion":false,"gettingstarted-task-toolbar-show-intro":true,"uls-preferences":"","language":"en","variant-gan":"gan","variant-iu":"iu","variant-kk":"kk","variant-ku":"ku","variant-shi":"shi","variant-sr":"sr","variant-tg":"tg","variant-uz":"uz","variant-zh":"zh","searchNs0":true,"searchNs1":false,"searchNs2":false,"searchNs3":false,"searchNs4":false,"searchNs5":false,"searchNs6":false,"searchNs7":false,"searchNs8":false,"searchNs9":false,"searchNs10":false,"searchNs11":false,"searchNs12":false,"searchNs13":false,"searchNs14":false,"searchNs15":false,"searchNs100":false,"searchNs101":false,"searchNs108":false,
"searchNs109":false,"searchNs118":false,"searchNs119":false,"searchNs446":false,"searchNs447":false,"searchNs710":false,"searchNs711":false,"searchNs828":false,"searchNs829":false,"gadget-teahouse":1,"gadget-ReferenceTooltips":1,"gadget-DRN-wizard":1,"gadget-charinsert":1,"gadget-mySandbox":1,"variant":"en"});},{},{});mw.loader.implement("user.tokens",function(){mw.user.tokens.set({"editToken":"+\\","patrolToken":false,"watchToken":false});},{},{});
/* cache key: enwiki:resourceloader:filter:minify-js:7:868e43d07ede2616d2d1dc3507cd8145 */
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","skins.vector.compactPersonalBar.defaultTracking","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","wikibase.client.init","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" /><!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static-1.23wmf19/skins/vector/csshover.min.htc")}</style><![endif]--></head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Amphetamine skin-vector action-view vector-animateLayout">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>
			<div id="mw-js-message" style="display:none;"></div>
						<div id="siteNotice"><!-- CentralNotice --></div>
						<h1 id="firstHeading" class="firstHeading" lang="en"><span dir="auto">Amphetamine</span></h1>
						<div id="bodyContent">
								<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-navigation">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="dablink">This article is about the free base and salts of amphetamine.  For other uses, see <a href="/wiki/Amphetamine_(disambiguation)" title="Amphetamine (disambiguation)">Amphetamine (disambiguation)</a>.</div>
<div style="display:none; right:10px;" class="metadata topicon nopopups" id="good-star"><a href="/wiki/Wikipedia:Good_articles" title="This is a good article. Click here for more information."><img alt="This is a good article. Click here for more information." src="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/15px-Symbol_support_vote.svg.png" width="15" height="15" srcset="//upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/23px-Symbol_support_vote.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/9/94/Symbol_support_vote.svg/30px-Symbol_support_vote.svg.png 2x" /></a></div>
<div class="metadata topicon nopopups" id="protected-icon" style="display:none; right:55px;"><a href="/wiki/Wikipedia:Protection_policy#semi" title="This article is semi-protected indefinitely in response to an ongoing high risk of vandalism."><img alt="Page semi-protected" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/20px-Padlock-silver.svg.png" width="20" height="20" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/30px-Padlock-silver.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/fc/Padlock-silver.svg/40px-Padlock-silver.svg.png 2x" /></a></div>
<table class="infobox" style="width: 22em">
<caption>Amphetamine</caption>
<tr>
<th colspan="2" style="text-align: center"><a href="/wiki/File:Amphetamine-2D-skeletal.svg" class="image" title="An image of the amphetamine compound"><img alt="An image of the amphetamine compound" src="//upload.wikimedia.org/wikipedia/commons/thumb/2/28/Amphetamine-2D-skeletal.svg/250px-Amphetamine-2D-skeletal.svg.png" width="250" height="120" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/28/Amphetamine-2D-skeletal.svg/375px-Amphetamine-2D-skeletal.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/28/Amphetamine-2D-skeletal.svg/500px-Amphetamine-2D-skeletal.svg.png 2x" /></a></th>
</tr>
<tr>
<th colspan="2" style="text-align: center"><a href="/wiki/File:Amphetamine-3d-CPK.png" class="image" title="A 3d image of the amphetamine compound"><img alt="A 3d image of the amphetamine compound" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/8c/Amphetamine-3d-CPK.png/250px-Amphetamine-3d-CPK.png" width="250" height="188" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/8c/Amphetamine-3d-CPK.png/375px-Amphetamine-3d-CPK.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/8c/Amphetamine-3d-CPK.png/500px-Amphetamine-3d-CPK.png 2x" /></a></th>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</th>
</tr>
<tr>
<td colspan="2" style="text-align: center"><span style="font-size:11px">(<i>RS</i>)-1-phenylpropan-2-amine<br />
(<i>RS</i>)-1-phenyl-2-aminopropane</span></td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Clinical data</th>
</tr>
<tr>
<th><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugs.com/amphetamine.html">entry</a></span></td>
</tr>
<tr>
<th><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Licence data</a></th>
<td><a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration" class="mw-redirect">US&#160;FDA</a>:<span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Adderall&amp;SearchType=BasicSearch">link</a></span></td>
</tr>
<tr>
<th><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy cat.</a></th>
<td>C <small>(<a href="/wiki/United_States" title="United States">US</a>)</small></td>
</tr>
<tr>
<th><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th>
<td><a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Drugs_and_Poisons#Schedule_8_Controlled_Drug" title="Standard for the Uniform Scheduling of Drugs and Poisons" class="mw-redirect">Controlled (S8)</a> <small>(<a href="/wiki/Australia" title="Australia">AU</a>)</small> <a href="/wiki/Controlled_Drugs_and_Substances_Act#Schedule_I" title="Controlled Drugs and Substances Act">Schedule I</a> <small>(<a href="/wiki/Canada" title="Canada">CA</a>)</small> CD <small>(<a href="/wiki/United_Kingdom" title="United Kingdom">UK</a>)</small> <a href="/wiki/Controlled_Substances_Act#Schedule_II_drugs" title="Controlled Substances Act">Schedule II</a> <small>(<a href="/wiki/United_States" title="United States">US</a>)</small> <span class="Unicode">℞</span> P<small>rescription only</small></td>
</tr>
<tr>
<th style="white-space: nowrap"><a href="/wiki/Drug_dependence" title="Drug dependence" class="mw-redirect">Dependence liability</a></th>
<td>Moderate</td>
</tr>
<tr>
<th><a href="/wiki/Route_of_administration" title="Route of administration">Routes</a></th>
<td><i>Medical</i>: <a href="/wiki/Oral_route" title="Oral route" class="mw-redirect">oral</a>, <a href="/wiki/Nasal_administration" title="Nasal administration">nasal inhalation</a><br />
<i>Recreational</i>: <a href="/wiki/Oral_route" title="Oral route" class="mw-redirect">oral</a>, <a href="/wiki/Nasal_administration" title="Nasal administration">nasal inhalation</a>, <a href="/wiki/Insufflation_(medicine)" title="Insufflation (medicine)">insufflation</a>, <a href="/wiki/Suppository" title="Suppository">rectal</a>, <a href="/wiki/Intravenous" title="Intravenous" class="mw-redirect">intravenous</a></td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Pharmacokinetic data</th>
</tr>
<tr>
<th><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></th>
<td>Rectal&#160;95–100%; <span class="nowrap">Oral 75–100%</span><sup id="cite_ref-Drugbank-dexamph_1-0" class="reference"><a href="#cite_note-Drugbank-dexamph-1"><span>[</span>1<span>]</span></a></sup></td>
</tr>
<tr>
<th><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></th>
<td>15–40%<sup id="cite_ref-Drugbank-amph_2-0" class="reference"><a href="#cite_note-Drugbank-amph-2"><span>[</span>2<span>]</span></a></sup></td>
</tr>
<tr>
<th><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></th>
<td><a href="/wiki/Hepatic" title="Hepatic" class="mw-redirect">Hepatic</a>: <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>,<sup id="cite_ref-FDA_Pharmacokinetics_3-0" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> <a href="/wiki/Dopamine_%CE%B2-hydroxylase" title="Dopamine β-hydroxylase" class="mw-redirect">DBH</a>,<sup id="cite_ref-DBH_ref_4-0" class="reference"><a href="#cite_note-DBH_ref-4"><span>[</span>4<span>]</span></a></sup> and <a href="/wiki/Flavin-containing_monooxygenase" title="Flavin-containing monooxygenase">FMO</a><sup id="cite_ref-FMO_5-0" class="reference"><a href="#cite_note-FMO-5"><span>[</span>5<span>]</span></a></sup></td>
</tr>
<tr>
<th><a href="/wiki/Biological_half-life" title="Biological half-life">Half-life</a></th>
<td><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">D-amph</a>:9–11h;<sup id="cite_ref-FDA_Pharmacokinetics_3-1" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> <span class="nowrap"><a href="/wiki/Levoamphetamine" title="Levoamphetamine">L-amph</a>:11–14h<sup id="cite_ref-FDA_Pharmacokinetics_3-2" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup></span></td>
</tr>
<tr>
<th><a href="/wiki/Excretion" title="Excretion">Excretion</a></th>
<td><a href="/wiki/Renal" title="Renal" class="mw-redirect">Renal</a>; <a href="/wiki/PH" title="PH">pH</a>-dependent <span class="nowrap">range: 1–75%</span><sup id="cite_ref-FDA_Pharmacokinetics_3-3" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup></td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Identifiers</th>
</tr>
<tr>
<th><a href="/wiki/CAS_registry_number" title="CAS registry number">CAS number</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=300-62-9&amp;rn=1">300-62-9</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th>
<td><a href="/wiki/ATC_code_N06" title="ATC code N06">N06</a><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.whocc.no/atc_ddd_index/?code=N06BA01">BA01</a></span></td>
</tr>
<tr>
<th><a href="/wiki/PubChem" title="PubChem">PubChem</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007">CID 3007</a></span></td>
</tr>
<tr>
<th><a href="/wiki/International_Union_of_Basic_and_Clinical_Pharmacology" title="International Union of Basic and Clinical Pharmacology">IUPHAR ligand</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=4804">4804</a></span></td>
</tr>
<tr>
<th><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182">DB00182</a></span></td>
</tr>
<tr>
<th><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.chemspider.com/Chemical-Structure.13852819">13852819</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=CK833KGX7E">CK833KGX7E</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/KEGG" title="KEGG">KEGG</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.kegg.jp/entry/D07445">D07445</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/ChEBI" title="ChEBI">ChEBI</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:2679">CHEBI:2679</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/ChEMBL" title="ChEMBL">ChEMBL</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL405">CHEMBL405</a></span><sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></td>
</tr>
<tr>
<th><a href="/wiki/NIAID_ChemDB" title="NIAID ChemDB">NIAID ChemDB</a></th>
<td><span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://chemdb.niaid.nih.gov/CompoundDetails.aspx?AIDSNO=018564">018564</a></span></td>
</tr>
<tr>
<th><a href="/wiki/Synonym" title="Synonym">Synonyms</a></th>
<td>α-methylphenethylamine</td>
</tr>
<tr>
<th><a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB</a> ligand ID</th>
<td>FRD (<span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.ebi.ac.uk/pdbe-srv/PDBeXplore/ligand/?ligand=FRD">PDBe</a></span>, <span class="reflink plainlinks nourlexpansion"><a rel="nofollow" class="external text" href="http://www.rcsb.org/pdb/search/smartSubquery.do?smartSearchSubtype=ChemCompIdQuery&amp;chemCompId=FRD&amp;polymericType=Any">RCSB PDB</a></span>)</td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Chemical data</th>
</tr>
<tr>
<th><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th>
<td><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>9</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>13</sub><a href="/wiki/Nitrogen" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><sup>&#160;</sup></td>
</tr>
<tr>
<th><a href="/wiki/Molecular_mass" title="Molecular mass">Mol. mass</a></th>
<td>135.2084 g/mol</td>
</tr>
<tr>
<td colspan="2">
<div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification" class="mw-redirect">SMILES</a></div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;">
<li style="line-height: inherit; margin: 0">NC(C)Cc1ccccc1</li>
</ul>
</div>
</td>
</tr>
<tr>
<td colspan="2">
<div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;"><a href="/wiki/International_Chemical_Identifier" title="International Chemical Identifier">InChI</a></div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;">
<li style="line-height: inherit; margin: 0">
<p style="word-wrap: break-word;">InChI=1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3<sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup><br />
Key:KWTSXDURSIMDCE-UHFFFAOYSA-N<sup>&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png" width="7" height="7" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/11px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png 2x" /><span style="display:none">Y</span></sup></p>
</li>
</ul>
</div>
</td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">Physical data</th>
</tr>
<tr>
<th><a href="/wiki/Density" title="Density">Density</a></th>
<td>0.9±0.1&#160;g/cm³</td>
</tr>
<tr>
<th><a href="/wiki/Melting_point" title="Melting point">Melt. point</a></th>
<td>11.3&#160;°C (52&#160;°F) <sup id="cite_ref-Chemspider_6-0" class="reference"><a href="#cite_note-Chemspider-6"><span>[</span>6<span>]</span></a></sup></td>
</tr>
<tr>
<th><a href="/wiki/Boiling_point" title="Boiling point">Boiling point</a></th>
<td>203&#160;°C (397&#160;°F) <sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span>[</span>7<span>]</span></a></sup></td>
</tr>
<tr>
<th colspan="2" style="background-color: #ddd; text-align: center">&#160;<img alt="Yes" src="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/14px-Yes_check.svg.png" width="14" height="14" srcset="//upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/21px-Yes_check.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/28px-Yes_check.svg.png 2x" /><span style="display:none">Y</span>&#160;<a href="/wiki/Wikipedia:WikiProject_Chemicals/Chembox_validation" title="Wikipedia:WikiProject Chemicals/Chembox validation">(what is this?)</a>&#160;&#160;<span class="reflink plainlinks nourlexpansion"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Special:ComparePages&amp;rev1=590855450&amp;page2=Amphetamine">(verify)</a></span></th>
</tr>
</table>
<p><b>Amphetamine</b><sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span>[</span>note 1<span>]</span></a></sup> (<span class="nowrap"><small>pronunciation:</small> <span class="noexcerpt"><a href="//upload.wikimedia.org/wikipedia/commons/8/8b/En-us-amphetamine.ogg" title="Listen"><img alt="Listen" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/3b/Speakerlink-new.svg/11px-Speakerlink-new.svg.png" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/3b/Speakerlink-new.svg/17px-Speakerlink-new.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/3b/Speakerlink-new.svg/22px-Speakerlink-new.svg.png 2x" /></a><sup><span style="color: #00e; font: bold 80% sans-serif; padding: 0 .1em;" class="IPA"><a href="/wiki/File:En-us-amphetamine.ogg" title="File:En-us-amphetamine.ogg">i</a></span></sup></span><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/</a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/æ/ short 'a' in 'bad'" style="border-bottom:1px dotted">æ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'m' in 'my'" style="border-bottom:1px dotted">m</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ˈ/ primary stress follows" style="border-bottom:1px dotted">ˈ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'f' in 'find'" style="border-bottom:1px dotted">f</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ɛ/ short 'e' in 'bed'" style="border-bottom:1px dotted">ɛ</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'t' in 'tie'" style="border-bottom:1px dotted">t</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/ə/ 'a' in 'about'" style="border-bottom:1px dotted">ə</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'m' in 'my'" style="border-bottom:1px dotted">m</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="/i/ 'y' in 'happy'" style="border-bottom:1px dotted">i</span></a></span><span class="IPA nopopups"><a href="/wiki/Help:IPA_for_English#Key" title="Help:IPA for English"><span title="'n' in 'nigh'" style="border-bottom:1px dotted">n</span></a></span><span title="Representation in the International Phonetic Alphabet (IPA)" class="IPA"><a href="/wiki/Help:IPA_for_English" title="Help:IPA for English">/</a></span></span>; contracted from <span class="nowrap"><a href="/wiki/Alpha_and_beta_carbon" title="Alpha and beta carbon">alpha</a>‑<a href="/wiki/Methylphenethylamine" title="Methylphenethylamine">methylphenethylamine</a></span>) is a potent <a href="/wiki/Central_nervous_system" title="Central nervous system">central nervous system</a> (CNS) <a href="/wiki/Stimulant" title="Stimulant">stimulant</a> of the <a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">phenethylamine class</a> that is used in the treatment of <a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">attention deficit hyperactivity disorder</a> (ADHD) and <a href="/wiki/Narcolepsy" title="Narcolepsy">narcolepsy</a>. Amphetamine was discovered in 1887 and exists as two <a href="/wiki/Enantiomer" title="Enantiomer">enantiomers</a>: <a href="/wiki/Levoamphetamine" title="Levoamphetamine">levoamphetamine</a> and <a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a>.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>note 2<span>]</span></a></sup> <i>Amphetamine</i> properly refers to the <a href="/wiki/Racemic" title="Racemic" class="mw-redirect">racemic</a> <a href="/wiki/Free_base" title="Free base">free base</a>, or equal parts of the enantiomers levoamphetamine and dextroamphetamine in their pure amine forms. Nonetheless, the term is frequently used informally to refer to any combination of the enantiomers, or to either of them alone. Historically, it has been used to treat nasal congestion, depression, and obesity. Amphetamine is also used as a <a href="/wiki/Performance_enhancer" title="Performance enhancer" class="mw-redirect">performance</a> and <a href="/wiki/Nootropic" title="Nootropic">cognitive enhancer</a>, and recreationally as an <a href="/wiki/Aphrodisiac" title="Aphrodisiac">aphrodisiac</a> and <a href="/wiki/Euphoriant" title="Euphoriant">euphoriant</a>. It is a prescription medication in many countries, and unauthorized possession and distribution of amphetamine is often tightly controlled due to the significant health risks associated with uncontrolled or heavy use. Amphetamine is illegally synthesized by <a href="/wiki/Clandestine_chemistry" title="Clandestine chemistry">clandestine chemists</a>, trafficked, and sold. Based upon the quantity of seized and confiscated drugs and <a href="/wiki/Drug_precursor" title="Drug precursor" class="mw-redirect">drug precursors</a> worldwide, illicit amphetamine production and trafficking is much less prevalent than that of <a href="/wiki/Methamphetamine" title="Methamphetamine">methamphetamine</a>; in parts of Europe, amphetamine is more prevalent than methamphetamine.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span>[</span>ref-note 1<span>]</span></a></sup></p>
<p>The first pharmaceutical amphetamine was <a href="/wiki/Benzedrine" title="Benzedrine">Benzedrine</a>, a brand of inhalers used to treat a variety of conditions. Presently, it is typically prescribed as <a href="/wiki/Adderall" title="Adderall">Adderall</a>,<sup id="cite_ref-Adderall_26-0" class="reference"><a href="#cite_note-Adderall-26"><span>[</span>note 3<span>]</span></a></sup> dextroamphetamine, or the inactive <a href="/wiki/Prodrug" title="Prodrug">prodrug</a> <a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">lisdexamfetamine</a>. Amphetamine, through activation of a <a href="/wiki/TAAR1" title="TAAR1">trace amine receptor</a>, increases <a href="/wiki/Biogenic_amine" title="Biogenic amine">biogenic amine</a> and <a href="/wiki/Neurotransmitter#Excitatory_and_inhibitory" title="Neurotransmitter">excitatory neurotransmitter</a> activity in the brain, with its most pronounced effects targeting the <a href="/wiki/Catecholamine" title="Catecholamine">catecholamine</a> neurotransmitters <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> and <a href="/wiki/Dopamine" title="Dopamine">dopamine</a>. At therapeutic doses, this causes emotional and cognitive effects such as euphoria, change in libido, increased arousal, and improved <a href="/wiki/Cognitive_control" title="Cognitive control" class="mw-redirect">cognitive control</a>. It induces physical effects such as decreased reaction time, fatigue resistance, and increased muscle strength.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span>[</span>ref-note 2<span>]</span></a></sup></p>
<p>Much larger doses of amphetamine are likely to impair cognitive function and induce rapid <a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">muscle breakdown</a>. <a href="/wiki/Substance_dependence" title="Substance dependence">Substance dependence</a> (i.e., addiction) is a serious risk of amphetamine abuse, but only rarely arises from medical use. Very high doses can result in a <a href="/wiki/Stimulant_psychosis#Amphetamines" title="Stimulant psychosis">psychosis</a> (e.g., delusions and paranoia) which rarely occurs at therapeutic doses even during long-term use. Recreational doses are generally much larger than prescribed therapeutic doses, and carry a far greater risk of serious side effects.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35"><span>[</span>ref-note 3<span>]</span></a></sup></p>
<p>Amphetamine is the parent compound of its own structural class, the <a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">substituted amphetamines</a>,<sup id="cite_ref-36" class="reference"><a href="#cite_note-36"><span>[</span>note 4<span>]</span></a></sup> which includes prominent substances such as <a href="/wiki/Bupropion" title="Bupropion">bupropion</a>, <a href="/wiki/Cathinone" title="Cathinone">cathinone</a>, <a href="/wiki/MDMA" title="MDMA">ecstasy</a>, and methamphetamine. Unlike methamphetamine, amphetamine's salts lack sufficient <a href="/wiki/Volatility_(chemistry)" title="Volatility (chemistry)">volatility</a> to be smoked. Amphetamine is also chemically related to the naturally occurring <a href="/wiki/Trace_amine" title="Trace amine">trace amines</a>, specifically <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamine</a> and <span class="nowrap"><a href="/wiki/N-methylphenethylamine" title="N-methylphenethylamine" class="mw-redirect"><i>N</i>-methylphenethylamine</a></span>, both of which are produced within the human body.<sup id="cite_ref-39" class="reference"><a href="#cite_note-39"><span>[</span>ref-note 4<span>]</span></a></sup></p>
<div class="toclimit-3">
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Uses"><span class="tocnumber">1</span> <span class="toctext">Uses</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#Medical"><span class="tocnumber">1.1</span> <span class="toctext">Medical</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Enhancing_performance"><span class="tocnumber">1.2</span> <span class="toctext">Enhancing performance</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-4"><a href="#Contraindications"><span class="tocnumber">2</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Side_effects"><span class="tocnumber">3</span> <span class="toctext">Side effects</span></a>
<ul>
<li class="toclevel-2 tocsection-6"><a href="#Physical"><span class="tocnumber">3.1</span> <span class="toctext">Physical</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Psychological"><span class="tocnumber">3.2</span> <span class="toctext">Psychological</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-8"><a href="#Overdose"><span class="tocnumber">4</span> <span class="toctext">Overdose</span></a>
<ul>
<li class="toclevel-2 tocsection-9"><a href="#Dependence.2C_addiction.2C_and_withdrawal"><span class="tocnumber">4.1</span> <span class="toctext">Dependence, addiction, and withdrawal</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Psychosis"><span class="tocnumber">4.2</span> <span class="toctext">Psychosis</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Toxicity"><span class="tocnumber">4.3</span> <span class="toctext">Toxicity</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Interactions"><span class="tocnumber">5</span> <span class="toctext">Interactions</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#Pharmacology"><span class="tocnumber">6</span> <span class="toctext">Pharmacology</span></a>
<ul>
<li class="toclevel-2 tocsection-14"><a href="#Pharmacodynamics"><span class="tocnumber">6.1</span> <span class="toctext">Pharmacodynamics</span></a>
<ul>
<li class="toclevel-3 tocsection-15"><a href="#Dopamine"><span class="tocnumber">6.1.1</span> <span class="toctext">Dopamine</span></a></li>
<li class="toclevel-3 tocsection-16"><a href="#Norepinephrine"><span class="tocnumber">6.1.2</span> <span class="toctext">Norepinephrine</span></a></li>
<li class="toclevel-3 tocsection-17"><a href="#Serotonin"><span class="tocnumber">6.1.3</span> <span class="toctext">Serotonin</span></a></li>
<li class="toclevel-3 tocsection-18"><a href="#Acetylcholine"><span class="tocnumber">6.1.4</span> <span class="toctext">Acetylcholine</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#Other_relevant_activity"><span class="tocnumber">6.1.5</span> <span class="toctext">Other relevant activity</span></a></li>
</ul>
</li>
<li class="toclevel-2 tocsection-20"><a href="#Pharmacokinetics"><span class="tocnumber">6.2</span> <span class="toctext">Pharmacokinetics</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Related_endogenous_compounds"><span class="tocnumber">6.3</span> <span class="toctext">Related endogenous compounds</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-22"><a href="#Physical_and_chemical_properties"><span class="tocnumber">7</span> <span class="toctext">Physical and chemical properties</span></a>
<ul>
<li class="toclevel-2 tocsection-23"><a href="#Derivatives"><span class="tocnumber">7.1</span> <span class="toctext">Derivatives</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#Synthesis"><span class="tocnumber">7.2</span> <span class="toctext">Synthesis</span></a></li>
<li class="toclevel-2 tocsection-25"><a href="#Detection_in_body_fluids"><span class="tocnumber">7.3</span> <span class="toctext">Detection in body fluids</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-26"><a href="#History.2C_society.2C_and_culture"><span class="tocnumber">8</span> <span class="toctext">History, society, and culture</span></a>
<ul>
<li class="toclevel-2 tocsection-27"><a href="#Legal_status"><span class="tocnumber">8.1</span> <span class="toctext">Legal status</span></a></li>
<li class="toclevel-2 tocsection-28"><a href="#Pharmaceutical_products"><span class="tocnumber">8.2</span> <span class="toctext">Pharmaceutical products</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-29"><a href="#Notes"><span class="tocnumber">9</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1 tocsection-30"><a href="#Reference_notes"><span class="tocnumber">10</span> <span class="toctext">Reference notes</span></a></li>
<li class="toclevel-1 tocsection-31"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-32"><a href="#External_links"><span class="tocnumber">12</span> <span class="toctext">External links</span></a></li>
</ul>
</div>
</div>
<h2><span class="mw-headline" id="Uses">Uses</span></h2>
<div class="rellink boilerplate seealso">See also: <a href="/wiki/Adderall" title="Adderall">Adderall</a>, <a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>,&#160;and <a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></div>
<h3><span class="mw-headline" id="Medical">Medical</span></h3>
<div class="rellink boilerplate seealso">See also: <a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">Attention deficit hyperactivity disorder</a>&#160;and <a href="/wiki/Narcolepsy" title="Narcolepsy">Narcolepsy</a></div>
<p>Amphetamine is used to treat <a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">attention deficit hyperactivity disorder</a> (ADHD) and narcolepsy, and is sometimes prescribed <a href="/wiki/Off-label" title="Off-label" class="mw-redirect">off-label</a> for its past <a href="/wiki/Indication_(medicine)" title="Indication (medicine)">indications</a>, including <a href="/wiki/Treatment-resistant_depression" title="Treatment-resistant depression">depression</a>, <a href="/wiki/Obesity" title="Obesity">obesity</a>, and <a href="/wiki/Nasal_congestion" title="Nasal congestion">nasal congestion</a>.<sup id="cite_ref-Amph_Uses_21-2" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-Adderall_IR_27-1" class="reference"><a href="#cite_note-Adderall_IR-27"><span>[</span>23<span>]</span></a></sup> Long-term amphetamine exposure in some species is known to produce abnormal <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">dopamine system</a> development or nerve damage,<sup id="cite_ref-pmid22392347_40-0" class="reference"><a href="#cite_note-pmid22392347-40"><span>[</span>32<span>]</span></a></sup><sup id="cite_ref-AbuseAndAbnormalities_41-0" class="reference"><a href="#cite_note-AbuseAndAbnormalities-41"><span>[</span>33<span>]</span></a></sup> but humans experience normal development and nerve growth.<sup id="cite_ref-Neuroplasticity_1_42-0" class="reference"><a href="#cite_note-Neuroplasticity_1-42"><span>[</span>34<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_2_43-0" class="reference"><a href="#cite_note-Neuroplasticity_2-43"><span>[</span>35<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_3_44-0" class="reference"><a href="#cite_note-Neuroplasticity_3-44"><span>[</span>36<span>]</span></a></sup> <a href="/wiki/MRI" title="MRI" class="mw-redirect">Magnetic resonance imaging</a> studies suggest that long-term treatment with amphetamine decrease the abnormalities of brain structure and function found in subjects with ADHD, and improve the function of the right <a href="/wiki/Caudate_nucleus" title="Caudate nucleus">caudate nucleus</a>.<sup id="cite_ref-Neuroplasticity_1_42-1" class="reference"><a href="#cite_note-Neuroplasticity_1-42"><span>[</span>34<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_2_43-1" class="reference"><a href="#cite_note-Neuroplasticity_2-43"><span>[</span>35<span>]</span></a></sup><sup id="cite_ref-Neuroplasticity_3_44-1" class="reference"><a href="#cite_note-Neuroplasticity_3-44"><span>[</span>36<span>]</span></a></sup></p>
<p>Reviews of clinical stimulant research have established the safety and effectiveness of long-term amphetamine use for ADHD.<sup id="cite_ref-Millichap_3_45-0" class="reference"><a href="#cite_note-Millichap_3-45"><span>[</span>37<span>]</span></a></sup><sup id="cite_ref-Safety_46-0" class="reference"><a href="#cite_note-Safety-46"><span>[</span>38<span>]</span></a></sup> An evidence review by Gordon Millichap noted the findings of a <a href="/wiki/Randomized_controlled_trial" title="Randomized controlled trial">randomized controlled trial</a> of amphetamine treatment for ADHD in Swedish children following 9&#160;months of amphetamine use.<sup id="cite_ref-Millichap_47-0" class="reference"><a href="#cite_note-Millichap-47"><span>[</span>39<span>]</span></a></sup> During treatment, the children experienced improvements in attention, disruptive behaviors, and hyperactivity, and an average change of&#160;+4.5 in <a href="/wiki/Intelligence_quotient" title="Intelligence quotient">IQ</a>.<sup id="cite_ref-Millichap_47-1" class="reference"><a href="#cite_note-Millichap-47"><span>[</span>39<span>]</span></a></sup> He noted that the population in the study had a high incidence of <a href="/wiki/Comorbid" title="Comorbid" class="mw-redirect">comorbid</a> disorders associated with ADHD and suggested that other long-term amphetamine trials with less comorbidity could find greater functional improvements.<sup id="cite_ref-Millichap_47-2" class="reference"><a href="#cite_note-Millichap-47"><span>[</span>39<span>]</span></a></sup></p>
<p>Current models of ADHD suggest that it is associated with functional impairments in some of the brain's <a href="/wiki/Neurotransmitter_systems" title="Neurotransmitter systems" class="mw-redirect">neurotransmitter systems</a>,<sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span>[</span>note 5<span>]</span></a></sup> particularly those involving <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> and <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a>.<sup id="cite_ref-Malenka_2009_03_48-1" class="reference"><a href="#cite_note-Malenka_2009_03-48"><span>[</span>40<span>]</span></a></sup> Psychostimulants like <a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a> and amphetamine may be effective in treating ADHD because they increase neurotransmitter activity in these systems.<sup id="cite_ref-Malenka_2009_03_48-2" class="reference"><a href="#cite_note-Malenka_2009_03-48"><span>[</span>40<span>]</span></a></sup> Approximately&#160;70% of those who use these stimulants see improvements in ADHD symptoms.<sup id="cite_ref-ADHD_50-0" class="reference"><a href="#cite_note-ADHD-50"><span>[</span>41<span>]</span></a></sup> Children with ADHD who use stimulant medications generally have better relationships with peers and family members,<sup id="cite_ref-Millichap_3_45-1" class="reference"><a href="#cite_note-Millichap_3-45"><span>[</span>37<span>]</span></a></sup><sup id="cite_ref-ADHD_50-1" class="reference"><a href="#cite_note-ADHD-50"><span>[</span>41<span>]</span></a></sup> generally perform better in school, are less distractible and impulsive, and have longer attention spans.<sup id="cite_ref-Millichap_3_45-2" class="reference"><a href="#cite_note-Millichap_3-45"><span>[</span>37<span>]</span></a></sup><sup id="cite_ref-ADHD_50-2" class="reference"><a href="#cite_note-ADHD-50"><span>[</span>41<span>]</span></a></sup> The <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a>'s review<sup id="cite_ref-52" class="reference"><a href="#cite_note-52"><span>[</span>note 6<span>]</span></a></sup> on the treatment of adult ADHD with amphetamines stated that amphetamines improve short-term symptoms, but have higher discontinuation rates than non-stimulant medications due to their adverse effects.<sup id="cite_ref-Cochrane_Amphetamines_ADHD_53-0" class="reference"><a href="#cite_note-Cochrane_Amphetamines_ADHD-53"><span>[</span>43<span>]</span></a></sup></p>
<p>A Cochrane Collaboration review on the treatment of ADHD in children with comorbid <a href="/wiki/Tic_disorder" title="Tic disorder">tic disorders</a> indicated that stimulants in general do not exacerbate tics, but high therapeutic doses of dextroamphetamine in such people should be avoided.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span>[</span>44<span>]</span></a></sup> Other Cochrane reviews on the use of amphetamine for improving recovery following stroke or acute brain injury indicated that it may improve recovery, but further research is needed to confirm this.<sup id="cite_ref-55" class="reference"><a href="#cite_note-55"><span>[</span>45<span>]</span></a></sup><sup id="cite_ref-56" class="reference"><a href="#cite_note-56"><span>[</span>46<span>]</span></a></sup><sup id="cite_ref-SpeedyRecovery_57-0" class="reference"><a href="#cite_note-SpeedyRecovery-57"><span>[</span>47<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Enhancing_performance">Enhancing performance</span></h3>
<p>Therapeutic doses of amphetamine improve cortical network efficiency, resulting in higher performance on <a href="/wiki/Working_memory" title="Working memory">working memory</a> tests both in normal functioning subjects and those with ADHD.<sup id="cite_ref-Malenka_2009_18-3" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup> Amphetamine and other ADHD stimulants also increase arousal and improve task <a href="/wiki/Salience_(neuroscience)" title="Salience (neuroscience)">saliency</a>.<sup id="cite_ref-Malenka_2009_18-4" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup> Stimulants such as amphetamine can improve performance on difficult and boring tasks,<sup id="cite_ref-Malenka_2009_18-5" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup> and are used by some students as a study and test-taking aid.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58"><span>[</span>48<span>]</span></a></sup> Based upon studies of self-reported illicit stimulant use, performance-enhancing use, rather than <a href="/wiki/Substance_abuse" title="Substance abuse">abuse</a> as a recreational drug, is the primary reason that students use stimulants.<sup id="cite_ref-pmid16999660_59-0" class="reference"><a href="#cite_note-pmid16999660-59"><span>[</span>49<span>]</span></a></sup> At <a href="//en.wiktionary.org/wiki/supratherapeutic" class="extiw" title="wikt:supratherapeutic">supratherapeutic</a> doses, stimulants can interfere with working memory and cognitive control.<sup id="cite_ref-Malenka_2009_18-6" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup></p>
<p>Amphetamine is used by some athletes for its psychological and <a href="/wiki/Performance-enhancing_drugs" title="Performance-enhancing drugs">performance-enhancing effects</a>.<sup id="cite_ref-Ergogenics_17-2" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Westfall_34-1" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-NCAA_60-0" class="reference"><a href="#cite_note-NCAA-60"><span>[</span>50<span>]</span></a></sup> In competitive sports, this is prohibited by <a href="/wiki/Doping_in_sport#Anti-Doping_organizations_and_legislation" title="Doping in sport">anti-doping regulations</a>.<sup id="cite_ref-Ergogenics_17-3" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup> In healthy people at oral therapeutic doses, amphetamine has been shown to increase physical strength,<sup id="cite_ref-Ergogenics_17-4" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_61-0" class="reference"><a href="#cite_note-Ergogenics2-61"><span>[</span>51<span>]</span></a></sup> acceleration,<sup id="cite_ref-Ergogenics_17-5" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_61-1" class="reference"><a href="#cite_note-Ergogenics2-61"><span>[</span>51<span>]</span></a></sup> stamina,<sup id="cite_ref-Ergogenics_17-6" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_62-0" class="reference"><a href="#cite_note-Roelands_2013-62"><span>[</span>52<span>]</span></a></sup> and endurance,<sup id="cite_ref-Ergogenics_17-7" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_62-1" class="reference"><a href="#cite_note-Roelands_2013-62"><span>[</span>52<span>]</span></a></sup> while reducing <a href="/wiki/Reaction_time" title="Reaction time" class="mw-redirect">reaction time</a>.<sup id="cite_ref-Ergogenics_17-8" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup> Like the psychostimulants <a href="/wiki/Methylphenidate" title="Methylphenidate">methylphenidate</a> and <a href="/wiki/Bupropion" title="Bupropion">bupropion</a>, amphetamine increases stamina and endurance in humans primarily through <a href="/wiki/Reuptake_inhibitor" title="Reuptake inhibitor">reuptake inhibition</a> and <a href="/wiki/Releasing_agent" title="Releasing agent">effluxion</a> of dopamine in the central nervous system.<sup id="cite_ref-Ergogenics2_61-2" class="reference"><a href="#cite_note-Ergogenics2-61"><span>[</span>51<span>]</span></a></sup><sup id="cite_ref-Roelands_2013_62-2" class="reference"><a href="#cite_note-Roelands_2013-62"><span>[</span>52<span>]</span></a></sup> As with cognitive enhancement, very high doses can induce side effects that impair performance, such as <a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">rhabdomyolysis</a> and <a href="/wiki/Hyperthermia" title="Hyperthermia">hyperthermia</a>.<sup id="cite_ref-FDA_Abuse_.26_OD_16-2" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-1" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Ergogenics2_61-3" class="reference"><a href="#cite_note-Ergogenics2-61"><span>[</span>51<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Contraindications">Contraindications</span></h2>
<p>The <a href="/wiki/United_States_Food_and_Drug_Administration" title="United States Food and Drug Administration" class="mw-redirect">United States Food and Drug Administration</a> (USFDA)<sup id="cite_ref-63" class="reference"><a href="#cite_note-63"><span>[</span>note 7<span>]</span></a></sup> states that amphetamine is <a href="/wiki/Contraindicated" title="Contraindicated" class="mw-redirect">contraindicated</a> in people with a history of <a href="/wiki/Drug_abuse" title="Drug abuse" class="mw-redirect">drug abuse</a>, <a href="/wiki/Heart_disease" title="Heart disease" class="mw-redirect">heart disease</a>, or severe <a href="/wiki/Irritability" title="Irritability">agitation</a> or anxiety, or in those currently experiencing <a href="/wiki/Arteriosclerosis" title="Arteriosclerosis">arteriosclerosis</a>, <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a>, <a href="/wiki/Hyperthyroidism" title="Hyperthyroidism">hyperthyroidism</a>, or severe <a href="/wiki/Hypertension" title="Hypertension">hypertension</a>.<sup id="cite_ref-FDA_Contra_Warnings_64-0" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup> People who have experienced <a href="/wiki/Hypersensitivity" title="Hypersensitivity">hypersensitivity</a> reactions to other stimulants in the past or are taking <a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">monoamine oxidase inhibitors</a> (MAOIs) are advised not to take amphetamine.<sup id="cite_ref-FDA_Contra_Warnings_64-1" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup> The USFDA advises anyone with <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a>, <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">depression</a>, elevated <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a>, liver or kidney problems, <a href="/wiki/Mania" title="Mania">mania</a>, <a href="/wiki/Psychosis" title="Psychosis">psychosis</a>, <a href="/wiki/Raynaud%27s_phenomenon" title="Raynaud's phenomenon">Raynaud's phenomenon</a>, <a href="/wiki/Seizure" title="Seizure" class="mw-redirect">seizures</a>, <a href="/wiki/Thyroid" title="Thyroid">thyroid</a> problems, <a href="/wiki/Tic" title="Tic">tics</a>, or <a href="/wiki/Tourette_syndrome" title="Tourette syndrome">Tourette syndrome</a> to monitor their symptoms while taking amphetamine.<sup id="cite_ref-FDA_Contra_Warnings_64-2" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup> Amphetamine is classified in <a href="/wiki/Pregnancy_category#United_States" title="Pregnancy category">US pregnancy category C</a>.<sup id="cite_ref-FDA_Contra_Warnings_64-3" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup> This means that detriments to the fetus have been observed in animal studies and adequate human studies have not been conducted; amphetamine may still be prescribed to pregnant women if the potential benefits outweigh the risks.<sup id="cite_ref-65" class="reference"><a href="#cite_note-65"><span>[</span>54<span>]</span></a></sup> Amphetamine has also been shown to pass into breast milk, so the USFDA advises mothers to avoid breastfeeding when using it.<sup id="cite_ref-FDA_Contra_Warnings_64-4" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup> Due to the potential for stunted growth, the USFDA advises monitoring the height and weight of growing children and adolescents during treatment.<sup id="cite_ref-FDA_Contra_Warnings_64-5" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Side_effects">Side effects</span></h2>
<p><a href="/wiki/Side_effects" title="Side effects" class="mw-redirect">Side effects</a> of amphetamine are varied, and the amount of amphetamine consumed is the primary factor in determining the likelihood and severity of side effects.<sup id="cite_ref-FDA_Abuse_.26_OD_16-3" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-2" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-2" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> Amphetamine products such as Adderall, Dexedrine, and their generic equivalents are currently approved by the USFDA for long-term therapeutic use.<sup id="cite_ref-FDA_Effects_29-3" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-66" class="reference"><a href="#cite_note-66"><span>[</span>55<span>]</span></a></sup> <a href="/wiki/Recreational_drug_use#Stimulants" title="Recreational drug use">Recreational use</a> of amphetamine generally involves far larger doses and therefore a much greater risk of serious side effects.<sup id="cite_ref-Westfall_34-3" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Physical">Physical</span></h3>
<p>At normal therapeutic doses, the physical side effects of amphetamine vary widely by age and among individual people.<sup id="cite_ref-FDA_Effects_29-4" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup> <a href="/wiki/Cardiovascular" title="Cardiovascular" class="mw-redirect">Cardiovascular</a> side effects can include <a href="/wiki/Arrhythmias" title="Arrhythmias" class="mw-redirect">irregular heartbeat</a> (usually <a href="/wiki/Tachycardia" title="Tachycardia">increased heart rate</a>), <a href="/wiki/Hypertension" title="Hypertension">hypertension</a> (high blood pressure) or <a href="/wiki/Hypotension" title="Hypotension">hypotension</a> (low blood pressure) from a <a href="/wiki/Vasovagal_response" title="Vasovagal response">vasovagal response</a>, and <a href="/wiki/Raynaud%27s_phenomenon" title="Raynaud's phenomenon">Raynaud's phenomenon</a>.<sup id="cite_ref-FDA_Effects_29-5" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-4" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-pmid18295156_67-0" class="reference"><a href="#cite_note-pmid18295156-67"><span>[</span>56<span>]</span></a></sup> Sexual side effects in males may include <a href="/wiki/Erectile_dysfunction" title="Erectile dysfunction">erectile dysfunction</a>, frequent erections, or <a href="/wiki/Priapism" title="Priapism">prolonged erections</a>. Other potential side effects include abdominal pain, acne, blurred vision, <a href="/wiki/Bruxism" title="Bruxism">excessive grinding of the teeth</a>, <a href="/wiki/Diaphoresis" title="Diaphoresis">profuse sweating</a>, <a href="/wiki/Xerostomia" title="Xerostomia">dry mouth</a>, loss of appetite, nausea, reduced <a href="/wiki/Seizure_threshold" title="Seizure threshold">seizure threshold</a>, <a href="/wiki/Tics" title="Tics" class="mw-redirect">tics</a>, and weight loss.<sup id="cite_ref-FDA_Effects_29-6" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-5" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-pmid18295156_67-1" class="reference"><a href="#cite_note-pmid18295156-67"><span>[</span>56<span>]</span></a></sup> Dangerous physical side effects are rare in typical pharmaceutical doses.<sup id="cite_ref-Westfall_34-6" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup></p>
<p>Amphetamine stimulates the <a href="/wiki/Medulla_oblongata" title="Medulla oblongata">medullary respiratory centers</a>, producing faster and deeper breaths.<sup id="cite_ref-Westfall_34-7" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> In a normal person at therapeutic doses, amphetamine does not noticeably increase the stimulate breathing, but when respiration is already compromised, it may stimulate it.<sup id="cite_ref-Westfall_34-8" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> Amphetamine also induces <a href="/wiki/Muscle_contraction" title="Muscle contraction">contraction</a> in the urinary <a href="/wiki/Detrusor_muscle" title="Detrusor muscle" class="mw-redirect">bladder sphincter</a>, which can result in difficulty urinating; this effect can be useful in treating <a href="/wiki/Enuresis" title="Enuresis">enuresis</a> and <a href="/wiki/Urinary_incontinence" title="Urinary incontinence">incontinence</a>.<sup id="cite_ref-Westfall_34-9" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> The effects of amphetamine on the gastrointestinal tract are unpredictable.<sup id="cite_ref-Westfall_34-10" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> Amphetamine may reduce <a href="/wiki/Gastrointestinal_motility" title="Gastrointestinal motility" class="mw-redirect">gastrointestinal motility</a> if <a href="/wiki/Intestinal" title="Intestinal" class="mw-redirect">intestinal</a> activity is high, or increase motility if the <a href="/wiki/Smooth_muscle_tissue" title="Smooth muscle tissue">smooth muscle</a> of the tract is relaxed.<sup id="cite_ref-Westfall_34-11" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> Amphetamine also has a slight <a href="/wiki/Analgesic" title="Analgesic">analgesic</a> effect and can enhance the analgesia of <a href="/wiki/Opiates" title="Opiates" class="mw-redirect">opiates</a>.<sup id="cite_ref-Westfall_34-12" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup></p>
<p>Recent studies by the USFDA indicate that, in children, young adults, and adults, there is no association between serious adverse cardiovascular events (<a href="/wiki/Sudden_cardiac_death" title="Sudden cardiac death">sudden death</a>, <a href="/wiki/Myocardial_infarction" title="Myocardial infarction">myocardial infarction</a>, and <a href="/wiki/Stroke" title="Stroke">stroke</a>) and the medical use of amphetamine or other ADHD stimulants.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72"><span>[</span>ref-note 5<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Psychological">Psychological</span></h3>
<p>Common psychological effects of therapeutic doses can include <a href="/wiki/Alertness" title="Alertness">alertness</a>, apprehension, <a href="/wiki/Concentration" title="Concentration">concentration</a>, decreased sense of fatigue, mood swings (elevated mood or elation and <a href="/wiki/Euphoria" title="Euphoria">euphoria</a> followed by mild <a href="/wiki/Dysphoria" title="Dysphoria">dysphoria</a>), increased initiative, <a href="/wiki/Insomnia" title="Insomnia">insomnia</a> or <a href="/wiki/Wakefulness" title="Wakefulness">wakefulness</a>, <a href="/wiki/Self-confidence" title="Self-confidence">self-confidence</a>, and sociability.<sup id="cite_ref-FDA_Effects_29-7" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-13" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> Less commonly, depending on the user's personality and current mental state, <a href="/wiki/Anxiety" title="Anxiety">anxiety</a>, change in <a href="/wiki/Libido" title="Libido">libido</a>, <a href="/wiki/Grandiosity" title="Grandiosity">grandiosity</a>, <a href="/wiki/Irritability" title="Irritability">irritability</a>, repetitive or <a href="/wiki/Fixation_(psychology)" title="Fixation (psychology)">obsessive</a> behaviors, and restlessness can occur.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74"><span>[</span>ref-note 6<span>]</span></a></sup> <a href="/wiki/Amphetamine_psychosis" title="Amphetamine psychosis" class="mw-redirect">Amphetamine psychosis</a> can occur in heavy users.<sup id="cite_ref-FDA_Abuse_.26_OD_16-4" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-9" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Cochrane_31-1" class="reference"><a href="#cite_note-Cochrane-31"><span>[</span>26<span>]</span></a></sup> Although very rare, this psychosis can also occur at therapeutic doses during long-term therapy as a side effect.<sup id="cite_ref-FDA_Abuse_.26_OD_16-5" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-10" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Stimulant_Misuse_32-1" class="reference"><a href="#cite_note-Stimulant_Misuse-32"><span>[</span>27<span>]</span></a></sup> According to the USFDA, "there is no systematic evidence that stimulants cause aggressive behavior or hostility."<sup id="cite_ref-FDA_Effects_29-11" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Overdose">Overdose</span></h2>
<p>An amphetamine overdose is rarely fatal with appropriate care.<sup id="cite_ref-Amphetamine_toxidrome_75-0" class="reference"><a href="#cite_note-Amphetamine_toxidrome-75"><span>[</span>62<span>]</span></a></sup> It can lead to different symptoms.<sup id="cite_ref-FDA_Abuse_.26_OD_16-6" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-12" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup> A <i>moderate overdose</i> may induce symptoms including <a href="/wiki/Arrhythmia" title="Arrhythmia" class="mw-redirect">irregular heartbeat</a>, confusion, <a href="/wiki/Dysuria" title="Dysuria">painful urination</a>, high or low <a href="/wiki/Blood_pressure" title="Blood pressure">blood pressure</a>, hyperthermia, <a href="/wiki/Hyperreflexia" title="Hyperreflexia">hyperreflexia</a>, <a href="/wiki/Myalgia" title="Myalgia">muscle pain</a>, severe agitation, <a href="/wiki/Tachypnea" title="Tachypnea">rapid breathing</a>, <a href="/wiki/Tremor" title="Tremor">tremor</a>, <a href="/wiki/Urinary_hesitancy" title="Urinary hesitancy" class="mw-redirect">urinary hesitancy</a>, and <a href="/wiki/Urinary_retention" title="Urinary retention">urinary retention</a>.<sup id="cite_ref-FDA_Abuse_.26_OD_16-7" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-13" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-15" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> An <i>extremely large overdose</i> may produce symptoms such as <a href="/wiki/Adrenergic_storm" title="Adrenergic storm">adrenergic storm</a>, amphetamine psychosis, <a href="/wiki/Anuria" title="Anuria">anuria</a>, <a href="/wiki/Cardiogenic_shock" title="Cardiogenic shock">cardiogenic shock</a>, <a href="/wiki/Cerebral_hemorrhage" title="Cerebral hemorrhage">cerebral hemorrhage</a>, <a href="/wiki/Circulatory_collapse" title="Circulatory collapse">circulatory collapse</a>, <a href="/wiki/Edema" title="Edema">edema</a> (<a href="/wiki/Peripheral_edema" title="Peripheral edema">peripheral</a> or <a href="/wiki/Pulmonary_edema" title="Pulmonary edema">pulmonary</a>), <a href="/wiki/Hyperpyrexia" title="Hyperpyrexia" class="mw-redirect">extreme fever</a>, <a href="/wiki/Pulmonary_hypertension" title="Pulmonary hypertension">pulmonary hypertension</a>, <a href="/wiki/Renal_failure" title="Renal failure">renal failure</a>, <a href="/wiki/Rhabdomyolysis" title="Rhabdomyolysis">rapid muscle breakdown</a>, <a href="/wiki/Serotonin_syndrome#Spectrum_concept" title="Serotonin syndrome">serotonin toxicity</a>, and <a href="/wiki/Stereotypy" title="Stereotypy">stereotypy</a>.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78"><span>[</span>ref-note 7<span>]</span></a></sup> Fatal amphetamine poisoning usually involves convulsions and <a href="/wiki/Coma" title="Coma">coma</a>.<sup id="cite_ref-FDA_Abuse_.26_OD_16-9" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Westfall_34-17" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Dependence.2C_addiction.2C_and_withdrawal">Dependence, addiction, and withdrawal</span></h3>
<p>Addiction is a serious risk with heavy recreational amphetamine use; it is unlikely to arise from typical medical use.<sup id="cite_ref-FDA_Abuse_.26_OD_16-10" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-EncycOfPsychopharm_33-1" class="reference"><a href="#cite_note-EncycOfPsychopharm-33"><span>[</span>28<span>]</span></a></sup><sup id="cite_ref-Westfall_34-18" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup> <a href="/wiki/Drug_tolerance" title="Drug tolerance">Tolerance</a> develops rapidly in amphetamine abuse, so periods of extended use require increasing doses of the drug in order to achieve the same effect.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79"><span>[</span>65<span>]</span></a></sup><sup id="cite_ref-80" class="reference"><a href="#cite_note-80"><span>[</span>66<span>]</span></a></sup></p>
<p>A <a href="/wiki/Cochrane_Collaboration" title="Cochrane Collaboration">Cochrane Collaboration</a> review on amphetamine and methamphetamine dependence and abuse indicates that the current evidence on effective treatments is extremely limited.<sup id="cite_ref-Cochrane_Addiction_81-0" class="reference"><a href="#cite_note-Cochrane_Addiction-81"><span>[</span>67<span>]</span></a></sup> The review indicated that <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a><sup id="cite_ref-82" class="reference"><a href="#cite_note-82"><span>[</span>note 8<span>]</span></a></sup> and <a href="/wiki/Imipramine" title="Imipramine">imipramine</a><sup id="cite_ref-83" class="reference"><a href="#cite_note-83"><span>[</span>note 9<span>]</span></a></sup> have some limited benefits in treating abuse and addiction, but concluded, "no treatment has been demonstrated to be effective for the treatment of amphetamine dependence and abuse."<sup id="cite_ref-Cochrane_Addiction_81-3" class="reference"><a href="#cite_note-Cochrane_Addiction-81"><span>[</span>67<span>]</span></a></sup> A corroborating review indicated that amphetamine dependence is mediated through increased activation of <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">dopamine receptors</a> and <span class="nowrap"><a href="//en.wiktionary.org/wiki/colocalize" class="extiw" title="wikt:colocalize">co-localized</a></span> <a href="/wiki/NMDA_receptor" title="NMDA receptor">NMDA receptors</a> in the <a href="/wiki/Mesolimbic_pathway" title="Mesolimbic pathway">mesolimbic pathway</a>.<sup id="cite_ref-Magnesium_84-0" class="reference"><a href="#cite_note-Magnesium-84"><span>[</span>68<span>]</span></a></sup> This review also noted that <a href="/wiki/Magnesium" title="Magnesium">magnesium ions</a>, which inhibit NMDA receptor <a href="/wiki/Calcium_channel" title="Calcium channel">calcium channels</a>, and serotonin have inhibitory effects on NMDA receptors.<sup id="cite_ref-Magnesium_84-1" class="reference"><a href="#cite_note-Magnesium-84"><span>[</span>68<span>]</span></a></sup> It also suggested that, based upon <a href="/wiki/Animal_testing" title="Animal testing">animal testing</a>, <a href="//en.wiktionary.org/wiki/pathological" class="extiw" title="wikt:pathological">pathological</a> amphetamine use significantly reduces the level of intracellular magnesium throughout the brain.<sup id="cite_ref-Magnesium_84-2" class="reference"><a href="#cite_note-Magnesium-84"><span>[</span>68<span>]</span></a></sup> Supplemental magnesium,<sup id="cite_ref-85" class="reference"><a href="#cite_note-85"><span>[</span>note 10<span>]</span></a></sup> like fluoxetine treatment, has been shown to reduce <a href="/wiki/Self-administration" title="Self-administration">self-administration</a> in both humans and lab animals.<sup id="cite_ref-Cochrane_Addiction_81-4" class="reference"><a href="#cite_note-Cochrane_Addiction-81"><span>[</span>67<span>]</span></a></sup><sup id="cite_ref-Magnesium_84-4" class="reference"><a href="#cite_note-Magnesium-84"><span>[</span>68<span>]</span></a></sup></p>
<p>According to another Cochrane Collaboration review on withdrawal in highly dependent amphetamine and methamphetamine abusers, "when chronic heavy users abruptly discontinue amphetamine use, many report a time-limited withdrawal syndrome that occurs within 24&#160;hours of their last dose."<sup id="cite_ref-Cochrane_Withdrawal_86-0" class="reference"><a href="#cite_note-Cochrane_Withdrawal-86"><span>[</span>69<span>]</span></a></sup> This review noted that withdrawal symptoms in chronic, high-dose users are frequent, occurring in up to 87.6% of cases, and persist for three to four weeks with a marked "crash" phase occurring during the first week.<sup id="cite_ref-Cochrane_Withdrawal_86-1" class="reference"><a href="#cite_note-Cochrane_Withdrawal-86"><span>[</span>69<span>]</span></a></sup> Amphetamine withdrawal symptoms can include anxiety, <a href="/wiki/Craving_(withdrawal)" title="Craving (withdrawal)">drug craving</a>, <a href="/wiki/Dysphoria" title="Dysphoria">dysphoric mood</a>, <a href="/wiki/Fatigue_(medical)" title="Fatigue (medical)">fatigue</a>, <a href="/wiki/Hyperphagia" title="Hyperphagia" class="mw-redirect">increased appetite</a>, <a href="/wiki/Psychomotor_agitation" title="Psychomotor agitation">increased movement</a> or <a href="/wiki/Psychomotor_retardation" title="Psychomotor retardation">decreased movement</a>, <a href="/wiki/Anhedonia" title="Anhedonia">lack of motivation</a>, <a href="/wiki/Insomnia" title="Insomnia">sleeplessness</a> or <a href="/wiki/Hypersomnia" title="Hypersomnia">sleepiness</a>, and <a href="/wiki/Lucid_dream" title="Lucid dream">vivid or lucid dreams</a>.<sup id="cite_ref-Cochrane_Withdrawal_86-2" class="reference"><a href="#cite_note-Cochrane_Withdrawal-86"><span>[</span>69<span>]</span></a></sup> The review suggested that withdrawal symptoms are associated with the degree of dependence, suggesting that therapeutic use would result in far milder discontinuation symptoms.<sup id="cite_ref-Cochrane_Withdrawal_86-3" class="reference"><a href="#cite_note-Cochrane_Withdrawal-86"><span>[</span>69<span>]</span></a></sup> The USFDA does not indicate the presence of withdrawal symptoms following discontinuation of amphetamine use after an extended period at therapeutic doses.<sup id="cite_ref-87" class="reference"><a href="#cite_note-87"><span>[</span>70<span>]</span></a></sup><sup id="cite_ref-88" class="reference"><a href="#cite_note-88"><span>[</span>71<span>]</span></a></sup><sup id="cite_ref-89" class="reference"><a href="#cite_note-89"><span>[</span>72<span>]</span></a></sup></p>
<p>Current models of addiction from chronic drug use involve alterations in <a href="/wiki/Gene_expression" title="Gene expression">gene expression</a> in certain parts of the brain.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-0" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Nestler_91-0" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup><sup id="cite_ref-Addiction_genetics_92-0" class="reference"><a href="#cite_note-Addiction_genetics-92"><span>[</span>75<span>]</span></a></sup> The most important <a href="/wiki/Transcription_factor" title="Transcription factor">transcription factors</a> that produce these alterations are <a href="/wiki/%CE%94FosB" title="ΔFosB" class="mw-redirect">ΔFosB</a>, <a href="/wiki/CAMP_response_element_binding_protein" title="CAMP response element binding protein" class="mw-redirect">cyclic adenosine monophosphate (cAMP) response element binding protein</a> (CREB), and <a href="/wiki/Nuclear_factor_kappa_B" title="Nuclear factor kappa B" class="mw-redirect">nuclear factor kappa B</a> (NFκB).<sup id="cite_ref-Nestler_91-1" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> ΔFosB is the most significant, since its overexpression in the <a href="/wiki/Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a> is <a href="/wiki/Necessary_and_sufficient" title="Necessary and sufficient" class="mw-redirect">necessary and sufficient</a> for many of the neural adaptations seen in drug addiction;<sup id="cite_ref-Nestler_91-2" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> it has been implicated in addictions to <a href="/wiki/Cannabinoid" title="Cannabinoid">cannabinoids</a>, <a href="/wiki/Cocaine" title="Cocaine">cocaine</a>, <a href="/wiki/Nicotine" title="Nicotine">nicotine</a>, <a href="/wiki/Phenylcyclidine" title="Phenylcyclidine" class="mw-redirect">phenylcyclidine</a>, and <a href="/wiki/Substituted_amphetamines" title="Substituted amphetamines" class="mw-redirect">substituted amphetamines</a>.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-1" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Nestler_91-3" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> <a href="/wiki/%CE%94JunD" title="ΔJunD" class="mw-redirect">ΔJunD</a> is the transcription factor which directly opposes ΔFosB.<sup id="cite_ref-Nestler_91-4" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> Increases in nucleus accumbens ΔJunD expression can reduce or, with a large increase, even block most of the neural alterations seen in chronic drug abuse (i.e., the alterations mediated by ΔFosB).<sup id="cite_ref-Nestler_91-5" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> ΔFosB also plays an important role in regulating behavioral responses to natural rewards, such as palatable food, sex, and exercise.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-2" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Nestler_91-6" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> Since natural rewards, like drugs of abuse, induce ΔFosB, chronic acquisition of these rewards can result in a similar pathological addictive state.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-3" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Nestler_91-7" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup> Consequently, ΔFosB is the key transcription factor involved in amphetamine addiction, especially amphetamine-induced <a href="/wiki/Sex_addiction" title="Sex addiction" class="mw-redirect">sex addictions</a>.<sup id="cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-4" class="reference"><a href="#cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span>[</span>73<span>]</span></a></sup><sup id="cite_ref-Nestler_91-8" class="reference"><a href="#cite_note-Nestler-91"><span>[</span>74<span>]</span></a></sup><sup id="cite_ref-Genetic_sex_addiction_93-0" class="reference"><a href="#cite_note-Genetic_sex_addiction-93"><span>[</span>76<span>]</span></a></sup> ΔFosB inhibitors (drugs that oppose its action) may be an effective treatment for addiction and addictive disorders.<sup id="cite_ref-Malenka_2009_04_94-0" class="reference"><a href="#cite_note-Malenka_2009_04-94"><span>[</span>77<span>]</span></a></sup></p>
<p>The effects of amphetamine on gene regulation are both dose- and route-dependent.<sup id="cite_ref-Addiction_genetics_92-1" class="reference"><a href="#cite_note-Addiction_genetics-92"><span>[</span>75<span>]</span></a></sup> Most of the research on gene regulation and addiction is based upon animal studies with intravenous amphetamine administration at very high doses.<sup id="cite_ref-Addiction_genetics_92-2" class="reference"><a href="#cite_note-Addiction_genetics-92"><span>[</span>75<span>]</span></a></sup> The few studies that have used equivalent (weight-adjusted) human therapeutic doses and oral administration show that these changes, if they occur, are relatively minor.<sup id="cite_ref-Addiction_genetics_92-3" class="reference"><a href="#cite_note-Addiction_genetics-92"><span>[</span>75<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Psychosis">Psychosis</span></h3>
<div class="rellink relarticle mainarticle">The main section for this topic is on the page <a href="/wiki/Stimulant_psychosis" title="Stimulant psychosis">Stimulant psychosis</a>, in the section <a href="/wiki/Stimulant_psychosis#Substituted_amphetamines" title="Stimulant psychosis">Substituted amphetamines</a>.</div>
<p>Abuse of amphetamine can result in a stimulant psychosis that may present with a variety of symptoms (e.g., <a href="/wiki/Paranoia" title="Paranoia">paranoia</a>, <a href="/wiki/Hallucination" title="Hallucination">hallucinations</a>, <a href="/wiki/Delusion" title="Delusion">delusions</a>).<sup id="cite_ref-Cochrane_31-2" class="reference"><a href="#cite_note-Cochrane-31"><span>[</span>26<span>]</span></a></sup> A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about&#160;5–15% of users fail to recover completely.<sup id="cite_ref-Cochrane_31-3" class="reference"><a href="#cite_note-Cochrane-31"><span>[</span>26<span>]</span></a></sup><sup id="cite_ref-Hofmann_95-0" class="reference"><a href="#cite_note-Hofmann-95"><span>[</span>78<span>]</span></a></sup> The same review asserts that, based upon at least one trial, <a href="/wiki/Antipsychotic" title="Antipsychotic">antipsychotic</a> medications effectively resolve the symptoms of acute amphetamine psychosis.<sup id="cite_ref-Cochrane_31-4" class="reference"><a href="#cite_note-Cochrane-31"><span>[</span>26<span>]</span></a></sup> Psychosis very rarely arises from therapeutic use.<sup id="cite_ref-Stimulant_Misuse_32-2" class="reference"><a href="#cite_note-Stimulant_Misuse-32"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-FDA_Contra_Warnings_64-6" class="reference"><a href="#cite_note-FDA_Contra_Warnings-64"><span>[</span>53<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Toxicity">Toxicity</span></h3>
<p>In rodents and primates, sufficiently high doses of amphetamine cause dopaminergic <a href="/wiki/Neurotoxicity" title="Neurotoxicity">neurotoxicity</a>, or damage to dopamine neurons, which is characterized as reduced transporter and receptor function.<sup id="cite_ref-Humans.26Animals_96-0" class="reference"><a href="#cite_note-Humans.26Animals-96"><span>[</span>79<span>]</span></a></sup> As of March 2014<sup class="plainlinks noprint asof-tag update" style="display:none;"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Amphetamine&amp;action=edit">[update]</a></sup>, there is no evidence that amphetamine is directly neurotoxic in humans.<sup id="cite_ref-97" class="reference"><a href="#cite_note-97"><span>[</span>80<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_02_98-0" class="reference"><a href="#cite_note-Malenka_2009_02-98"><span>[</span>81<span>]</span></a></sup> High-dose amphetamine can cause indirect neurotoxicity as a result of increased oxidative stress from <a href="/wiki/Reactive_oxygen_species" title="Reactive oxygen species">reactive oxygen species</a> and <a href="/wiki/Autoxidation" title="Autoxidation">autoxidation</a> of dopamine.<sup id="cite_ref-pmid22392347_40-1" class="reference"><a href="#cite_note-pmid22392347-40"><span>[</span>32<span>]</span></a></sup><sup id="cite_ref-Autoxidation1_99-0" class="reference"><a href="#cite_note-Autoxidation1-99"><span>[</span>82<span>]</span></a></sup><sup id="cite_ref-Autoxidation2_100-0" class="reference"><a href="#cite_note-Autoxidation2-100"><span>[</span>83<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Interactions">Interactions</span></h2>
<p>Many types of substances are known to <a href="/wiki/Drug_interaction" title="Drug interaction">interact</a> with amphetamine, resulting in altered <a href="/wiki/Drug_action" title="Drug action">drug action</a> or <a href="/wiki/Drug_metabolism" title="Drug metabolism">metabolism</a> of amphetamine, the interacting substance, or both.<sup id="cite_ref-FDA_Pharmacokinetics_3-4" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-FDA_Interactions_101-0" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Since amphetamine is metabolized by the liver enzyme <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a>, inhibitors of this enzyme, such as <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> (a <a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">selective serotonin reuptake inhibitor</a> (SSRI)) and bupropion, will prolong the <a href="/wiki/Elimination_half-life" title="Elimination half-life" class="mw-redirect">elimination half-life</a> of amphetamine.<sup id="cite_ref-FDA_Interactions_101-1" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Amphetamine also interacts with <a href="/wiki/Monoamine_oxidase_inhibitors" title="Monoamine oxidase inhibitors" class="mw-redirect"><abbr title="monoamine oxidase inhibitors">MAOIs</abbr></a>, particularly <a href="/wiki/Monoamine_oxidase_A" title="Monoamine oxidase A">monoamine oxidase A</a> inhibitors, since both MAOIs and amphetamine increase plasma catecholamines; therefore, concurrent use of both is dangerous.<sup id="cite_ref-FDA_Interactions_101-2" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Amphetamine will modulate the activity of most psychoactive drugs. In particular, amphetamine may decrease the effects of <a href="/wiki/Sedative" title="Sedative">sedatives</a> and <a href="/wiki/Depressant" title="Depressant">depressants</a> and increase the effects of <a href="/wiki/Stimulant" title="Stimulant">stimulants</a> and <a href="/wiki/Antidepressant" title="Antidepressant">antidepressants</a>.<sup id="cite_ref-FDA_Interactions_101-3" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Amphetamine may also decrease the effects of <a href="/wiki/Antihypertensives" title="Antihypertensives" class="mw-redirect">antihypertensives</a> and <a href="/wiki/Antipsychotic" title="Antipsychotic">antipsychotics</a> due to its effects on blood pressure and dopamine respectively.<sup id="cite_ref-FDA_Interactions_101-4" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> There is no significant effect on consuming amphetamine with food in general, but the <a href="/wiki/PH" title="PH">pH</a> of gastrointestinal content and urine affects the absorption and excretion of amphetamine, respectively.<sup id="cite_ref-FDA_Interactions_101-5" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Acidic substances reduce the absorption of amphetamine and increase urinary excretion, and alkaline substances do the opposite.<sup id="cite_ref-FDA_Interactions_101-6" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Due to the effect pH has on absorption, amphetamine also interacts with gastric acid reducers such as <a href="/wiki/Proton_pump_inhibitor" title="Proton pump inhibitor" class="mw-redirect">proton pump inhibitors</a> and <a href="/wiki/H2_antagonist" title="H2 antagonist">H<sub>2</sub> antihistamines</a>, which decrease gastrointestinal pH.<sup id="cite_ref-FDA_Interactions_101-7" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Pharmacology">Pharmacology</span></h2>
<h3><span class="mw-headline" id="Pharmacodynamics">Pharmacodynamics</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:542px;">
<div style="clear: both; font-weight: bold; text-align: center; background-color: #F0F8FF">
<p>Pharmacodynamics of amphetamine enantiomers in a dopamine neuron</p>
</div>
<div style="position:relative; width:540px; height:685px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:0px; top:0px; width:540px; position:absolute"><a href="/wiki/File:TAAR1_Dopamine.svg" class="image"><img alt="A pharmacodynamic model of amphetamine and TAAR1" src="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/540px-TAAR1_Dopamine.svg.png" width="540" height="685" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/810px-TAAR1_Dopamine.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/10/TAAR1_Dopamine.svg/1080px-TAAR1_Dopamine.svg.png 2x" /></a></div>
<div style="text-align:center; font-size:13px; line-height:110%;">
<div id="annotation_190x45" style="position:absolute; left:190px; top:45px; line-height:110%"><span style="background-color:transparent; color:black"><span style="background-color:transparent;">via <b><a href="/wiki/Aromatic_L-amino_acid_decarboxylase" title="Aromatic L-amino acid decarboxylase">AADC</a></b></span></span></div>
</div>
</div>
<div class="thumbcaption" style="clear:left">Amphetamine enters the presynaptic neuron across the neuronal membrane or through <abbr title="dopamine transporter">DAT</abbr>. Once inside, it binds to <abbr title="trace amine-associated receptor 1">TAAR1</abbr> or enters synaptic vesicles through <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>. When amphetamine binds to TAAR1, it reduces dopamine receptor firing rate and triggers <a href="/wiki/Protein_kinase_A" title="Protein kinase A">protein kinase A</a> (PKA) and <a href="/wiki/Protein_kinase_C" title="Protein kinase C">protein kinase C</a> (PKC) signaling, resulting in DAT phosphorylation. <span class="nowrap">PKC-phosphorylated</span> DAT operates in reverse, while <span class="nowrap">PKA-phosphorylated</span> DAT withdraws into the presynaptic neuron and ceases transport. When amphetamine enters the synaptic vesicles through VMAT2, dopamine is released into the cytosol (yellow-orange area).</div>
</div>
</div>
<p>Amphetamine has been identified as a potent <a href="/wiki/Full_agonist" title="Full agonist" class="mw-redirect">full agonist</a> of <a href="/wiki/TAAR1" title="TAAR1">trace amine-associated receptor 1</a> (TAAR1), a <span class="nowrap"><a href="/wiki/Gs_alpha_subunit" title="Gs alpha subunit">G<sub>s</sub>-coupled</a></span> and <span class="nowrap"><a href="/wiki/Gq_alpha_subunit" title="Gq alpha subunit">G<sub>q</sub>-coupled</a></span> <a href="/wiki/G_protein-coupled_receptor" title="G protein-coupled receptor">G protein-coupled receptor</a> (GPCR) discovered in 2001, which is important for regulation of brain <a href="/wiki/Monoamines" title="Monoamines" class="mw-redirect">monoamines</a>.<sup id="cite_ref-Miller_28-1" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-DrugBank_2_102-0" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-103" class="reference"><a href="#cite_note-103"><span>[</span>86<span>]</span></a></sup> Activation of <abbr title="trace amine-associated receptor 1">TAAR1</abbr> increases <a href="/wiki/Cyclic_adenosine_monophosphate" title="Cyclic adenosine monophosphate"><abbr title="cyclic adenosine monophosphate">cAMP</abbr></a> production via <a href="/wiki/Adenylyl_cyclase" title="Adenylyl cyclase" class="mw-redirect">adenylyl cyclase</a> activation and inhibits <a href="/wiki/Monoamine_transporter" title="Monoamine transporter">monoamine transporter</a> function.<sup id="cite_ref-Miller_28-2" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-pmid11459929_104-0" class="reference"><a href="#cite_note-pmid11459929-104"><span>[</span>87<span>]</span></a></sup> Monoamine <a href="/wiki/Autoreceptors" title="Autoreceptors" class="mw-redirect">autoreceptors</a> (e.g., <a href="/wiki/D2sh" title="D2sh" class="mw-redirect">D<sub>2</sub> short</a>, <a href="/wiki/Alpha-2_adrenergic_receptor" title="Alpha-2 adrenergic receptor">presynaptic α<sub>2</sub></a>, and <a href="/wiki/5-HT1A#Autoreceptors" title="5-HT1A" class="mw-redirect">presynaptic 5-HT<sub>1A</sub></a>) have the opposite effect of TAAR1, and together these receptors provide a regulatory system for monoamines.<sup id="cite_ref-Miller_28-3" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> Notably, amphetamine and <a href="/wiki/Trace_amine" title="Trace amine">trace amines</a> activate TAAR1, but not monoamine autoreceptors.<sup id="cite_ref-Miller_28-4" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup></p>
<p>In addition to the neuronal monoamine <a href="/wiki/Membrane_transport_protein" title="Membrane transport protein">transporters</a>, amphetamine also inhibits <a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">vesicular monoamine transporter 2</a> (VMAT2), <a href="/wiki/SLC22A3" title="SLC22A3">SLC22A3</a>, and <a href="/wiki/SLC22A5" title="SLC22A5">SLC22A5</a>.<sup id="cite_ref-PubChem_Targets_105-0" class="reference"><a href="#cite_note-PubChem_Targets-105"><span>[</span>88<span>]</span></a></sup><sup id="cite_ref-DrugBank_Transporters_106-0" class="reference"><a href="#cite_note-DrugBank_Transporters-106"><span>[</span>89<span>]</span></a></sup> SLC22A3 is an extraneuronal monoamine transporter that is present in <a href="/wiki/Astrocyte" title="Astrocyte">astrocytes</a> and SLC22A5 is a high-affinity <a href="/wiki/Carnitine" title="Carnitine">carnitine</a> transporter.<sup id="cite_ref-PubChem_Targets_105-1" class="reference"><a href="#cite_note-PubChem_Targets-105"><span>[</span>88<span>]</span></a></sup><sup id="cite_ref-pmid13677912_107-0" class="reference"><a href="#cite_note-pmid13677912-107"><span>[</span>90<span>]</span></a></sup> Amphetamine also mildly inhibits both the <a href="/wiki/CYP2A6" title="CYP2A6">CYP2A6</a> and CYP2D6 liver enzymes.<sup id="cite_ref-DrugBank_2_102-1" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup> Amphetamine is known to strongly induce <a href="/wiki/Cocaine_and_amphetamine_regulated_transcript" title="Cocaine and amphetamine regulated transcript">cocaine and amphetamine regulated transcript</a> (CART) <a href="/wiki/Gene_expression" title="Gene expression">gene expression</a>,<sup id="cite_ref-DrugBank_2_102-2" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-PubChem_Targets_105-2" class="reference"><a href="#cite_note-PubChem_Targets-105"><span>[</span>88<span>]</span></a></sup> a <a href="/wiki/Neuropeptide" title="Neuropeptide">neuropeptide</a> involved in feeding behavior, stress, and reward, which induces observable increases in neuronal development and survival <i><a href="/wiki/In_vitro" title="In vitro">in vitro</a></i>.<sup id="cite_ref-PubChem_Targets_105-3" class="reference"><a href="#cite_note-PubChem_Targets-105"><span>[</span>88<span>]</span></a></sup><sup id="cite_ref-CART_108-0" class="reference"><a href="#cite_note-CART-108"><span>[</span>91<span>]</span></a></sup> The CART receptor has yet to be identified, but there is significant evidence that CART binds to a unique <abbr title="G protein-coupled receptor">GPCR</abbr> coupled to <a href="/wiki/Gi_alpha_subunit" title="Gi alpha subunit">G<sub>i</sub>/G<sub>o</sub></a>.<sup id="cite_ref-CART_108-1" class="reference"><a href="#cite_note-CART-108"><span>[</span>91<span>]</span></a></sup><sup id="cite_ref-pmid21855138_109-0" class="reference"><a href="#cite_note-pmid21855138-109"><span>[</span>92<span>]</span></a></sup> Amphetamine also inhibits <a href="/wiki/Monoamine_oxidase_B" title="Monoamine oxidase B">monoamine oxidase B</a> (MAO-B) at high doses, resulting in less dopamine and phenethylamine metabolism and consequently higher concentrations of synaptic monoamines.<sup id="cite_ref-FDA_Pharmacokinetics_3-5" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-PubChem_Header_8-2" class="reference"><a href="#cite_note-PubChem_Header-8"><span>[</span>8<span>]</span></a></sup></p>
<p>Amphetamine exerts its behavioral effects by modulating monoamine neurotransmission in the brain, primarily in <a href="/wiki/Catecholamine" title="Catecholamine">catecholamine</a> neurons.<sup id="cite_ref-Miller_28-5" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-DrugBank_2_102-3" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup> The full profile of amphetamine drug effects is derived almost entirely from increasing the neurotransmission of <a href="/wiki/Dopamine" title="Dopamine">dopamine</a>,<sup id="cite_ref-Miller_28-6" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> <a href="/wiki/Serotonin" title="Serotonin">serotonin</a>,<sup id="cite_ref-Miller_28-7" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a>,<sup id="cite_ref-Miller_28-8" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> <a href="/wiki/Epinephrine" title="Epinephrine">epinephrine</a>,<sup id="cite_ref-E_Weihe_110-0" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup> <a href="/wiki/Histamine" title="Histamine">histamine</a>,<sup id="cite_ref-E_Weihe_110-1" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup> <a href="/wiki/Cocaine_and_amphetamine_regulated_transcript" title="Cocaine and amphetamine regulated transcript">CART peptides</a>,<sup id="cite_ref-DrugBank_2_102-4" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup> <a href="/wiki/Acetylcholine" title="Acetylcholine">acetylcholine</a>,<sup id="cite_ref-Acetylcholine_111-0" class="reference"><a href="#cite_note-Acetylcholine-111"><span>[</span>94<span>]</span></a></sup><sup id="cite_ref-MEDRS-Cholinergic_112-0" class="reference"><a href="#cite_note-MEDRS-Cholinergic-112"><span>[</span>95<span>]</span></a></sup> and <a href="/wiki/Glutamate" title="Glutamate" class="mw-redirect">glutamate</a>,<sup id="cite_ref-glutamate1_113-0" class="reference"><a href="#cite_note-glutamate1-113"><span>[</span>96<span>]</span></a></sup><sup id="cite_ref-glutamate2_114-0" class="reference"><a href="#cite_note-glutamate2-114"><span>[</span>97<span>]</span></a></sup> which it effects through interactions with <abbr title="cocaine and amphetamine regulated transcript">CART</abbr>, <abbr title="trace amine-associated receptor 1">TAAR1</abbr>, and <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>.<sup id="cite_ref-Miller_28-9" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-DrugBank_2_102-5" class="reference"><a href="#cite_note-DrugBank_2-102"><span>[</span>85<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-2" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup></p>
<p>The effect of amphetamine on monoamine transporters in the brain appears to be site-specific.<sup id="cite_ref-Miller_28-10" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> Imaging studies indicate that monoamine reuptake inhibition by amphetamine and trace amines is dependent upon the presence of <abbr title="trace amine-associated receptor 1">TAAR1</abbr> <span class="nowrap">co-localization</span> in the associated monoamine neurons.<sup id="cite_ref-Miller_28-11" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> As of 2010, <span class="nowrap">co-localization</span> of TAAR1 and the <a href="/wiki/Dopamine_transporter" title="Dopamine transporter">dopamine transporter</a> (DAT) has been visualized in rhesus monkeys, but <span class="nowrap">co-localization</span> of TAAR1 with the <a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">norepinephrine transporter</a> (NET) and the <a href="/wiki/Serotonin_transporter" title="Serotonin transporter">serotonin transporter</a> (SERT) has only been evidenced by <a href="/wiki/Messenger_RNA" title="Messenger RNA">messenger RNA</a> (mRNA) expression.<sup id="cite_ref-Miller_28-12" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup></p>
<p>The major neural systems affected by amphetamine are largely implicated in the reward and executive function pathways of the brain, collectively known as the <a href="/wiki/Mesocorticolimbic_projection" title="Mesocorticolimbic projection" class="mw-redirect">mesocorticolimbic projection</a>.<sup id="cite_ref-cognition_enhancers_115-0" class="reference"><a href="#cite_note-cognition_enhancers-115"><span>[</span>98<span>]</span></a></sup> The concentrations of the primary neurotransmitters involved in reward circuitry and executive functioning, dopamine and norepinephrine, are markedly increased in a dose-dependent manner by amphetamine due to its effects on monoamine transporters.<sup id="cite_ref-Miller_28-13" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-3" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup><sup id="cite_ref-cognition_enhancers_115-1" class="reference"><a href="#cite_note-cognition_enhancers-115"><span>[</span>98<span>]</span></a></sup> The reinforcing and task saliency effects of amphetamine are mostly due to enhanced dopaminergic activity in the <a href="/wiki/Mesolimbic_pathway" title="Mesolimbic pathway">mesolimbic pathway</a>.<sup id="cite_ref-Malenka_2009_18-7" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup></p>
<p>Dextroamphetamine is a more potent agonist of <abbr title="trace amine-associated receptor 1">TAAR1</abbr> than levoamphetamine.<sup id="cite_ref-TAAR1_stereoselective_116-0" class="reference"><a href="#cite_note-TAAR1_stereoselective-116"><span>[</span>99<span>]</span></a></sup> Consequently, dextroamphetamine produces greater <abbr title="central nervous system">CNS</abbr> stimulation than levoamphetamine, roughly three to four times more, but levoamphetamine has slightly stronger cardiovascular and peripheral effects.<sup id="cite_ref-Westfall_34-19" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-TAAR1_stereoselective_116-1" class="reference"><a href="#cite_note-TAAR1_stereoselective-116"><span>[</span>99<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Dopamine">Dopamine</span></h4>
<p>In certain brain regions, amphetamine increases the concentrations of dopamine in the <a href="/wiki/Synaptic_cleft" title="Synaptic cleft" class="mw-redirect">synaptic cleft</a>, heightening the response of the post-synaptic neuron.<sup id="cite_ref-Miller_28-14" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> Through a <abbr title="trace amine-associated receptor 1">TAAR1</abbr>-mediated mechanism, the <a href="/wiki/Action_potential" title="Action potential">firing rate</a> of <a href="/wiki/Dopamine_receptor" title="Dopamine receptor">dopamine receptors</a> decreases, preventing a hyper-dopaminergic state.<sup id="cite_ref-Miller_28-15" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-TAAR1-Paradoxical_117-0" class="reference"><a href="#cite_note-TAAR1-Paradoxical-117"><span>[</span>100<span>]</span></a></sup> Amphetamine can can enter the <a href="/wiki/Presynaptic_neuron" title="Presynaptic neuron" class="mw-redirect">presynaptic neuron</a> either through <abbr title="dopamine transporter">DAT</abbr> or by diffusing across the neuronal membrane directly.<sup id="cite_ref-Miller_28-16" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> As a consequence of DAT uptake, amphetamine produces competitive reuptake inhibition at the transporter.<sup id="cite_ref-Miller_28-17" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> Upon entering the presynaptic neuron, amphetamine activates TAAR1 which, through <a href="/wiki/Protein_kinase_A" title="Protein kinase A">protein kinase A</a> (PKA) and <a href="/wiki/Protein_kinase_C" title="Protein kinase C">protein kinase C</a> (PKC) signaling, causes DAT <a href="/wiki/Phosphorylation" title="Phosphorylation">phosphorylation</a>.<sup id="cite_ref-Miller_28-18" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup> Phosphorylation by either protein kinase can result in DAT <a href="/wiki/Endocytosis" title="Endocytosis">internalization</a> (<span class="nowrap">non-competitive</span> reuptake inhibition), but <span class="nowrap">PKC-mediated</span> phosphorylation alone induces reverse transporter function (dopamine <a href="//en.wiktionary.org/wiki/efflux" class="extiw" title="wikt:efflux">efflux</a>).<sup id="cite_ref-Miller_28-19" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-TAAR1_Review_118-0" class="reference"><a href="#cite_note-TAAR1_Review-118"><span>[</span>101<span>]</span></a></sup></p>
<p>Amphetamine is also a substrate for the presynaptic vesicular transporter, <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>.<sup id="cite_ref-E_Weihe_110-4" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup> Following amphetamine uptake at VMAT2, the <a href="/wiki/Synaptic_vesicle" title="Synaptic vesicle">synaptic vesicle</a> releases dopamine molecules into the <a href="/wiki/Cytosol" title="Cytosol">cytosol</a> in exchange.<sup id="cite_ref-E_Weihe_110-5" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup> Subsequently, the cytosolic dopamine molecules exit the presynaptic neuron via reverse transport at <abbr title="dopamine transporter">DAT</abbr>.<sup id="cite_ref-Miller_28-20" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-6" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Norepinephrine">Norepinephrine</span></h4>
<p>Similar to dopamine, amphetamine dose-dependently increases the level of synaptic norepinephrine, the direct precursor of <a href="/wiki/Epinephrine" title="Epinephrine">epinephrine</a>.<sup id="cite_ref-Trace_Amines_38-1" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup><sup id="cite_ref-cognition_enhancers_115-2" class="reference"><a href="#cite_note-cognition_enhancers-115"><span>[</span>98<span>]</span></a></sup> Based upon neuronal <abbr title="trace amine-associated receptor 1">TAAR1</abbr> <abbr title="messenger RNA">mRNA</abbr> expression, amphetamine is thought to affect norepinephrine analogously to dopamine.<sup id="cite_ref-Miller_28-21" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-7" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup><sup id="cite_ref-TAAR1_Review_118-1" class="reference"><a href="#cite_note-TAAR1_Review-118"><span>[</span>101<span>]</span></a></sup> In other words, amphetamine induces TAAR1-mediated efflux and <span class="nowrap">non-competitive</span> reuptake inhibition at phosphorylated <abbr title="norepinephrine transporter">NET</abbr>, competitive NET reuptake inhibition, and norepinephrine release from <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>.<sup id="cite_ref-Miller_28-22" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-8" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Serotonin">Serotonin</span></h4>
<p>Amphetamine exerts analogous, yet less pronounced, effects on serotonin as on dopamine and norepinephrine.<sup id="cite_ref-Miller_28-23" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-cognition_enhancers_115-3" class="reference"><a href="#cite_note-cognition_enhancers-115"><span>[</span>98<span>]</span></a></sup> Amphetamine affects serotonin via <abbr title="vesicular monoamine transporter 2">VMAT2</abbr> and, like norepinephrine, is thought to phosphorylate <abbr title="serotonin transporter">SERT</abbr> via <abbr title="trace amine-associated receptor 1">TAAR1</abbr>.<sup id="cite_ref-Miller_28-24" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-E_Weihe_110-9" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Acetylcholine">Acetylcholine</span></h4>
<p>Amphetamine has no direct effect on acetylcholine, but several studies have noted that acetylcholine release increases after its use.<sup id="cite_ref-Acetylcholine_111-1" class="reference"><a href="#cite_note-Acetylcholine-111"><span>[</span>94<span>]</span></a></sup><sup id="cite_ref-MEDRS-Cholinergic_112-1" class="reference"><a href="#cite_note-MEDRS-Cholinergic-112"><span>[</span>95<span>]</span></a></sup> In lab animals, high doses of amphetamine greatly increase acetylcholine levels in certain brain regions, including the <a href="/wiki/Hippocampus" title="Hippocampus">hippocampus</a>, <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a>, and <a href="/wiki/Nucleus_accumbens" title="Nucleus accumbens">nucleus accumbens</a>.<sup id="cite_ref-Acetylcholine_111-2" class="reference"><a href="#cite_note-Acetylcholine-111"><span>[</span>94<span>]</span></a></sup> In humans, a similar phenomenon occurs via the cholinergic–dopaminergic link, mediated by the neuropeptide <a href="/wiki/Ghrelin" title="Ghrelin">ghrelin</a>, in the <a href="/wiki/Ventral_tegmentum" title="Ventral tegmentum" class="mw-redirect">ventral tegmentum</a>.<sup id="cite_ref-MEDRS-Cholinergic_112-2" class="reference"><a href="#cite_note-MEDRS-Cholinergic-112"><span>[</span>95<span>]</span></a></sup> This heightened <a href="/wiki/Cholinergic" title="Cholinergic">cholinergic</a> activity leads to increased <a href="/wiki/Nicotinic_receptor" title="Nicotinic receptor" class="mw-redirect">nicotinic receptor</a> activation in the <abbr title="central nervous system">CNS</abbr>, a factor which likely contributes to the <a href="/wiki/Nootropic" title="Nootropic">nootropic</a> effects of amphetamine.<sup id="cite_ref-pmid21334367_119-0" class="reference"><a href="#cite_note-pmid21334367-119"><span>[</span>102<span>]</span></a></sup></p>
<h4><span class="mw-headline" id="Other_relevant_activity">Other relevant activity</span></h4>
<p>Extracellular levels of <a href="/wiki/Glutamate" title="Glutamate" class="mw-redirect">glutamate</a>, the primary <a href="/wiki/Neurotransmitter#Excitatory_and_inhibitory" title="Neurotransmitter">excitatory neurotransmitter</a> in the brain, have been shown to increase upon exposure to amphetamine.<sup id="cite_ref-glutamate1_113-1" class="reference"><a href="#cite_note-glutamate1-113"><span>[</span>96<span>]</span></a></sup><sup id="cite_ref-glutamate2_114-1" class="reference"><a href="#cite_note-glutamate2-114"><span>[</span>97<span>]</span></a></sup> This <a href="/wiki/Cotransmission" title="Cotransmission" class="mw-redirect">cotransmission</a> effect was found in the mesolimbic pathway, an area of the brain implicated in reward, where amphetamine is known to affect dopamine neurotransmission.<sup id="cite_ref-glutamate1_113-2" class="reference"><a href="#cite_note-glutamate1-113"><span>[</span>96<span>]</span></a></sup><sup id="cite_ref-glutamate2_114-2" class="reference"><a href="#cite_note-glutamate2-114"><span>[</span>97<span>]</span></a></sup> Amphetamine also induces effluxion of <a href="/wiki/Histamine" title="Histamine">histamine</a> from synaptic vesicles in <abbr title="central nervous system">CNS</abbr> <a href="/wiki/Mast_cell" title="Mast cell">mast cells</a> and histaminergic neurons through <abbr title="vesicular monoamine transporter 2">VMAT2</abbr>.<sup id="cite_ref-E_Weihe_110-10" class="reference"><a href="#cite_note-E_Weihe-110"><span>[</span>93<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pharmacokinetics">Pharmacokinetics</span></h3>
<p>The oral <a href="/wiki/Bioavailability" title="Bioavailability">bioavailability</a> of amphetamine varies with gastrointestinal pH;<sup id="cite_ref-FDA_Interactions_101-8" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> it is well absorbed from the gut, and bioavailability is typically over&#160;75% for dextroamphetamine.<sup id="cite_ref-Drugbank-dexamph_1-1" class="reference"><a href="#cite_note-Drugbank-dexamph-1"><span>[</span>1<span>]</span></a></sup> Amphetamine is a weak base with a <a href="/wiki/Acid_dissociation_constant" title="Acid dissociation constant">pKa</a> of <span class="nowrap">9–10</span>;<sup id="cite_ref-FDA_Pharmacokinetics_3-6" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> consequently, when the pH is basic, more of the drug is in its <a href="/wiki/Lipid" title="Lipid">lipid</a> soluble <a href="/wiki/Free_base" title="Free base">free base</a> form, and more is absorbed through the lipid-rich <a href="/wiki/Cell_membranes" title="Cell membranes" class="mw-redirect">cell membranes</a> of the gut <a href="/wiki/Epithelium" title="Epithelium">epithelium</a>.<sup id="cite_ref-FDA_Pharmacokinetics_3-7" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-FDA_Interactions_101-9" class="reference"><a href="#cite_note-FDA_Interactions-101"><span>[</span>84<span>]</span></a></sup> Conversely, an acidic pH means the drug is predominantly in a water soluble <a href="/wiki/Cation" title="Cation" class="mw-redirect">cationic</a> (salt) form, and less is absorbed.<sup id="cite_ref-FDA_Pharmacokinetics_3-8" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> Approximately <span class="nowrap">15–40%</span> of amphetamine circulating in the bloodstream is bound to <a href="/wiki/Plasma_protein" title="Plasma protein" class="mw-redirect">plasma proteins</a>.<sup id="cite_ref-Drugbank-amph_2-1" class="reference"><a href="#cite_note-Drugbank-amph-2"><span>[</span>2<span>]</span></a></sup></p>
<p>The <a href="/wiki/Biological_half-life" title="Biological half-life">half-life</a> of amphetamine enantiomers differ and vary with urine pH.<sup id="cite_ref-FDA_Pharmacokinetics_3-9" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are <span class="nowrap">9–11</span>&#160;hours and <span class="nowrap">11–14</span>&#160;hours, respectively.<sup id="cite_ref-FDA_Pharmacokinetics_3-10" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> An acidic diet will reduce the enantiomer half-lives to <span class="nowrap">8–11</span>&#160;hours; an alkaline diet will increase the range to <span class="nowrap">16–31</span>&#160;hours.<sup id="cite_ref-Pubchem_Kinetics_120-0" class="reference"><a href="#cite_note-Pubchem_Kinetics-120"><span>[</span>103<span>]</span></a></sup><sup id="cite_ref-121" class="reference"><a href="#cite_note-121"><span>[</span>104<span>]</span></a></sup> The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3&#160;hours and 7&#160;hours post-dose respectively.<sup id="cite_ref-FDA_Pharmacokinetics_3-11" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> Amphetamine is eliminated via the kidneys, with <span class="nowrap">30–40%</span> of the drug being excreted unchanged at normal urinary pH.<sup id="cite_ref-FDA_Pharmacokinetics_3-12" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> When the urinary pH is basic, amphetamine is in its free base form, so less is excreted.<sup id="cite_ref-FDA_Pharmacokinetics_3-13" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> When urine pH is abnormal, the urinary recovery of amphetamine may range from a low of&#160;1% to a high of&#160;75%, depending mostly upon whether urine is too basic or acidic, respectively.<sup id="cite_ref-FDA_Pharmacokinetics_3-14" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> Amphetamine is usually eliminated within two days of the last oral dose.<sup id="cite_ref-Pubchem_Kinetics_120-1" class="reference"><a href="#cite_note-Pubchem_Kinetics-120"><span>[</span>103<span>]</span></a></sup> Apparent half-life and duration of effect increase with repeated use and accumulation of the drug.<sup id="cite_ref-Flomenbaum_2006_122-0" class="reference"><a href="#cite_note-Flomenbaum_2006-122"><span>[</span>105<span>]</span></a></sup></p>
<p>The prodrug lisdexamfetamine is not as sensitive to pH as amphetamine when being absorbed in the gastrointestinal tract;<sup id="cite_ref-FDA_Vyvanse_123-0" class="reference"><a href="#cite_note-FDA_Vyvanse-123"><span>[</span>106<span>]</span></a></sup> following absorption into the blood stream, it is converted by red blood cells to dextroamphetamine via <a href="/wiki/Hydrolysis" title="Hydrolysis">hydrolysis</a>.<sup id="cite_ref-FDA_Vyvanse_123-1" class="reference"><a href="#cite_note-FDA_Vyvanse-123"><span>[</span>106<span>]</span></a></sup> The elimination half-life of lisdexamfetamine is generally less than one hour.<sup id="cite_ref-FDA_Vyvanse_123-2" class="reference"><a href="#cite_note-FDA_Vyvanse-123"><span>[</span>106<span>]</span></a></sup></p>
<p>CYP2D6, <a href="/wiki/Dopamine_%CE%B2-hydroxylase" title="Dopamine β-hydroxylase" class="mw-redirect">dopamine β-hydroxylase</a>, and <a href="/wiki/Flavin-containing_monooxygenase" title="Flavin-containing monooxygenase">flavin-containing monooxygenase</a> are the only enzymes currently known to metabolize amphetamine in humans.<sup id="cite_ref-DBH_ref_4-1" class="reference"><a href="#cite_note-DBH_ref-4"><span>[</span>4<span>]</span></a></sup><sup id="cite_ref-FMO_5-1" class="reference"><a href="#cite_note-FMO-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-DrugBank_Enzymes_124-0" class="reference"><a href="#cite_note-DrugBank_Enzymes-124"><span>[</span>107<span>]</span></a></sup> Amphetamine has a variety of excreted metabolic products, including <span class="nowrap"><a href="/wiki/4-hydroxyamfetamine" title="4-hydroxyamfetamine" class="mw-redirect">4-hydroxyamfetamine</a></span>, <span class="nowrap"><a href="/wiki/4-hydroxynorephedrine" title="4-hydroxynorephedrine" class="mw-redirect">4-hydroxynorephedrine</a></span>, <span class="nowrap"><a href="/wiki/4-hydroxyphenylacetone" title="4-hydroxyphenylacetone" class="mw-redirect">4-hydroxyphenylacetone</a></span>, <a href="/wiki/Benzoic_acid" title="Benzoic acid">benzoic acid</a>, <a href="/wiki/Hippuric_acid" title="Hippuric acid">hippuric acid</a>, <a href="/wiki/Norephedrine" title="Norephedrine" class="mw-redirect">norephedrine</a>, and <a href="/wiki/Phenylacetone" title="Phenylacetone">phenylacetone</a>.<sup id="cite_ref-FDA_Pharmacokinetics_3-15" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-Pubchem_Kinetics_120-2" class="reference"><a href="#cite_note-Pubchem_Kinetics-120"><span>[</span>103<span>]</span></a></sup><sup id="cite_ref-Metabolites_125-0" class="reference"><a href="#cite_note-Metabolites-125"><span>[</span>108<span>]</span></a></sup> Among these metabolites, the active <a href="/wiki/Sympathomimetics" title="Sympathomimetics" class="mw-redirect">sympathomimetics</a> are <span class="nowrap">4‑hydroxyamphetamine</span>,<sup id="cite_ref-126" class="reference"><a href="#cite_note-126"><span>[</span>109<span>]</span></a></sup> <span class="nowrap">4‑hydroxynorephedrine</span>,<sup id="cite_ref-127" class="reference"><a href="#cite_note-127"><span>[</span>110<span>]</span></a></sup> and norephedrine.<sup id="cite_ref-128" class="reference"><a href="#cite_note-128"><span>[</span>111<span>]</span></a></sup> The main metabolic pathways involve aromatic para-hydroxylation, aliphatic alpha- and beta-hydroxylation, N-oxidation, N-dealkylation, and deamination.<sup id="cite_ref-FDA_Pharmacokinetics_3-16" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-Pubchem_Kinetics_120-3" class="reference"><a href="#cite_note-Pubchem_Kinetics-120"><span>[</span>103<span>]</span></a></sup> The known pathways and detectable metabolites include:<sup id="cite_ref-FDA_Pharmacokinetics_3-17" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup><sup id="cite_ref-FMO_5-2" class="reference"><a href="#cite_note-FMO-5"><span>[</span>5<span>]</span></a></sup><sup id="cite_ref-Metabolites_125-1" class="reference"><a href="#cite_note-Metabolites-125"><span>[</span>108<span>]</span></a></sup></p>
<center>
<div class="thumb tnone">
<div class="thumbinner" style="width:692px;">
<div style="clear: both; font-weight: bold; text-align: center; background-color: transparent">
<p>Metabolic pathways of amphetamine</p>
</div>
<div style="position:relative; width:690px; height:375px; overflow:hidden; border:solid #ccc 1px; background-color:white;">
<div style="left:-10px; top:3px; width:700px; position:absolute"><a href="/wiki/File:Amph_Pathway.png" class="image"><img alt="Graphic of several routes of amphetamine metabolism" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/4e/Amph_Pathway.png/700px-Amph_Pathway.png" width="700" height="386" srcset="//upload.wikimedia.org/wikipedia/commons/4/4e/Amph_Pathway.png 1.5x, //upload.wikimedia.org/wikipedia/commons/4/4e/Amph_Pathway.png 2x" /></a></div>
<div style="text-align:center; font-size:16px; line-height:110%;">
<div id="annotation_10x350" style="position:absolute; left:10px; top:350px; line-height:110%"><span style="background-color:transparent; color:black"><span style="background-color:transparent;"><a href="/wiki/P-hydroxyphenylacetone" title="P-hydroxyphenylacetone" class="mw-redirect">4-Hydroxyphenylacetone</a></span></span></div>
<div id="annotation_220x350" style="position:absolute; left:220px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Phenylacetone" title="Phenylacetone">Phenylacetone</a></span></div>
<div id="annotation_390x350" style="position:absolute; left:390px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Benzoic_acid" title="Benzoic acid">Benzoic acid</a></span></div>
<div id="annotation_560x350" style="position:absolute; left:560px; top:350px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Hippuric_acid" title="Hippuric acid">Hippuric acid</a></span></div>
<div id="annotation_45x220" style="position:absolute; left:45px; top:220px; line-height:110%"><span style="background-color:transparent;">Amphetamine</span></div>
<div id="annotation_300x220" style="position:absolute; left:300px; top:220px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></span></div>
<div id="annotation_255x90" style="position:absolute; left:255px; top:90px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/4-Hydroxyamphetamine" title="4-Hydroxyamphetamine" class="mw-redirect">4-Hydroxyamphetamine</a></span></div>
<div id="annotation_490x90" style="position:absolute; left:490px; top:90px; line-height:110%"><span style="background-color:transparent;"><a href="/wiki/P-Hydroxynorephedrine" title="P-Hydroxynorephedrine">4-Hydroxynorephedrine</a></span></div>
<div id="annotation_145x115" style="position:absolute; left:145px; top:115px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_385x115" style="position:absolute; left:385px; top:115px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_165x270" style="position:absolute; left:165px; top:270px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Para-<br />
Hydroxylation</span></div>
<div id="annotation_190x160" style="position:absolute; left:190px; top:160px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Beta-<br />
Hydroxylation</span></div>
<div id="annotation_415x20" style="position:absolute; left:415px; top:20px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Beta-<br />
Hydroxylation</span></div>
<div id="annotation_210x220" style="position:absolute; left:210px; top:220px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Oxidative<br />
Deamination</span></div>
<div id="annotation_335x282" style="position:absolute; left:335px; top:282px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Oxidation</span></div>
<div id="annotation_480x270" style="position:absolute; left:480px; top:270px; font-size:10px; line-height:12px;"><span style="background-color:transparent;">Glycine<br />
Conjugation</span></div>
</div>
</div>
<div class="thumbcaption" style="clear:left">The primary active metabolites of amphetamine are <span class="nowrap">4-hydroxyamphetamine</span> and norephedrine;<sup id="cite_ref-Metabolites_125-2" class="reference"><a href="#cite_note-Metabolites-125"><span>[</span>108<span>]</span></a></sup> at normal urine pH, about <span class="nowrap">30–40%</span> of amphetamine is excreted unchanged and roughly&#160;50% is excreted as the inactive metabolites (bottom row).<sup id="cite_ref-FDA_Pharmacokinetics_3-18" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup> The remaining <span class="nowrap">10–20%</span> is excreted as the active metabolites.<sup id="cite_ref-FDA_Pharmacokinetics_3-19" class="reference"><a href="#cite_note-FDA_Pharmacokinetics-3"><span>[</span>3<span>]</span></a></sup></div>
</div>
</div>
</center>
<div style="clear:both;"></div>
<h3><span class="mw-headline" id="Related_endogenous_compounds">Related endogenous compounds</span></h3>
<div class="rellink boilerplate seealso">For more details on related compounds, see <a href="/wiki/Trace_amines" title="Trace amines" class="mw-redirect">Trace amines</a>.</div>
<p>Amphetamine has a very similar structure and function to the <a href="//en.wiktionary.org/wiki/endogenous" class="extiw" title="wikt:endogenous">endogenous</a> trace amines, which are naturally occurring molecules produced in the human body and brain.<sup id="cite_ref-Miller_28-25" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_38-2" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup> Among this group, the most closely related compounds are <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamine</a>, the parent compound of amphetamine, and <span class="nowrap"><a href="/wiki/N-methylphenethylamine" title="N-methylphenethylamine" class="mw-redirect"><i>N</i>-methylphenethylamine</a></span>, an <a href="/wiki/Isomer" title="Isomer">isomer</a> of amphetamine (i.e., it has an identical molecular formula).<sup id="cite_ref-Miller_28-26" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_38-3" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_129-0" class="reference"><a href="#cite_note-Renaissance_GPCR-129"><span>[</span>112<span>]</span></a></sup> In humans, phenethylamine is produced directly from <a href="/wiki/L-phenylalanine" title="L-phenylalanine" class="mw-redirect">L-phenylalanine</a> by the <a href="/wiki/Aromatic_amino_acid_decarboxylase" title="Aromatic amino acid decarboxylase" class="mw-redirect">aromatic amino acid decarboxylase</a> (AADC) enzyme, which converts <a href="/wiki/L-DOPA" title="L-DOPA">L-DOPA</a> into dopamine as well.<sup id="cite_ref-Trace_Amines_38-4" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_129-1" class="reference"><a href="#cite_note-Renaissance_GPCR-129"><span>[</span>112<span>]</span></a></sup> In turn, <span class="nowrap"><i>N</i>‑methylphenethylamine</span> is metabolized from phenethylamine by <a href="/wiki/Phenylethanolamine_N-methyltransferase" title="Phenylethanolamine N-methyltransferase">phenylethanolamine N-methyltransferase</a>, the same enzyme that metabolizes norepinephrine into epinephrine.<sup id="cite_ref-Trace_Amines_38-5" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_129-2" class="reference"><a href="#cite_note-Renaissance_GPCR-129"><span>[</span>112<span>]</span></a></sup> Like amphetamine, both phenethylamine and <span class="nowrap"><i>N</i>‑methylphenethylamine</span> regulate monoamine neurotransmission via <abbr title="trace amine-associated receptor 1">TAAR1</abbr>;<sup id="cite_ref-Miller_28-27" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_129-3" class="reference"><a href="#cite_note-Renaissance_GPCR-129"><span>[</span>112<span>]</span></a></sup> unlike amphetamine, both of these substances are broken down by <abbr title="monoamine oxidase B">MAO-B</abbr>, and therefore have a shorter half-life than amphetamine.<sup id="cite_ref-Trace_Amines_38-6" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup><sup id="cite_ref-Renaissance_GPCR_129-4" class="reference"><a href="#cite_note-Renaissance_GPCR-129"><span>[</span>112<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Physical_and_chemical_properties">Physical and chemical properties</span></h2>
<div class="thumb tright" style="width: 262px;">
<div class="thumbinner">
<div style="margin: 1px; width: 252px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Freebase.png" class="image"><img alt="An image of amphetamine free base" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/51/Amphetamine_Freebase.png/250px-Amphetamine_Freebase.png" width="250" height="211" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/51/Amphetamine_Freebase.png/375px-Amphetamine_Freebase.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/51/Amphetamine_Freebase.png/500px-Amphetamine_Freebase.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">A vial of the colorless amphetamine free base</div>
</div>
<div style="margin: 1px; width: 252px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Structural_Formulae.png" class="image"><img alt="Graphical representation of Amphetamine stereoisomers" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e1/Amphetamine_Structural_Formulae.png/250px-Amphetamine_Structural_Formulae.png" width="250" height="63" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e1/Amphetamine_Structural_Formulae.png/375px-Amphetamine_Structural_Formulae.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e1/Amphetamine_Structural_Formulae.png/500px-Amphetamine_Structural_Formulae.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">The <a href="/wiki/Skeletal_structure" title="Skeletal structure" class="mw-redirect">skeletal structures</a> of <abbr title="Levoamphetamine">L-amph</abbr> and <abbr title="Dextroamphetamine">D-amph</abbr></div>
</div>
<div style="margin: 1px; width: 252px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_and_P2P.png" class="image"><img alt="An image of phenyl-2-nitropropene and amphetamine hydrochloride" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/49/Amphetamine_and_P2P.png/250px-Amphetamine_and_P2P.png" width="250" height="202" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/49/Amphetamine_and_P2P.png/375px-Amphetamine_and_P2P.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/49/Amphetamine_and_P2P.png/500px-Amphetamine_and_P2P.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Amphetamine hydrochloride (left bowl)<br />
<a href="/wiki/Phenyl-2-nitropropene" title="Phenyl-2-nitropropene">Phenyl-2-nitropropene</a> (right cups)</div>
</div>
</div>
</div>
<p>Amphetamine is a <a href="/wiki/Methyl" title="Methyl" class="mw-redirect">methyl</a> <a href="/wiki/Homologous_series" title="Homologous series">homolog</a> of the mammalian neurotransmitter <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamine</a> with the chemical formula <a href="/wiki/Carbon" title="Carbon">C</a><sub>9</sub><a href="/wiki/Hydrogen" title="Hydrogen">H</a><sub>13</sub><a href="/wiki/Nitrogen" title="Nitrogen">N</a>. The carbon atom adjacent to the <a href="/wiki/Primary_amine" title="Primary amine" class="mw-redirect">primary amine</a> is a <a href="/wiki/Stereogenic_center" title="Stereogenic center" class="mw-redirect">stereogenic center</a>, and amphetamine is composed of a <a href="/wiki/Racemic" title="Racemic" class="mw-redirect">racemic</a> 1:1 mixture of two <a href="/wiki/Enantiomer" title="Enantiomer">enantiomeric</a> mirror images.<sup id="cite_ref-DrugBank1_9-1" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup> This racemic mixture can be separated into its optical isomers:<sup id="cite_ref-130" class="reference"><a href="#cite_note-130"><span>[</span>note 11<span>]</span></a></sup> <a href="/wiki/Levoamphetamine" title="Levoamphetamine">levoamphetamine</a> and <a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">dextroamphetamine</a>.<sup id="cite_ref-DrugBank1_9-2" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup> Physically, at room temperature, the pure <a href="/wiki/Free_base" title="Free base">free base</a> of amphetamine is a mobile, colorless, and <a href="/wiki/Volatility_(chemistry)" title="Volatility (chemistry)">volatile</a> <a href="/wiki/Liquid" title="Liquid">liquid</a> with a characteristically strong <a href="/wiki/Amine" title="Amine">amine</a> odor, and acrid, burning taste.<sup id="cite_ref-Properties_131-0" class="reference"><a href="#cite_note-Properties-131"><span>[</span>113<span>]</span></a></sup> Frequently prepared solid salts of amphetamine include amphetamine aspartate,<sup id="cite_ref-FDA_Abuse_.26_OD_16-11" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup> hydrochloride,<sup id="cite_ref-132" class="reference"><a href="#cite_note-132"><span>[</span>114<span>]</span></a></sup> phosphate,<sup id="cite_ref-133" class="reference"><a href="#cite_note-133"><span>[</span>115<span>]</span></a></sup> saccharate,<sup id="cite_ref-FDA_Abuse_.26_OD_16-12" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup> and sulfate,<sup id="cite_ref-FDA_Abuse_.26_OD_16-13" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup> the last of which is the most common amphetamine salt.<sup id="cite_ref-EMC_37-1" class="reference"><a href="#cite_note-EMC-37"><span>[</span>30<span>]</span></a></sup> Amphetamine is also the parent compound of <a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">its own structural class</a>, which includes a number of psychoactive <a href="/wiki/Derivative_(chemistry)" title="Derivative (chemistry)">derivatives</a>.<sup id="cite_ref-DrugBank1_9-3" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup> In organic chemistry, amphetamine is an excellent <a href="/wiki/Chiral_ligand" title="Chiral ligand">chiral ligand</a> for the <a href="/wiki/Stereoselective_synthesis" title="Stereoselective synthesis" class="mw-redirect">stereoselective synthesis</a> of <span class="nowrap"><a href="/wiki/1,1%27-bi-2-naphthol" title="1,1'-bi-2-naphthol" class="mw-redirect">1,1'-bi-2-naphthol</a></span>.<sup id="cite_ref-Chiral_Ligand_134-0" class="reference"><a href="#cite_note-Chiral_Ligand-134"><span>[</span>116<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Derivatives">Derivatives</span></h3>
<div class="rellink">For a more comprehensive list, see <a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">Substituted amphetamine</a>.</div>
<p>Amphetamine derivatives, often referred to as "amphetamines" or "substituted amphetamines", are a broad range of chemicals that contain amphetamine as a "backbone".<sup id="cite_ref-DrugBank_Header_135-0" class="reference"><a href="#cite_note-DrugBank_Header-135"><span>[</span>117<span>]</span></a></sup><sup id="cite_ref-Schep_136-0" class="reference"><a href="#cite_note-Schep-136"><span>[</span>118<span>]</span></a></sup> The class includes stimulants like <a href="/wiki/Methamphetamine" title="Methamphetamine">methamphetamine</a>, serotonergic <a href="/wiki/Empathogens" title="Empathogens" class="mw-redirect">empathogens</a> like <a href="/wiki/MDMA" title="MDMA">MDMA</a> (ecstasy), and <a href="/wiki/Decongestant" title="Decongestant">decongestants</a> like <a href="/wiki/Ephedrine" title="Ephedrine">ephedrine</a>, among other subgroups.<sup id="cite_ref-DrugBank_Header_135-1" class="reference"><a href="#cite_note-DrugBank_Header-135"><span>[</span>117<span>]</span></a></sup><sup id="cite_ref-Schep_136-1" class="reference"><a href="#cite_note-Schep-136"><span>[</span>118<span>]</span></a></sup> This class of chemicals is sometimes referred to collectively as the "amphetamine family."<sup id="cite_ref-137" class="reference"><a href="#cite_note-137"><span>[</span>119<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Synthesis">Synthesis</span></h3>
<div class="dablink">For more details on illicit amphetamine synthesis, see <a href="/wiki/History_and_culture_of_amphetamines#Illegal_synthesis" title="History and culture of amphetamines">Illegal synthesis of substituted amphetamines</a>.</div>
<p>Since the first preparation was reported in 1887,<sup id="cite_ref-Vermont_138-0" class="reference"><a href="#cite_note-Vermont-138"><span>[</span>120<span>]</span></a></sup> many synthetic routes to amphetamine have been developed.<sup id="cite_ref-Allen_Cantrell_1989_139-0" class="reference"><a href="#cite_note-Allen_Cantrell_1989-139"><span>[</span>121<span>]</span></a></sup><sup id="cite_ref-Allen_Ely_2009_140-0" class="reference"><a href="#cite_note-Allen_Ely_2009-140"><span>[</span>122<span>]</span></a></sup> Many are based on classic <a href="/wiki/Organic_reaction" title="Organic reaction">organic reactions</a>. One such example is the <a href="/wiki/Friedel%E2%80%93Crafts_reaction#Friedel.E2.80.93Crafts_alkylation" title="Friedel–Crafts reaction">Friedel–Crafts alkylation</a> of <a href="/wiki/Chlorobenzene" title="Chlorobenzene">chlorobenzene</a> by <a href="/wiki/Allyl_chloride" title="Allyl chloride">allyl chloride</a> to yield beta chloropropylbenzene which is then reacted with ammonia to produce <a href="/wiki/Racemic" title="Racemic" class="mw-redirect">racemic</a> amphetamine (method 1).<sup id="cite_ref-pmid20985610_141-0" class="reference"><a href="#cite_note-pmid20985610-141"><span>[</span>123<span>]</span></a></sup> Another example employs the <a href="/wiki/Ritter_reaction" title="Ritter reaction">Ritter reaction</a> (method 2). In this route, <a href="/wiki/Allylbenzene" title="Allylbenzene" class="mw-redirect">allylbenzene</a> is reacted <a href="/wiki/Acetonitrile" title="Acetonitrile">acetonitrile</a> in <a href="/wiki/Sulfuric_acid" title="Sulfuric acid">sulfuric acid</a> to yield an <a href="/wiki/Organosulfate" title="Organosulfate">organosulfate</a> which in turn is treated with <a href="/wiki/Sodium_hydroxide" title="Sodium hydroxide">sodium hydroxide</a> to give amphetamine via an <a href="/wiki/Acetamide" title="Acetamide">acetamide</a> intermediate.<sup id="cite_ref-pmid18105933_142-0" class="reference"><a href="#cite_note-pmid18105933-142"><span>[</span>124<span>]</span></a></sup><sup id="cite_ref-Krimen_Cota_1969_143-0" class="reference"><a href="#cite_note-Krimen_Cota_1969-143"><span>[</span>125<span>]</span></a></sup> A third route starts with <span class="nowrap"><a href="/wiki/Ethyl_acetoacetate" title="Ethyl acetoacetate">ethyl 3-oxobutanoate</a></span> which through a double alkylation with <a href="/wiki/Methyl_iodide" title="Methyl iodide">methyl iodide</a> followed by <a href="/wiki/Benzyl_chloride" title="Benzyl chloride">benzyl chloride</a> can be converted into <span class="nowrap">2-methyl-3-phenyl-propanoic</span> acid. This synthetic intermediate can be transformed into amphetamine using either a <a href="/wiki/Hofmann_rearrangement" title="Hofmann rearrangement">Hofmann</a> or <a href="/wiki/Curtius_rearrangement" title="Curtius rearrangement">Curtius</a> rearrangement (method 3).<sup id="cite_ref-US2413493_144-0" class="reference"><a href="#cite_note-US2413493-144"><span>[</span>126<span>]</span></a></sup></p>
<p>A significant number of amphetamine syntheses feature a <a href="/wiki/Organic_redox_reaction#Organic_reductions" title="Organic redox reaction">reduction</a> of a <a href="/wiki/Nitro_group" title="Nitro group" class="mw-redirect">nitro</a>, <a href="/wiki/Imine" title="Imine">imine</a>, <a href="/wiki/Oxime" title="Oxime">oxime</a> or other nitrogen-containing <a href="/wiki/Functional_group" title="Functional group">functional group</a>.<sup id="cite_ref-Allen_Cantrell_1989_139-1" class="reference"><a href="#cite_note-Allen_Cantrell_1989-139"><span>[</span>121<span>]</span></a></sup> In one such example, a <a href="/wiki/Knoevenagel_condensation" title="Knoevenagel condensation">Knoevenagel condensation</a> of <a href="/wiki/Benzaldehyde" title="Benzaldehyde">benzaldehyde</a> with <a href="/wiki/Nitroethane" title="Nitroethane">nitroethane</a> yields <span class="nowrap"><a href="/wiki/Phenyl-2-nitropropene" title="Phenyl-2-nitropropene">phenyl-2-nitropropene</a></span>. The double bond and nitro group of this intermediate is <a href="/wiki/Organic_redox_reaction" title="Organic redox reaction">reduced</a> using either catalytic <a href="/wiki/Hydrogenation" title="Hydrogenation">hydrogenation</a> or by treatment with <a href="/wiki/Lithium_aluminium_hydride" title="Lithium aluminium hydride">lithium aluminium hydride</a> (method 4).<sup id="cite_ref-Delta_Isotope_145-0" class="reference"><a href="#cite_note-Delta_Isotope-145"><span>[</span>127<span>]</span></a></sup><sup id="cite_ref-Amph_Synth_146-0" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup> Another method is the reaction of <a href="/wiki/Phenylacetone" title="Phenylacetone">phenylacetone</a> with <a href="/wiki/Ammonia" title="Ammonia">ammonia</a>, producing an imine intermediate that is reduced to the primary amine using hydrogen over a palladium catalyst or lithium aluminum hydride (method 5).<sup id="cite_ref-Amph_Synth_146-1" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup></p>
<p>The most common route of both legal and illicit amphetamine synthesis employs a non-metal reduction known as the <a href="/wiki/Leuckart_reaction" title="Leuckart reaction">Leuckart reaction</a> (method 6).<sup id="cite_ref-EMC_37-2" class="reference"><a href="#cite_note-EMC-37"><span>[</span>30<span>]</span></a></sup><sup id="cite_ref-Amph_Synth_146-2" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup> In the first step, a reaction between phenylacetone and <a href="/wiki/Formamide" title="Formamide">formamide</a>, either using additional <a href="/wiki/Formic_acid" title="Formic acid">formic acid</a> or formamide itself as a reducing agent, yields <span class="nowrap"><a href="/wiki/N-formylamphetamine" title="N-formylamphetamine" class="mw-redirect"><i>N</i>-formylamphetamine</a></span>.<sup id="cite_ref-Amph_Synth_146-3" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup><sup id="cite_ref-147" class="reference"><a href="#cite_note-147"><span>[</span>129<span>]</span></a></sup> This intermediate is then hydrolyzed using hydrochloric acid, and subsequently basified, extracted with organic solvent, concentrated, and distilled to yield the free base.<sup id="cite_ref-Amph_Synth_146-4" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup> The free base is then dissolved in an organic solvent, sulfuric acid added, and amphetamine precipitates out as the sulfate salt.<sup id="cite_ref-Amph_Synth_146-5" class="reference"><a href="#cite_note-Amph_Synth-146"><span>[</span>128<span>]</span></a></sup></p>
<p>A number of <a href="/wiki/Chiral_resolution" title="Chiral resolution">chiral resolutions</a> have been developed to separate the two <a href="/wiki/Enantiomer" title="Enantiomer">enantiomers</a> of amphetamine.<sup id="cite_ref-Allen_Ely_2009_140-1" class="reference"><a href="#cite_note-Allen_Ely_2009-140"><span>[</span>122<span>]</span></a></sup> For example, racemic amphetamine can be treated with <span class="nowrap">d-<a href="/wiki/Tartaric_acid" title="Tartaric acid">tartaric acid</a></span> to form a <a href="/wiki/Diastereoisomer" title="Diastereoisomer" class="mw-redirect">diastereoisomeric</a> salt which is <a href="/wiki/Fractional_crystallization_(chemistry)" title="Fractional crystallization (chemistry)">fractionally crystallized</a> to yield dextroamphetamine.<sup id="cite_ref-US2276508_148-0" class="reference"><a href="#cite_note-US2276508-148"><span>[</span>130<span>]</span></a></sup> Chiral resolution remains the most economical method for obtaining optically pure amphetamine on a large scale.<sup id="cite_ref-Gray_2007_149-0" class="reference"><a href="#cite_note-Gray_2007-149"><span>[</span>131<span>]</span></a></sup> In addition, several <a href="/wiki/Enantioselective_synthesis" title="Enantioselective synthesis">enantioselective syntheses</a> of amphetamine have been developed. In one example, <a href="/wiki/Optically_pure" title="Optically pure" class="mw-redirect">optically pure</a> <span class="nowrap">(<i>R</i>)-1-phenyl-ethanamine</span> is condensed with <a href="/wiki/Phenylacetone" title="Phenylacetone">phenylacetone</a> to yield a chiral <a href="/wiki/Schiff_base" title="Schiff base">schiff base</a>. In the key step, this intermediate is reduced by <a href="/wiki/Catalytic_hydrogenation" title="Catalytic hydrogenation" class="mw-redirect">catalytic hydrogenation</a> with a transfer of chirality to the carbon atom alpha to the amino group. Cleavage of the <a href="/wiki/Benzylic" title="Benzylic" class="mw-redirect">benzylic</a> amine bond by hydrogenation yields optically pure dextroamphetamine.<sup id="cite_ref-Gray_2007_149-1" class="reference"><a href="#cite_note-Gray_2007-149"><span>[</span>131<span>]</span></a></sup></p>
<center>
<table>
<caption><b>Amphetamine synthetic routes</b></caption>
<tr valign="top">
<td>
<table>
<tr>
<td>
<div class="thumb tnone" style="width: 372px; margin: 0 auto;">
<div class="thumbinner">
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Friedel-Crafts_alkylation.svg" class="image"><img alt="Diagram of amphetamine synthesis by Friedel–Crafts alkylation" src="//upload.wikimedia.org/wikipedia/commons/thumb/3/37/Amphetamine_Friedel-Crafts_alkylation.svg/360px-Amphetamine_Friedel-Crafts_alkylation.svg.png" width="360" height="67" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/3/37/Amphetamine_Friedel-Crafts_alkylation.svg/540px-Amphetamine_Friedel-Crafts_alkylation.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/37/Amphetamine_Friedel-Crafts_alkylation.svg/720px-Amphetamine_Friedel-Crafts_alkylation.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 1: Synthesis by Friedel–Crafts alkylation</div>
</div>
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Ritter_Synthesis.svg" class="image"><img alt="Diagram of amphetamine via Ritter synthesis" src="//upload.wikimedia.org/wikipedia/commons/thumb/4/41/Amphetamine_Ritter_Synthesis.svg/360px-Amphetamine_Ritter_Synthesis.svg.png" width="360" height="136" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/4/41/Amphetamine_Ritter_Synthesis.svg/540px-Amphetamine_Ritter_Synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/4/41/Amphetamine_Ritter_Synthesis.svg/720px-Amphetamine_Ritter_Synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 2: Ritter synthesis</div>
</div>
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Hofmann_Curtius_Synthesis.svg" class="image"><img alt="Diagram of amphetamine synthesis via Hofmann and Curtius rearrangements" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Amphetamine_Hofmann_Curtius_Synthesis.svg/360px-Amphetamine_Hofmann_Curtius_Synthesis.svg.png" width="360" height="110" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Amphetamine_Hofmann_Curtius_Synthesis.svg/540px-Amphetamine_Hofmann_Curtius_Synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/bd/Amphetamine_Hofmann_Curtius_Synthesis.svg/720px-Amphetamine_Hofmann_Curtius_Synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 3: Synthesis via Hofmann and Curtius rearrangements</div>
</div>
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Knoevenagel_synthesis.svg" class="image"><img alt="Diagram of amphetamine synthesis by Knoevenagel condensation" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Amphetamine_Knoevenagel_synthesis.svg/360px-Amphetamine_Knoevenagel_synthesis.svg.png" width="360" height="58" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/99/Amphetamine_Knoevenagel_synthesis.svg/540px-Amphetamine_Knoevenagel_synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/99/Amphetamine_Knoevenagel_synthesis.svg/720px-Amphetamine_Knoevenagel_synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 4: Synthesis by Knoevenagel condensation</div>
</div>
</div>
</div>
</td>
</tr>
</table>
</td>
<td>
<table>
<tr>
<td>
<div class="thumb tnone" style="width: 372px; margin: 0 auto;">
<div class="thumbinner">
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_p2p_ammonia_synthesis.svg" class="image"><img alt="Diagram of amphetamine synthesis from phenylacetone and ammonia" src="//upload.wikimedia.org/wikipedia/commons/thumb/7/72/Amphetamine_p2p_ammonia_synthesis.svg/360px-Amphetamine_p2p_ammonia_synthesis.svg.png" width="360" height="60" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/7/72/Amphetamine_p2p_ammonia_synthesis.svg/540px-Amphetamine_p2p_ammonia_synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/72/Amphetamine_p2p_ammonia_synthesis.svg/720px-Amphetamine_p2p_ammonia_synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 5: Synthesis using phenylacetone and ammonia<br />
&#160;</div>
</div>
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_Leukart_synthesis.svg" class="image"><img alt="Diagram of amphetamine synthesis by the Leuckart reaction" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/8b/Amphetamine_Leukart_synthesis.svg/360px-Amphetamine_Leukart_synthesis.svg.png" width="360" height="127" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/8b/Amphetamine_Leukart_synthesis.svg/540px-Amphetamine_Leukart_synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/8b/Amphetamine_Leukart_synthesis.svg/720px-Amphetamine_Leukart_synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Method 6: Synthesis by the Leuckart reaction<br />
&#160;</div>
</div>
<div style="margin: 1px; width: 362px">
<div class="thumbimage"><a href="/wiki/File:Amphetamine_resolution_and_chiral_synthesis.svg" class="image"><img alt="Diagram of a chiral resolution of racemic amphetamine and a stereoselective synthesis" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/85/Amphetamine_resolution_and_chiral_synthesis.svg/360px-Amphetamine_resolution_and_chiral_synthesis.svg.png" width="360" height="164" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/85/Amphetamine_resolution_and_chiral_synthesis.svg/540px-Amphetamine_resolution_and_chiral_synthesis.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/85/Amphetamine_resolution_and_chiral_synthesis.svg/720px-Amphetamine_resolution_and_chiral_synthesis.svg.png 2x" /></a></div>
<div class="thumbcaption" style="clear:left">Top: Chiral resolution of amphetamine<br />
Bottom: Stereoselective synthesis of amphetamine</div>
</div>
</div>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</center>
<div style="clear:both;"></div>
<h3><span class="mw-headline" id="Detection_in_body_fluids">Detection in body fluids</span></h3>
<p>Amphetamine is frequently measured in urine or blood as part of a <a href="/wiki/Drug_test" title="Drug test">drug test</a> for sports, employment, poisoning diagnostics, and forensics.<sup id="cite_ref-153" class="reference"><a href="#cite_note-153"><span>[</span>ref-note 8<span>]</span></a></sup> Techniques such as <a href="/wiki/Immunoassay" title="Immunoassay">immunoassay</a>, which is the most common form of amphetamine test, may cross-react with a number of sympathomimetic drugs.<sup id="cite_ref-NAHMSA_testing_154-0" class="reference"><a href="#cite_note-NAHMSA_testing-154"><span>[</span>135<span>]</span></a></sup> Chromatographic methods specific for amphetamine are employed to prevent false positive results.<sup id="cite_ref-pmid15516295_155-0" class="reference"><a href="#cite_note-pmid15516295-155"><span>[</span>136<span>]</span></a></sup> Chiral separation techniques may be employed to help distinguish the source of the drug, whether prescription amphetamine, prescription amphetamine prodrugs, (e.g., <a href="/wiki/Selegiline" title="Selegiline">selegiline</a>), <a href="/wiki/Over-the-counter_drug" title="Over-the-counter drug">over-the-counter drug</a> products (e.g., <a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Vicks Vapoinhaler</a>) or illicitly obtained substituted amphetamines.<sup id="cite_ref-pmid15516295_155-1" class="reference"><a href="#cite_note-pmid15516295-155"><span>[</span>136<span>]</span></a></sup><sup id="cite_ref-pmid16105261_156-0" class="reference"><a href="#cite_note-pmid16105261-156"><span>[</span>137<span>]</span></a></sup><sup id="cite_ref-Baselt_2011_157-0" class="reference"><a href="#cite_note-Baselt_2011-157"><span>[</span>138<span>]</span></a></sup> Several prescription drugs produce amphetamine as a <a href="/wiki/Metabolite" title="Metabolite">metabolite</a>, including <a href="/wiki/Benzphetamine" title="Benzphetamine">benzphetamine</a>, <a href="/wiki/Clobenzorex" title="Clobenzorex">clobenzorex</a>, <a href="/wiki/Famprofazone" title="Famprofazone">famprofazone</a>, <a href="/wiki/Fenproporex" title="Fenproporex">fenproporex</a>, <a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">lisdexamfetamine</a>, <a href="/wiki/Mesocarb" title="Mesocarb">mesocarb</a>, <a href="/wiki/Methamphetamine" title="Methamphetamine">methamphetamine</a>, <a href="/wiki/Prenylamine" title="Prenylamine">prenylamine</a>, and <a href="/wiki/Selegiline" title="Selegiline">selegiline</a>, among others.<sup id="cite_ref-Amph_Uses_21-3" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-pmid10711406_158-0" class="reference"><a href="#cite_note-pmid10711406-158"><span>[</span>139<span>]</span></a></sup><sup id="cite_ref-pmid12024689_159-0" class="reference"><a href="#cite_note-pmid12024689-159"><span>[</span>140<span>]</span></a></sup> These compounds may produce positive results for amphetamine on <a href="/wiki/Drug_test" title="Drug test">drug tests</a>.<sup id="cite_ref-pmid10711406_158-1" class="reference"><a href="#cite_note-pmid10711406-158"><span>[</span>139<span>]</span></a></sup><sup id="cite_ref-pmid12024689_159-1" class="reference"><a href="#cite_note-pmid12024689-159"><span>[</span>140<span>]</span></a></sup> Amphetamine is generally only detectable by a standard drug test for approximately 24&#160;hours, although a high dose may be detectable for two to four days.<sup id="cite_ref-NAHMSA_testing_154-1" class="reference"><a href="#cite_note-NAHMSA_testing-154"><span>[</span>135<span>]</span></a></sup></p>
<p>For the assays, a study noted that an <a href="/wiki/Enzyme_multiplied_immunoassay_technique" title="Enzyme multiplied immunoassay technique">enzyme multiplied immunoassay technique</a> (EMIT) assay for amphetamine and methamphetamine may produce more false positives than <a href="/wiki/Liquid_chromatography%E2%80%93mass_spectrometry#Proteomics.2Fmetabolomics" title="Liquid chromatography–mass spectrometry">liquid chromatography–tandem mass spectrometry</a>.<sup id="cite_ref-pmid16105261_156-1" class="reference"><a href="#cite_note-pmid16105261-156"><span>[</span>137<span>]</span></a></sup> <a href="/wiki/Gas_chromatography%E2%80%93mass_spectrometry" title="Gas chromatography–mass spectrometry">Gas chromatography–mass spectrometry</a> (GC–MS) of amphetamine and methamphetamine with the derivatizing agent <span class="nowrap">(<i>S</i>)-(−)-trifluoroacetylprolyl</span> chloride allows for the detection of methamphetamine in urine.<sup id="cite_ref-pmid15516295_155-2" class="reference"><a href="#cite_note-pmid15516295-155"><span>[</span>136<span>]</span></a></sup> GC–MS of amphetamine and methamphetamine with the chiral derivatizing agent <a href="/wiki/Mosher%27s_acid" title="Mosher's acid">Mosher's&#160;acid chloride</a> allows for the detection of both dextroamphetamine and dextromethamphetamine in urine.<sup id="cite_ref-pmid15516295_155-3" class="reference"><a href="#cite_note-pmid15516295-155"><span>[</span>136<span>]</span></a></sup> Hence, the latter method may be used on samples that test positive using other methods to help distinguish between the various sources of the drug.<sup id="cite_ref-pmid15516295_155-4" class="reference"><a href="#cite_note-pmid15516295-155"><span>[</span>136<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History.2C_society.2C_and_culture">History, society, and culture</span></h2>
<div class="rellink relarticle mainarticle">Main article: <a href="/wiki/History_and_culture_of_amphetamines" title="History and culture of amphetamines">History and culture of substituted amphetamines</a></div>
<p>Amphetamine was first synthesized in 1887 in Germany by Romanian chemist <a href="/wiki/Laz%C4%83r_Edeleanu" title="Lazăr Edeleanu">Lazăr Edeleanu</a> who named it <i>phenylisopropylamine</i>;<sup id="cite_ref-Edeleanu_160-0" class="reference"><a href="#cite_note-Edeleanu-160"><span>[</span>141<span>]</span></a></sup><sup id="cite_ref-Vermont_138-1" class="reference"><a href="#cite_note-Vermont-138"><span>[</span>120<span>]</span></a></sup><sup id="cite_ref-161" class="reference"><a href="#cite_note-161"><span>[</span>142<span>]</span></a></sup><sup id="cite_ref-SynthHistory_162-0" class="reference"><a href="#cite_note-SynthHistory-162"><span>[</span>143<span>]</span></a></sup> its stimulant effects remained unknown until 1927, when it was independently resynthesized by Gordon Alles and reported to have <a href="/wiki/Sympathomimetic" title="Sympathomimetic" class="mw-redirect">sympathomimetic</a> properties.<sup id="cite_ref-SynthHistory_162-1" class="reference"><a href="#cite_note-SynthHistory-162"><span>[</span>143<span>]</span></a></sup> Amphetamine had no pharmacological use until 1934, when <a href="/wiki/Smith,_Kline_and_French" title="Smith, Kline and French" class="mw-redirect">Smith, Kline and French</a> began selling it as an <a href="/wiki/Inhaler" title="Inhaler">inhaler</a> under the trade name <a href="/wiki/Benzedrine" title="Benzedrine">Benzedrine</a> as a decongestant.<sup id="cite_ref-Benzedrine_22-2" class="reference"><a href="#cite_note-Benzedrine-22"><span>[</span>20<span>]</span></a></sup> During World War II, amphetamines and methamphetamine were used extensively by both the Allied and Axis forces for their stimulant and performance-enhancing effects.<sup id="cite_ref-Vermont_138-2" class="reference"><a href="#cite_note-Vermont-138"><span>[</span>120<span>]</span></a></sup><sup id="cite_ref-163" class="reference"><a href="#cite_note-163"><span>[</span>144<span>]</span></a></sup><sup id="cite_ref-pmid22849208_164-0" class="reference"><a href="#cite_note-pmid22849208-164"><span>[</span>145<span>]</span></a></sup> As the addictive properties of the drug became known, governments began to place strict controls on the sale of amphetamine.<sup id="cite_ref-Vermont_138-3" class="reference"><a href="#cite_note-Vermont-138"><span>[</span>120<span>]</span></a></sup> For example, during the early 1970s in the United States, amphetamine became a <a href="/wiki/Schedule_II_(US)" title="Schedule II (US)" class="mw-redirect">schedule II controlled substance</a> under the <a href="/wiki/Controlled_Substances_Act" title="Controlled Substances Act">Controlled Substances Act</a>.<sup id="cite_ref-165" class="reference"><a href="#cite_note-165"><span>[</span>146<span>]</span></a></sup> In spite of strict government controls, amphetamine has been used legally or illicitly by people from a variety of backgrounds, including authors,<sup id="cite_ref-166" class="reference"><a href="#cite_note-166"><span>[</span>147<span>]</span></a></sup> musicians,<sup id="cite_ref-167" class="reference"><a href="#cite_note-167"><span>[</span>148<span>]</span></a></sup> mathematicians,<sup id="cite_ref-168" class="reference"><a href="#cite_note-168"><span>[</span>149<span>]</span></a></sup> and athletes.<sup id="cite_ref-Ergogenics_17-10" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Legal_status">Legal status</span></h3>
<p>As a result of the <a href="/wiki/United_Nations" title="United Nations">United Nations</a> <a href="/wiki/Convention_on_Psychotropic_Substances" title="Convention on Psychotropic Substances">Convention on Psychotropic Substances</a>, amphetamine became a schedule II controlled substance, as defined in the treaty, in all (183) state parties.<sup id="cite_ref-UN_Convention_15-1" class="reference"><a href="#cite_note-UN_Convention-15"><span>[</span>13<span>]</span></a></sup> Consequently, it is heavily regulated in most countries.<sup id="cite_ref-isbn92-1-148223-2_169-0" class="reference"><a href="#cite_note-isbn92-1-148223-2-169"><span>[</span>150<span>]</span></a></sup><sup id="cite_ref-170" class="reference"><a href="#cite_note-170"><span>[</span>151<span>]</span></a></sup> Some countries, such as South Korea and Japan, have banned substituted amphetamines even for medical use.<sup id="cite_ref-urlMoving_to_Korea_brings_medical.2C_social_changes_171-0" class="reference"><a href="#cite_note-urlMoving_to_Korea_brings_medical.2C_social_changes-171"><span>[</span>152<span>]</span></a></sup><sup id="cite_ref-172" class="reference"><a href="#cite_note-172"><span>[</span>153<span>]</span></a></sup> In other nations, such as Canada (<a href="/wiki/Controlled_Drugs_and_Substances_Act" title="Controlled Drugs and Substances Act">schedule I drug</a>),<sup id="cite_ref-Canada_Control_173-0" class="reference"><a href="#cite_note-Canada_Control-173"><span>[</span>154<span>]</span></a></sup> the United States (<a href="/wiki/Schedule_II_(US)" title="Schedule II (US)" class="mw-redirect">schedule II drug</a>),<sup id="cite_ref-FDA_Abuse_.26_OD_16-14" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup> Thailand (<a href="/wiki/Law_of_Thailand#Criminal_Law" title="Law of Thailand">category 1 narcotic</a>),<sup id="cite_ref-174" class="reference"><a href="#cite_note-174"><span>[</span>155<span>]</span></a></sup> and United Kingdom (<a href="/wiki/Misuse_of_Drugs_Act_1971" title="Misuse of Drugs Act 1971">class B drug</a>),<sup id="cite_ref-175" class="reference"><a href="#cite_note-175"><span>[</span>156<span>]</span></a></sup> amphetamine is in a restrictive national drug schedule that allows for its use as a medical treatment.<sup id="cite_ref-Nonmedical_20-1" class="reference"><a href="#cite_note-Nonmedical-20"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-World_Drug_Report_23-1" class="reference"><a href="#cite_note-World_Drug_Report-23"><span>[</span>21<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="Pharmaceutical_products">Pharmaceutical products</span></h3>
<p>The only currently prescribed amphetamine formulation that contains both enantiomers is <a href="/wiki/Adderall" title="Adderall">Adderall</a>.<sup id="cite_ref-Adderall_26-1" class="reference"><a href="#cite_note-Adderall-26"><span>[</span>note 3<span>]</span></a></sup><sup id="cite_ref-DrugBank1_9-4" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-Amph_Uses_21-4" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup> Amphetamine is also prescribed in <a href="/wiki/Enantiopure_drug" title="Enantiopure drug">enantiopure</a> and <a href="/wiki/Prodrug" title="Prodrug">prodrug</a> form as dextroamphetamine and lisdexamfetamine respectively.<sup id="cite_ref-NDCD_25-1" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup><sup id="cite_ref-Vyvanse_176-0" class="reference"><a href="#cite_note-Vyvanse-176"><span>[</span>157<span>]</span></a></sup> Lisdexamfetamine is structurally different from amphetamine, and is inactive until it metabolizes into dextroamphetamine.<sup id="cite_ref-Vyvanse_176-1" class="reference"><a href="#cite_note-Vyvanse-176"><span>[</span>157<span>]</span></a></sup> The free base of racemic amphetamine was previously available as Benzedrine, Psychedrine, and Sympatedrine.<sup id="cite_ref-DrugBank1_9-5" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-Amph_Uses_21-5" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup> Levoamphetamine was previously available as Cydril.<sup id="cite_ref-Amph_Uses_21-6" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup> All current amphetamine pharmaceuticals are <a href="/wiki/Salt_(chemistry)" title="Salt (chemistry)">salts</a> due to the comparatively high volatility of the free base.<sup id="cite_ref-Amph_Uses_21-7" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-NDCD_25-2" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup><sup id="cite_ref-EMC_37-3" class="reference"><a href="#cite_note-EMC-37"><span>[</span>30<span>]</span></a></sup> Some of the current brands and their generic equivalents are listed below.</p>
<table style="width: 80%">
<tr>
<td>
<table class="wikitable sortable" style="text-align:center; width:430px;">
<caption>Amphetamine pharmaceuticals</caption>
<tr>
<th scope="col">Brand<br />
name</th>
<th scope="col"><a href="/wiki/United_States_Adopted_Name" title="United States Adopted Name">United States<br />
Adopted Name</a></th>
<th scope="col" class="unsortable" style="text-align:center"><a href="//en.wiktionary.org/wiki/enantiomeric_ratio" class="extiw" title="wikt:enantiomeric ratio">(D:L) ratio</a><br />
of salts</th>
<th scope="col">Dosage<br />
form</th>
<th scope="col" class="unsortable"><small>Source</small></th>
</tr>
<tr>
<td>Adderall</td>
<td>–</td>
<td>3:1</td>
<td>tablet</td>
<td><sup id="cite_ref-Amph_Uses_21-8" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-NDCD_25-3" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup></td>
</tr>
<tr>
<td>Adderall XR</td>
<td>–</td>
<td>3:1</td>
<td>capsule</td>
<td><sup id="cite_ref-Amph_Uses_21-9" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-NDCD_25-4" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup></td>
</tr>
<tr>
<td>Dexedrine</td>
<td>dextroamphetamine sulfate</td>
<td>1:0</td>
<td>capsule</td>
<td><sup id="cite_ref-Amph_Uses_21-10" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-NDCD_25-5" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup></td>
</tr>
<tr>
<td>ProCentra</td>
<td>dextroamphetamine sulfate</td>
<td>1:0</td>
<td>tablet</td>
<td><sup id="cite_ref-NDCD_25-6" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup></td>
</tr>
<tr>
<td>Vyvanse</td>
<td>lisdexamfetamine dimesylate</td>
<td>1:0</td>
<td>capsule</td>
<td><sup id="cite_ref-Amph_Uses_21-11" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-Vyvanse_176-2" class="reference"><a href="#cite_note-Vyvanse-176"><span>[</span>157<span>]</span></a></sup></td>
</tr>
<tr>
<td>Zenzedi</td>
<td>dextroamphetamine sulfate</td>
<td>1:0</td>
<td>liquid</td>
<td><sup id="cite_ref-NDCD_25-7" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup></td>
</tr>
</table>
</td>
<td>
<table>
<caption>&#160;</caption>
<tr>
<td>
<div class="thumb tleft">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Lisdexamfetamine-Structural_Formula_V.1.svg" class="image"><img alt="An image of the lisdexamphetamine compound" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Lisdexamfetamine-Structural_Formula_V.1.svg/220px-Lisdexamfetamine-Structural_Formula_V.1.svg.png" width="220" height="95" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Lisdexamfetamine-Structural_Formula_V.1.svg/330px-Lisdexamfetamine-Structural_Formula_V.1.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/0/0b/Lisdexamfetamine-Structural_Formula_V.1.svg/440px-Lisdexamfetamine-Structural_Formula_V.1.svg.png 2x" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Lisdexamfetamine-Structural_Formula_V.1.svg" class="internal" title="Enlarge"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
The skeletal structure of lisdexamfetamine</div>
</div>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<h2><span class="mw-headline" id="Notes">Notes</span></h2>
<ol class="references">
<li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text">Synonyms and alternate spellings include: <span class="nowrap">α-methylphenethylamine</span>, amfetamine (<a href="/wiki/International_Nonproprietary_Name" title="International Nonproprietary Name">International Nonproprietary Name [INN]</a>, <a href="/wiki/British_Approved_Name" title="British Approved Name">British Approved Name [BAN]</a>), <span class="nowrap">β-phenylisopropylamine</span>, speed, <span class="nowrap">1-phenylpropan-2-amine</span>, <span class="nowrap">α-methylbenzeneethanamine</span>, and desoxynorephedrine.<sup id="cite_ref-PubChem_Header_8-0" class="reference"><a href="#cite_note-PubChem_Header-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-DrugBank1_9-0" class="reference"><a href="#cite_note-DrugBank1-9"><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-url_myDr.com.au_10-0" class="reference"><a href="#cite_note-url_myDr.com.au-10"><span>[</span>10<span>]</span></a></sup></span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text">Enantiomers are molecules that are <i>mirror images</i> of one another; they are structurally identical, but of the opposite orientation.<sup id="cite_ref-Enantiomers_12-0" class="reference"><a href="#cite_note-Enantiomers-12"><span>[</span>11<span>]</span></a></sup><br />
Levoamphetamine and dextroamphetamine are also known as L-amph or levamfetamine (<a href="/wiki/International_Nonproprietary_Name" title="International Nonproprietary Name">INN</a>) and D-amph or dexamfetamine (INN) respectively.<sup id="cite_ref-PubChem_Header_8-1" class="reference"><a href="#cite_note-PubChem_Header-8"><span>[</span>8<span>]</span></a></sup></span></li>
<li id="cite_note-Adderall-26"><span class="mw-cite-backlink">^ <a href="#cite_ref-Adderall_26-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Adderall_26-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">"Adderall" is a <a href="/wiki/Brand_name" title="Brand name" class="mw-redirect">brand name</a> as opposed to a nonproprietary name; because the latter ("<i>dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine sulfate, and amphetamine aspartate</i>"<sup id="cite_ref-NDCD_25-0" class="reference"><a href="#cite_note-NDCD-25"><span>[</span>22<span>]</span></a></sup>) is excessively long, this article exclusively refers to this amphetamine mixture by the brand name.</span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text">Due to confusion that may arise from use of the plural form, this article will only use the terms "amphetamine" and "amphetamines" to refer to <a href="/wiki/Racemic" title="Racemic" class="mw-redirect">racemic</a> amphetamine, levoamphetamine, and dextroamphetamine and reserve the term "substituted amphetamines" for the class.</span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text">This involves impaired dopamine neurotransmission in the <a href="/wiki/Mesocortical_pathway" title="Mesocortical pathway">mesocortical</a> and <a href="/wiki/Mesolimbic_pathway" title="Mesolimbic pathway">mesolimbic</a> pathways and norepinephrine neurotransmission in the <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a> and <a href="/wiki/Locus_coeruleus" title="Locus coeruleus">locus coeruleus</a>.<sup id="cite_ref-Malenka_2009_03_48-0" class="reference"><a href="#cite_note-Malenka_2009_03-48"><span>[</span>40<span>]</span></a></sup></span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text">Cochrane Collaboration reviews are high quality meta-analytic systematic reviews of randomized controlled trials.<sup id="cite_ref-pmid16052183_51-0" class="reference"><a href="#cite_note-pmid16052183-51"><span>[</span>42<span>]</span></a></sup></span></li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text">The prescribing information in a <a href="/wiki/Package_insert" title="Package insert">package insert</a> is the property of the manufacturer, but the final version is approved by the USFDA. For simplicity, this section will refer to the USFDA, since multiple versions of the amphetamine prescribing information exist.</span></li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text">During short-term treatment, fluoxetine may decrease drug craving.<sup id="cite_ref-Cochrane_Addiction_81-1" class="reference"><a href="#cite_note-Cochrane_Addiction-81"><span>[</span>67<span>]</span></a></sup></span></li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text">During "medium-term treatment," imipramine may extend the duration of adherence to addiction treatment.<sup id="cite_ref-Cochrane_Addiction_81-2" class="reference"><a href="#cite_note-Cochrane_Addiction-81"><span>[</span>67<span>]</span></a></sup></span></li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text">The review indicated that <a href="/wiki/Magnesium_aspartate" title="Magnesium aspartate">magnesium L-aspartate</a> and <a href="/wiki/Magnesium_chloride" title="Magnesium chloride">magnesium chloride</a> produce significant changes in addictive behavior;<sup id="cite_ref-Magnesium_84-3" class="reference"><a href="#cite_note-Magnesium-84"><span>[</span>68<span>]</span></a></sup> other forms of magnesium were not mentioned.</span></li>
<li id="cite_note-130"><span class="mw-cite-backlink"><b><a href="#cite_ref-130">^</a></b></span> <span class="reference-text">Enantiomers are molecules that are <i>mirror images</i> of one another; they are structurally identical, but of the opposite orientation.<sup id="cite_ref-Enantiomers_12-1" class="reference"><a href="#cite_note-Enantiomers-12"><span>[</span>11<span>]</span></a></sup></span></li>
</ol>
<h2><span class="mw-headline" id="Reference_notes">Reference notes</span></h2>
<ol class="references">
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>12<span>]</span></a></sup><sup id="cite_ref-UN_Convention_15-0" class="reference"><a href="#cite_note-UN_Convention-15"><span>[</span>13<span>]</span></a></sup><sup id="cite_ref-FDA_Abuse_.26_OD_16-0" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Ergogenics_17-0" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_18-0" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-Libido_19-0" class="reference"><a href="#cite_note-Libido-19"><span>[</span>17<span>]</span></a></sup><sup id="cite_ref-Nonmedical_20-0" class="reference"><a href="#cite_note-Nonmedical-20"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-Amph_Uses_21-0" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-Benzedrine_22-0" class="reference"><a href="#cite_note-Benzedrine-22"><span>[</span>20<span>]</span></a></sup><sup id="cite_ref-World_Drug_Report_23-0" class="reference"><a href="#cite_note-World_Drug_Report-23"><span>[</span>21<span>]</span></a></sup></span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Ergogenics_17-1" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_18-1" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-Libido_19-1" class="reference"><a href="#cite_note-Libido-19"><span>[</span>17<span>]</span></a></sup><sup id="cite_ref-Amph_Uses_21-1" class="reference"><a href="#cite_note-Amph_Uses-21"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-Benzedrine_22-1" class="reference"><a href="#cite_note-Benzedrine-22"><span>[</span>20<span>]</span></a></sup><sup id="cite_ref-Adderall_IR_27-0" class="reference"><a href="#cite_note-Adderall_IR-27"><span>[</span>23<span>]</span></a></sup><sup id="cite_ref-Miller_28-0" class="reference"><a href="#cite_note-Miller-28"><span>[</span>24<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-0" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup></span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text"><sup id="cite_ref-FDA_Abuse_.26_OD_16-1" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-Malenka_2009_18-2" class="reference"><a href="#cite_note-Malenka_2009-18"><span>[</span>16<span>]</span></a></sup><sup id="cite_ref-Cochrane_31-0" class="reference"><a href="#cite_note-Cochrane-31"><span>[</span>26<span>]</span></a></sup><sup id="cite_ref-Stimulant_Misuse_32-0" class="reference"><a href="#cite_note-Stimulant_Misuse-32"><span>[</span>27<span>]</span></a></sup><sup id="cite_ref-EncycOfPsychopharm_33-0" class="reference"><a href="#cite_note-EncycOfPsychopharm-33"><span>[</span>28<span>]</span></a></sup><sup id="cite_ref-Westfall_34-0" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup></span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text"><sup id="cite_ref-EMC_37-0" class="reference"><a href="#cite_note-EMC-37"><span>[</span>30<span>]</span></a></sup><sup id="cite_ref-Trace_Amines_38-0" class="reference"><a href="#cite_note-Trace_Amines-38"><span>[</span>31<span>]</span></a></sup></span></li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><sup id="cite_ref-68" class="reference"><a href="#cite_note-68"><span>[</span>57<span>]</span></a></sup><sup id="cite_ref-pmid22043968_69-0" class="reference"><a href="#cite_note-pmid22043968-69"><span>[</span>58<span>]</span></a></sup><sup id="cite_ref-70" class="reference"><a href="#cite_note-70"><span>[</span>59<span>]</span></a></sup><sup id="cite_ref-pmid22161946_71-0" class="reference"><a href="#cite_note-pmid22161946-71"><span>[</span>60<span>]</span></a></sup></span></li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Libido_19-2" class="reference"><a href="#cite_note-Libido-19"><span>[</span>17<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-8" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-14" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-Merck_Manual_Amphetamines_73-0" class="reference"><a href="#cite_note-Merck_Manual_Amphetamines-73"><span>[</span>61<span>]</span></a></sup></span></li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><sup id="cite_ref-FDA_Abuse_.26_OD_16-8" class="reference"><a href="#cite_note-FDA_Abuse_.26_OD-16"><span>[</span>14<span>]</span></a></sup><sup id="cite_ref-FDA_Effects_29-14" class="reference"><a href="#cite_note-FDA_Effects-29"><span>[</span>25<span>]</span></a></sup><sup id="cite_ref-Westfall_34-16" class="reference"><a href="#cite_note-Westfall-34"><span>[</span>29<span>]</span></a></sup><sup id="cite_ref-Merck_Manual_Amphetamines_73-1" class="reference"><a href="#cite_note-Merck_Manual_Amphetamines-73"><span>[</span>61<span>]</span></a></sup><sup id="cite_ref-Amphetamine_toxidrome_75-1" class="reference"><a href="#cite_note-Amphetamine_toxidrome-75"><span>[</span>62<span>]</span></a></sup><sup id="cite_ref-Albertson_2011_76-0" class="reference"><a href="#cite_note-Albertson_2011-76"><span>[</span>63<span>]</span></a></sup><sup id="cite_ref-Amph_OD_77-0" class="reference"><a href="#cite_note-Amph_OD-77"><span>[</span>64<span>]</span></a></sup></span></li>
<li id="cite_note-153"><span class="mw-cite-backlink"><b><a href="#cite_ref-153">^</a></b></span> <span class="reference-text"><sup id="cite_ref-Ergogenics_17-9" class="reference"><a href="#cite_note-Ergogenics-17"><span>[</span>15<span>]</span></a></sup><sup id="cite_ref-pmid9700558_150-0" class="reference"><a href="#cite_note-pmid9700558-150"><span>[</span>132<span>]</span></a></sup><sup id="cite_ref-pmid17468860_151-0" class="reference"><a href="#cite_note-pmid17468860-151"><span>[</span>133<span>]</span></a></sup><sup id="cite_ref-pmid8075776_152-0" class="reference"><a href="#cite_note-pmid8075776-152"><span>[</span>134<span>]</span></a></sup></span></li>
</ol>
<h2><span class="mw-headline" id="References">References</span></h2>
<div class="reflist columns references-column-count references-column-count-2" style="-moz-column-count: 2; -webkit-column-count: 2; column-count: 2; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-Drugbank-dexamph-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Drugbank-dexamph_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Drugbank-dexamph_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB01576#pharmacology"><i>Pharmacology</i></a>. "Dextroamphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 5 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Dextroamphetamine&amp;rft.btitle=Pharmacology&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01576%23pharmacology&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Drugbank-amph-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-Drugbank-amph_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Drugbank-amph_2-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#pharmacology"><i>Pharmacology</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 5 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Pharmacology&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23pharmacology&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Pharmacokinetics-3"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Pharmacokinetics_3-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-FDA_Pharmacokinetics_3-19"><sup><i><b>t</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;12–13<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=12%26ndash%3B13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DBH_ref-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-DBH_ref_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DBH_ref_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Lemke TL, Williams DA, Roche VF, Zito W (2013). <i>Foye's Principles of Medicinal Chemistry</i> (7th ed. ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins. p.&#160;648. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/1609133455" title="Special:BookSources/1609133455">1609133455</a>. "Alternatively, direct oxidation of amphetamine by DA β-hydroxylase can afford norephedrine."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.aulast=Lemke+TL%2C+Williams+DA%2C+Roche+VF%2C+Zito+W&amp;rft.au=Lemke+TL%2C+Williams+DA%2C+Roche+VF%2C+Zito+W&amp;rft.btitle=Foye%27s+Principles+of+Medicinal+Chemistry&amp;rft.date=2013&amp;rft.edition=7th+ed.&amp;rft.genre=book&amp;rft.isbn=1609133455&amp;rft.pages=648&amp;rft.place=Philadelphia&amp;rft.pub=Wolters+Kluwer+Health%2FLippincott+Williams+%26+Wilkins&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FMO-5"><span class="mw-cite-backlink">^ <a href="#cite_ref-FMO_5-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FMO_5-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FMO_5-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Krueger SK, Williams DE (June 2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602">"Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism"</a>. <i>Pharmacol. Ther.</i> <b>106</b> (3): 357–387. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pharmthera.2005.01.001">10.1016/j.pharmthera.2005.01.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1828602">1828602</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15922018">15922018</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Mammalian+flavin-containing+monooxygenases%3A+structure%2Ffunction%2C+genetic+polymorphisms+and+role+in+drug+metabolism&amp;rft.au=Krueger+SK%2C+Williams+DE&amp;rft.aulast=Krueger+SK%2C+Williams+DE&amp;rft.date=June+2005&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1828602&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2005.01.001&amp;rft_id=info%3Apmc%2F1828602&amp;rft_id=info%3Apmid%2F15922018&amp;rft.issue=3&amp;rft.jtitle=Pharmacol.+Ther.&amp;rft.pages=357%26ndash%3B387&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Chemspider-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-Chemspider_6-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.chemspider.com/Chemical-Structure.13852819"><i>Properties: Predicted - EP|Suite</i></a>. "Amphetamine". <i>Chemspider</i><span class="reference-accessdate">. Retrieved 6 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Properties%3A+Predicted+-+EP%26%23124%3BSuite&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.chemspider.com%2FChemical-Structure.13852819&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x27"><i>Chemical and Physical Properties</i></a>. "Amphetamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 5 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Chemical+and+Physical+Properties&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23x27&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-PubChem_Header-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-PubChem_Header_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-PubChem_Header_8-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-PubChem_Header_8-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007"><i>Compound Summary</i></a>. "Amphetamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Compound+Summary&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DrugBank1-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-DrugBank1_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DrugBank1_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-DrugBank1_9-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-DrugBank1_9-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-DrugBank1_9-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-DrugBank1_9-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#identification"><i>Description, Synonyms, Brand names, and Brand mixtures</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Description%2C+Synonyms%2C+Brand+names%2C+and+Brand+mixtures&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23identification&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-url_myDr.com.au-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-url_myDr.com.au_10-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.mydr.com.au/addictions/amphetamines-speed-what-are-the-effects">"Amphetamines (speed): what are the effects?"</a>. <i>Monthly Index of Medical Specialities</i>. 27 January 2012<span class="reference-accessdate">. Retrieved 10 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamines+%28speed%29%3A+what+are+the+effects%3F&amp;rft.date=27+January+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.mydr.com.au%2Faddictions%2Famphetamines-speed-what-are-the-effects&amp;rft.jtitle=Monthly+Index+of+Medical+Specialities&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Enantiomers-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Enantiomers_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Enantiomers_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20130317002318/http://goldbook.iupac.org/E02069.html">"Enantiomer"</a>. <i>IUPAC Goldbook</i>. International Union of Pure and Applied Chemistry. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1351%2Fgoldbook.E02069">10.1351/goldbook.E02069</a>. Archived from <a rel="nofollow" class="external text" href="http://goldbook.iupac.org/E02069.html">the original</a> on 17 March 2013<span class="reference-accessdate">. Retrieved 14 March 2014</span>. "One of a pair of molecular entities which are mirror images of each other and non-superposable."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Enantiomer&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fgoldbook.iupac.org%2FE02069.html&amp;rft_id=info%3Adoi%2F10.1351%2Fgoldbook.E02069&amp;rft.jtitle=IUPAC+Goldbook&amp;rft.pub=International+Union+of+Pure+and+Applied+Chemistry&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?mode=&amp;term=Amphetamine">"Amphetamine"</a>. <i>National Library of Medicine - Medical Subject Headings</i>. National Institutes of Health<span class="reference-accessdate">. Retrieved 16 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nlm.nih.gov%2Fcgi%2Fmesh%2F2009%2FMB_cgi%3Fmode%3D%26term%3DAmphetamine&amp;rft.jtitle=National+Library+of+Medicine+-+Medical+Subject+Headings&amp;rft.pub=National+Institutes+of+Health&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-UN_Convention-15"><span class="mw-cite-backlink">^ <a href="#cite_ref-UN_Convention_15-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-UN_Convention_15-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://treaties.un.org/Pages/ViewDetails.aspx?src=TREATY&amp;mtdsg_no=VI-16&amp;chapter=6&amp;lang=en">"Convention on psychotropic substances"</a>. <i>United Nations Treaty Collection</i>. United Nations<span class="reference-accessdate">. Retrieved 11 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Convention+on+psychotropic+substances&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Ftreaties.un.org%2FPages%2FViewDetails.aspx%3Fsrc%3DTREATY%26mtdsg_no%3DVI-16%26chapter%3D6%26lang%3Den&amp;rft.jtitle=United+Nations+Treaty+Collection&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Abuse_.26_OD-16"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Abuse_.26_OD_16-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-FDA_Abuse_.26_OD_16-14"><sup><i><b>o</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. p.&#160;11<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=11&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ergogenics-17"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ergogenics_17-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Ergogenics_17-10"><sup><i><b>k</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Liddle DG, Connor DJ (June 2013). "Nutritional supplements and ergogenic AIDS". <i>Prim. Care</i> <b>40</b> (2): 487–505. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pop.2013.02.009">10.1016/j.pop.2013.02.009</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23668655">23668655</a>. "Amphetamines and caffeine are stimulants that increase alertness, improve focus, decrease reaction time, and delay fatigue, allowing for an increased intensity and duration of training&#160;...<br />
Physiologic and performance effects<br />
&#160;• Amphetamines increase dopamine/norepinephrine release and inhibit their reuptake, leading to central nervous system (CNS) stimulation<br />
&#160;• Amphetamines seem to enhance athletic performance in anaerobic conditions 39 40<br />
&#160;• Improved reaction time<br />
&#160;• Increased muscle strength and delayed muscle fatigue<br />
&#160;• Increased acceleration<br />
&#160;• Increased alertness and attention to task"</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Nutritional+supplements+and+ergogenic+AIDS&amp;rft.aulast=Liddle+DG%2C+Connor+DJ&amp;rft.au=Liddle+DG%2C+Connor+DJ&amp;rft.date=June+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pop.2013.02.009&amp;rft_id=info%3Apmid%2F23668655&amp;rft.issue=2&amp;rft.jtitle=Prim.+Care&amp;rft.pages=487%26ndash%3B505&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=40" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-Malenka_2009_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Malenka_2009_18-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. p.&#160;318. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. "Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in in normal subjects and those with ADHD. Positron emission tomography (PET) demonstrates that methylphenidate decreases regional cerebral blood flow in the doroslateral prefrontal cortex and posterior parietal cortex while improving performance of a spacial working memory task. This suggests that cortical networks that normally process spatial working memory become more efficient in response to the drug.&#160;...&#160;[It] is now believed that dopamine and norepinephrine, but not serotonin, produce the beneficial effects of stimulants on working memory. At abused (relatively high) doses, stimulants can interfere with working memory and cognitive control&#160;...&#160;stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks&#160;...&#160;through indirect stimulation of dopamine and norepinephrine receptors."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.aulast=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Chapter+13%3A+Higher+Cognitive+Function+and+Behavioral+Control&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=318&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Libido-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-Libido_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Libido_19-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Libido_19-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Montgomery KA (June 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750">"Sexual desire disorders"</a>. <i>Psychiatry (Edgmont)</i> <b>5</b> (6): 50–55. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750">2695750</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19727285">19727285</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Sexual+desire+disorders&amp;rft.aulast=Montgomery+KA&amp;rft.au=Montgomery+KA&amp;rft.date=June+2008&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2695750&amp;rft_id=info%3Apmc%2F2695750&amp;rft_id=info%3Apmid%2F19727285&amp;rft.issue=6&amp;rft.jtitle=Psychiatry+%28Edgmont%29&amp;rft.pages=50%26ndash%3B55&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=5" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nonmedical-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nonmedical_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nonmedical_20-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S (January 2008). "Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature". <i>J. Am. Acad. Child Adolesc. Psychiatry</i> <b>47</b> (1): 21–31. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1097%2Fchi.0b013e31815a56f1">10.1097/chi.0b013e31815a56f1</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18174822">18174822</a>. "Stimulant misuse appears to occur both for performance enhancement and their euphorogenic effects, the latter being related to the intrinsic properties of the stimulants (e.g., IR versus ER profile)&#160;...<br />
<br />
Although useful in the treatment of ADHD, stimulants are controlled II substances with a history of preclinical and human studies showing potential abuse liability."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Misuse+and+diversion+of+stimulants+prescribed+for+ADHD%3A+a+systematic+review+of+the+literature&amp;rft.aulast=Wilens+TE%2C+Adler+LA%2C+Adams+J%2C+Sgambati+S%2C+Rotrosen+J%2C+Sawtelle+R%2C+Utzinger+L%2C+Fusillo+S&amp;rft.au=Wilens+TE%2C+Adler+LA%2C+Adams+J%2C+Sgambati+S%2C+Rotrosen+J%2C+Sawtelle+R%2C+Utzinger+L%2C+Fusillo+S&amp;rft.date=January+2008&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2Fchi.0b013e31815a56f1&amp;rft_id=info%3Apmid%2F18174822&amp;rft.issue=1&amp;rft.jtitle=J.+Am.+Acad.+Child+Adolesc.+Psychiatry&amp;rft.pages=21%26ndash%3B31&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=47" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph_Uses-21"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amph_Uses_21-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Amph_Uses_21-11"><sup><i><b>l</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Heal DJ, Smith SL, Gosden J, Nutt DJ (June 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194">"Amphetamine, past and present – a pharmacological and clinical perspective"</a>. <i>J. Psychopharmacol.</i> <b>27</b> (6): 479–496. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F0269881113482532">10.1177/0269881113482532</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3666194">3666194</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23539642">23539642</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine%2C+past+and+present+%26ndash%3B+a+pharmacological+and+clinical+perspective&amp;rft.au=Heal+DJ%2C+Smith+SL%2C+Gosden+J%2C+Nutt+DJ&amp;rft.aulast=Heal+DJ%2C+Smith+SL%2C+Gosden+J%2C+Nutt+DJ&amp;rft.date=June+2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3666194&amp;rft_id=info%3Adoi%2F10.1177%2F0269881113482532&amp;rft_id=info%3Apmc%2F3666194&amp;rft_id=info%3Apmid%2F23539642&amp;rft.issue=6&amp;rft.jtitle=J.+Psychopharmacol.&amp;rft.pages=479%26ndash%3B496&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Benzedrine-22"><span class="mw-cite-backlink">^ <a href="#cite_ref-Benzedrine_22-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Benzedrine_22-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Benzedrine_22-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Rasmussen N (July 2006). "Making the first anti-depressant: amphetamine in American medicine, 1929–1950". <i>J . Hist. Med. Allied Sci.</i> <b>61</b> (3): 288–323. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1093%2Fjhmas%2Fjrj039">10.1093/jhmas/jrj039</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16492800">16492800</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Making+the+first+anti-depressant%3A+amphetamine+in+American+medicine%2C+1929%26ndash%3B1950&amp;rft.aulast=Rasmussen+N&amp;rft.au=Rasmussen+N&amp;rft.date=July+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjhmas%2Fjrj039&amp;rft_id=info%3Apmid%2F16492800&amp;rft.issue=3&amp;rft.jtitle=J+.+Hist.+Med.+Allied+Sci.&amp;rft.pages=288%26ndash%3B323&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-World_Drug_Report-23"><span class="mw-cite-backlink">^ <a href="#cite_ref-World_Drug_Report_23-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-World_Drug_Report_23-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web">Chawla S, Le Pichon T (2006). <a rel="nofollow" class="external text" href="http://www.unodc.org/pdf/WDR_2006/wdr2006_volume1.pdf">"World Drug Report 2006"</a>. <i>United Nations Office on Drugs and Crime</i>. pp.&#160;128–135<span class="reference-accessdate">. Retrieved 2 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=World+Drug+Report+2006&amp;rft.au=Chawla+S%2C+Le+Pichon+T&amp;rft.aulast=Chawla+S%2C+Le+Pichon+T&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.unodc.org%2Fpdf%2FWDR_2006%2Fwdr2006_volume1.pdf&amp;rft.jtitle=United+Nations+Office+on+Drugs+and+Crime&amp;rft.pages=128%26ndash%3B135&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NDCD-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-NDCD_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NDCD_25-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NDCD_25-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NDCD_25-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NDCD_25-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-NDCD_25-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-NDCD_25-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-NDCD_25-7"><sup><i><b>h</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20131216080856/http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&amp;numberperpage=160&amp;searchfield=amphetamine&amp;searchtype=ActiveIngredient&amp;OrderBy=ProprietaryName">"National Drug Code Amphetamine Search Results"</a>. <i>National Drug Code Directory</i>. United States Food and Drug Administration. Archived from <a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&amp;numberperpage=160&amp;searchfield=amphetamine&amp;searchtype=ActiveIngredient&amp;OrderBy=ProprietaryName">the original</a> on 7 February 2014<span class="reference-accessdate">. Retrieved 16 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=National+Drug+Code+Amphetamine+Search+Results&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fndc%2Fresults.cfm%3Fbeginrow%3D1%26numberperpage%3D160%26searchfield%3Damphetamine%26searchtype%3DActiveIngredient%26OrderBy%3DProprietaryName&amp;rft.jtitle=National+Drug+Code+Directory&amp;rft.pub=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Adderall_IR-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-Adderall_IR_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Adderall_IR_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf">"Adderall IR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. March 2007. p.&#160;5<span class="reference-accessdate">. Retrieved 2 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+IR+Prescribing+Information&amp;rft.date=March+2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F011522s040lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=5&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Miller-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-Miller_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Miller_28-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Miller_28-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Miller_28-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Miller_28-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Miller_28-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Miller_28-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Miller_28-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Miller_28-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Miller_28-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Miller_28-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Miller_28-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Miller_28-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Miller_28-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Miller_28-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Miller_28-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Miller_28-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Miller_28-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Miller_28-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Miller_28-19"><sup><i><b>t</b></i></sup></a> <a href="#cite_ref-Miller_28-20"><sup><i><b>u</b></i></sup></a> <a href="#cite_ref-Miller_28-21"><sup><i><b>v</b></i></sup></a> <a href="#cite_ref-Miller_28-22"><sup><i><b>w</b></i></sup></a> <a href="#cite_ref-Miller_28-23"><sup><i><b>x</b></i></sup></a> <a href="#cite_ref-Miller_28-24"><sup><i><b>y</b></i></sup></a> <a href="#cite_ref-Miller_28-25"><sup><i><b>z</b></i></sup></a> <a href="#cite_ref-Miller_28-26"><sup><i><b>aa</b></i></sup></a> <a href="#cite_ref-Miller_28-27"><sup><i><b>ab</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Miller GM (January 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101">"The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity"</a>. <i>J. Neurochem.</i> <b>116</b> (2): 164–176. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1471-4159.2010.07109.x">10.1111/j.1471-4159.2010.07109.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3005101">3005101</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21073468">21073468</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+emerging+role+of+trace+amine-associated+receptor+1+in+the+functional+regulation+of+monoamine+transporters+and+dopaminergic+activity&amp;rft.aulast=Miller+GM&amp;rft.au=Miller+GM&amp;rft.date=January+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3005101&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1471-4159.2010.07109.x&amp;rft_id=info%3Apmc%2F3005101&amp;rft_id=info%3Apmid%2F21073468&amp;rft.issue=2&amp;rft.jtitle=J.+Neurochem.&amp;rft.pages=164%26ndash%3B176&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=116" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Effects-29"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Effects_29-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-FDA_Effects_29-14"><sup><i><b>o</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;4–8<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=4%26ndash%3B8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane-31"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_31-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_31-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cochrane_31-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cochrane_31-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Cochrane_31-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Shoptaw SJ, Kao U, Ling W (2009). "Treatment for amphetamine psychosis". In Shoptaw SJ, Ali R. <i>Cochrane Database Syst. Rev.</i> (1): CD003026. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003026.pub3">10.1002/14651858.CD003026.pub3</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19160215">19160215</a>. "A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention&#160;...<br />
About 5-15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983)&#160;...<br />
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Treatment+for+amphetamine+psychosis&amp;rft.aulast=Shoptaw+SJ%2C+Kao+U%2C+Ling+W&amp;rft.au=Shoptaw+SJ%2C+Kao+U%2C+Ling+W&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003026.pub3&amp;rft_id=info%3Apmid%2F19160215&amp;rft.issue=1&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003026&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Stimulant_Misuse-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-Stimulant_Misuse_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Stimulant_Misuse_32-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Stimulant_Misuse_32-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web">Greydanus D. <a rel="nofollow" class="external text" href="http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf">"Stimulant Misuse: Strategies to Manage a Growing Problem"</a>. <i>American College Health Association</i> (Review Article). ACHA Professional Development Program. p.&#160;20<span class="reference-accessdate">. Retrieved 2 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Stimulant+Misuse%3A+Strategies+to+Manage+a+Growing+Problem&amp;rft.au=Greydanus+D&amp;rft.aulast=Greydanus+D&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.acha.org%2Fprof_dev%2FADHD_docs%2FADHD_PDprogram_Article2.pdf&amp;rft.jtitle=American+College+Health+Association&amp;rft.pages=20&amp;rft.pub=ACHA+Professional+Development+Program&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EncycOfPsychopharm-33"><span class="mw-cite-backlink">^ <a href="#cite_ref-EncycOfPsychopharm_33-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-EncycOfPsychopharm_33-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Stolerman IP (2010). Stolerman IP, ed. <i>Encyclopedia of Psychopharmacology</i>. Berlin; London: Springer. p.&#160;78. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9783540686989" title="Special:BookSources/9783540686989">9783540686989</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.aulast=Stolerman+IP&amp;rft.au=Stolerman+IP&amp;rft.btitle=Encyclopedia+of+Psychopharmacology&amp;rft.date=2010&amp;rft.genre=book&amp;rft.isbn=9783540686989&amp;rft.pages=78&amp;rft.place=Berlin%3B+London&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Westfall-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-Westfall_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Westfall_34-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Westfall_34-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Westfall_34-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Westfall_34-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Westfall_34-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Westfall_34-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Westfall_34-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Westfall_34-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Westfall_34-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Westfall_34-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-Westfall_34-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-Westfall_34-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-Westfall_34-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-Westfall_34-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-Westfall_34-15"><sup><i><b>p</b></i></sup></a> <a href="#cite_ref-Westfall_34-16"><sup><i><b>q</b></i></sup></a> <a href="#cite_ref-Westfall_34-17"><sup><i><b>r</b></i></sup></a> <a href="#cite_ref-Westfall_34-18"><sup><i><b>s</b></i></sup></a> <a href="#cite_ref-Westfall_34-19"><sup><i><b>t</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Westfall DP, Westfall TC (2010). <a rel="nofollow" class="external text" href="http://www.accessmedicine.com/content.aspx?aID=16661601">"Miscellaneous Sympathomimetic Agonists"</a>. In Brunton LL, Chabner BA, Knollmann BC. <i>Goodman &amp; Gilman's Pharmacological Basis of Therapeutics</i> (12th ed.). New York: McGraw-Hill. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071624428" title="Special:BookSources/9780071624428">9780071624428</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Goodman+%26+Gilman%27s+Pharmacological+Basis+of+Therapeutics&amp;rft.aulast=Westfall+DP%2C+Westfall+TC&amp;rft.au=Westfall+DP%2C+Westfall+TC&amp;rft.btitle=Miscellaneous+Sympathomimetic+Agonists&amp;rft.date=2010&amp;rft.edition=12th&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.accessmedicine.com%2Fcontent.aspx%3FaID%3D16661601&amp;rft.isbn=9780071624428&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-EMC-37"><span class="mw-cite-backlink">^ <a href="#cite_ref-EMC_37-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-EMC_37-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-EMC_37-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-EMC_37-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.emcdda.europa.eu/publications/drug-profiles/amphetamine">"Amphetamine"</a>. <i>European Monitoring Centre for Drugs and Drug Addiction</i><span class="reference-accessdate">. Retrieved 19 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.emcdda.europa.eu%2Fpublications%2Fdrug-profiles%2Famphetamine&amp;rft.jtitle=European+Monitoring+Centre+for+Drugs+and+Drug+Addiction&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Trace_Amines-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-Trace_Amines_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Trace_Amines_38-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines". <i>Pharmacol. Ther.</i> <b>125</b> (3): 363–375. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pharmthera.2009.11.005">10.1016/j.pharmthera.2009.11.005</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19948186">19948186</a>. "<b>Fig. 2.</b> Synthetic and metabolic pathways for endogenous and exogenously administered trace amines and sympathomimetic amines&#160;...<br />
Trace amines are metabolized in the mammalian body via monoamine oxidase (MAO; EC 1.4.3.4) (Berry, 2004) (Fig. 2)&#160;...&#160;It deaminates primary and secondary amines that are free in the neuronal cytoplasm but not those bound in storage vesicles of the sympathetic neurone&#160;...<br />
Thus, MAO inhibitors potentiate the peripheral effects of indirectly acting sympathomimetic amines&#160;...&#160;this potentiation occurs irrespective of whether the amine is a substrate for MAO. An α-methyl group on the side chain, as in amphetamine and ephedrine, renders the amine immune to deamination so that they are not metabolized in the gut. Similarly, β-PEA would not be deaminated in the gut as it is a selective substrate for MAO-B which is not found in the gut&#160;...<br />
Brain levels of endogenous trace amines are several hundred-fold below those for the classical neurotransmitters noradrenaline, dopamine and serotonin but their rates of synthesis are equivalent to those of noradrenaline and dopamine and they have a very rapid turnover rate (Berry, 2004). Endogenous extracellular tissue levels of trace amines measured in the brain are in the low nanomolar range. These low concentrations arise because of their very short half-life&#160;..."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+vascular+effects+of+trace+amines+and+amphetamines&amp;rft.au=Broadley+KJ&amp;rft.aulast=Broadley+KJ&amp;rft.date=March+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pharmthera.2009.11.005&amp;rft_id=info%3Apmid%2F19948186&amp;rft.issue=3&amp;rft.jtitle=Pharmacol.+Ther.&amp;rft.pages=363%26ndash%3B375&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=125" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22392347-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid22392347_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid22392347_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L (August 2012). "Toxicity of amphetamines: an update". <i>Arch. Toxicol.</i> <b>86</b> (8): 1167–1231. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs00204-012-0815-5">10.1007/s00204-012-0815-5</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22392347">22392347</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Toxicity+of+amphetamines%3A+an+update&amp;rft.au=Carvalho+M%2C+Carmo+H%2C+Costa+VM%2C+Capela+JP%2C+Pontes+H%2C+Remi%C3%A3o+F%2C+Carvalho+F%2C+Bastos+Mde+L&amp;rft.aulast=Carvalho+M%2C+Carmo+H%2C+Costa+VM%2C+Capela+JP%2C+Pontes+H%2C+Remi%C3%A3o+F%2C+Carvalho+F%2C+Bastos+Mde+L&amp;rft.date=August+2012&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00204-012-0815-5&amp;rft_id=info%3Apmid%2F22392347&amp;rft.issue=8&amp;rft.jtitle=Arch.+Toxicol.&amp;rft.pages=1167%26ndash%3B1231&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=86" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-AbuseAndAbnormalities-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-AbuseAndAbnormalities_41-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Berman S, O'Neill J, Fears S, Bartzokis G, London ED (2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923">"Abuse of amphetamines and structural abnormalities in the brain"</a>. <i>Ann. N. Y. Acad. Sci.</i> <b>1141</b>: 195–220. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1196%2Fannals.1441.031">10.1196/annals.1441.031</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2769923">2769923</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18991959">18991959</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Abuse+of+amphetamines+and+structural+abnormalities+in+the+brain&amp;rft.au=Berman+S%2C+O%27Neill+J%2C+Fears+S%2C+Bartzokis+G%2C+London+ED&amp;rft.aulast=Berman+S%2C+O%27Neill+J%2C+Fears+S%2C+Bartzokis+G%2C+London+ED&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2769923&amp;rft_id=info%3Adoi%2F10.1196%2Fannals.1441.031&amp;rft_id=info%3Apmc%2F2769923&amp;rft_id=info%3Apmid%2F18991959&amp;rft.jtitle=Ann.+N.+Y.+Acad.+Sci.&amp;rft.pages=195%26ndash%3B220&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1141" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_1-42"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_1_42-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_1_42-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". <i>JAMA Psychiatry</i> <b>70</b> (2): 185–198. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1001%2Fjamapsychiatry.2013.277">10.1001/jamapsychiatry.2013.277</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23247506">23247506</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Meta-analysis+of+functional+magnetic+resonance+imaging+studies+of+inhibition+and+attention+in+attention-deficit%2Fhyperactivity+disorder%3A+exploring+task-specific%2C+stimulant+medication%2C+and+age+effects&amp;rft.au=Hart+H%2C+Radua+J%2C+Nakao+T%2C+Mataix-Cols+D%2C+Rubia+K&amp;rft.aulast=Hart+H%2C+Radua+J%2C+Nakao+T%2C+Mataix-Cols+D%2C+Rubia+K&amp;rft.date=February+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Fjamapsychiatry.2013.277&amp;rft_id=info%3Apmid%2F23247506&amp;rft.issue=2&amp;rft.jtitle=JAMA+Psychiatry&amp;rft.pages=185%26ndash%3B198&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=70" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_2-43"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_2_43-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_2_43-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J (September 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446">"Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies"</a>. <i>J. Clin. Psychiatry</i> <b>74</b> (9): 902–917. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.4088%2FJCP.12r08287">10.4088/JCP.12r08287</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3801446">3801446</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/24107764">24107764</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Effect+of+psychostimulants+on+brain+structure+and+function+in+ADHD%3A+a+qualitative+literature+review+of+magnetic+resonance+imaging-based+neuroimaging+studies&amp;rft.aulast=Spencer+TJ%2C+Brown+A%2C+Seidman+LJ%2C+Valera+EM%2C+Makris+N%2C+Lomedico+A%2C+Faraone+SV%2C+Biederman+J&amp;rft.au=Spencer+TJ%2C+Brown+A%2C+Seidman+LJ%2C+Valera+EM%2C+Makris+N%2C+Lomedico+A%2C+Faraone+SV%2C+Biederman+J&amp;rft.date=September+2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3801446&amp;rft_id=info%3Adoi%2F10.4088%2FJCP.12r08287&amp;rft_id=info%3Apmc%2F3801446&amp;rft_id=info%3Apmid%2F24107764&amp;rft.issue=9&amp;rft.jtitle=J.+Clin.+Psychiatry&amp;rft.pages=902%26ndash%3B917&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=74" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Neuroplasticity_3-44"><span class="mw-cite-backlink">^ <a href="#cite_ref-Neuroplasticity_3_44-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Neuroplasticity_3_44-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects.". <i>Acta psychiatrica Scand.</i> <b>125</b> (2): 114–126. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22118249">22118249</a>. "Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Meta-analysis+of+structural+MRI+studies+in+children+and+adults+with+attention+deficit+hyperactivity+disorder+indicates+treatment+effects.&amp;rft.au=Frodl+T%2C+Skokauskas+N&amp;rft.aulast=Frodl+T%2C+Skokauskas+N&amp;rft.date=February+2012&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22118249&amp;rft.issue=2&amp;rft.jtitle=Acta+psychiatrica+Scand.&amp;rft.pages=114%26ndash%3B126&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=125" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Millichap_3-45"><span class="mw-cite-backlink">^ <a href="#cite_ref-Millichap_3_45-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Millichap_3_45-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Millichap_3_45-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Millichap JG (2010). "Chapter 3: Medications for ADHD". In Millichap JG. <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York: Springer. p.&#160;111–113. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781441913968" title="Special:BookSources/9781441913968">9781441913968</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Attention+Deficit+Hyperactivity+Disorder+Handbook%3A+A+Physician%27s+Guide+to+ADHD&amp;rft.aulast=Millichap+JG&amp;rft.au=Millichap+JG&amp;rft.btitle=Chapter+3%3A+Medications+for+ADHD&amp;rft.date=2010&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9781441913968&amp;rft.pages=111%26ndash%3B113&amp;rft.place=New+York&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Safety-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-Safety_46-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Chavez B, Sopko MA, Ehret MJ, Paulino RE, Goldberg KR, Angstadt K, Bogart GT (June 2009). "An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder". <i>Ann. Pharmacother.</i> <b>43</b> (6): 1084–1095. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1345%2Faph.1L523">10.1345/aph.1L523</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19470858">19470858</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=An+update+on+central+nervous+system+stimulant+formulations+in+children+and+adolescents+with+attention-deficit%2Fhyperactivity+disorder&amp;rft.au=Chavez+B%2C+Sopko+MA%2C+Ehret+MJ%2C+Paulino+RE%2C+Goldberg+KR%2C+Angstadt+K%2C+Bogart+GT&amp;rft.aulast=Chavez+B%2C+Sopko+MA%2C+Ehret+MJ%2C+Paulino+RE%2C+Goldberg+KR%2C+Angstadt+K%2C+Bogart+GT&amp;rft.date=June+2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1345%2Faph.1L523&amp;rft_id=info%3Apmid%2F19470858&amp;rft.issue=6&amp;rft.jtitle=Ann.+Pharmacother.&amp;rft.pages=1084%26ndash%3B1095&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=43" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Millichap-47"><span class="mw-cite-backlink">^ <a href="#cite_ref-Millichap_47-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Millichap_47-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Millichap_47-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Millichap JG (2010). Millichap JG, ed. <i>Attention Deficit Hyperactivity Disorder Handbook: A Physician's Guide to ADHD</i> (2nd ed.). New York: Springer. pp.&#160;122–123. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9781441913968" title="Special:BookSources/9781441913968">9781441913968</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.aulast=Millichap+JG&amp;rft.au=Millichap+JG&amp;rft.btitle=Attention+Deficit+Hyperactivity+Disorder+Handbook%3A+A+Physician%27s+Guide+to+ADHD&amp;rft.date=2010&amp;rft.edition=2nd&amp;rft.genre=book&amp;rft.isbn=9781441913968&amp;rft.pages=122%26ndash%3B123&amp;rft.place=New+York&amp;rft.pub=Springer&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009_03-48"><span class="mw-cite-backlink">^ <a href="#cite_ref-Malenka_2009_03_48-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_48-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Malenka_2009_03_48-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 6: Widely Projecting Systems: Monoamines, Acetylcholine, and Orexin". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.&#160;154–157. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.aulast=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Chapter+6%3A+Widely+Projecting+Systems%3A+Monoamines%2C+Acetylcholine%2C+and+Orexin&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=154%26ndash%3B157&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-ADHD-50"><span class="mw-cite-backlink">^ <a href="#cite_ref-ADHD_50-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ADHD_50-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-ADHD_50-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.webmd.com/add-adhd/childhood-adhd/stimulants-for-attention-deficit-hyperactivity-disorder">"Stimulants for Attention Deficit Hyperactivity Disorder"</a>. <i>WebMD</i>. Healthwise. 12 April 2010<span class="reference-accessdate">. Retrieved 12 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Stimulants+for+Attention+Deficit+Hyperactivity+Disorder&amp;rft.date=12+April+2010&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.webmd.com%2Fadd-adhd%2Fchildhood-adhd%2Fstimulants-for-attention-deficit-hyperactivity-disorder&amp;rft.jtitle=WebMD&amp;rft.pub=Healthwise&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16052183-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16052183_51-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Scholten RJ, Clarke M, Hetherington J (August 2005). "The Cochrane Collaboration". <i>Eur. J. Clin. Nutr</i>. 59 Suppl 1: S147–S149; discussion S195–S196. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1038%2Fsj.ejcn.1602188">10.1038/sj.ejcn.1602188</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16052183">16052183</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+Cochrane+Collaboration&amp;rft.aulast=Scholten+RJ%2C+Clarke+M%2C+Hetherington+J&amp;rft.au=Scholten+RJ%2C+Clarke+M%2C+Hetherington+J&amp;rft.date=August+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.ejcn.1602188&amp;rft_id=info%3Apmid%2F16052183&amp;rft.jtitle=Eur.+J.+Clin.+Nutr.&amp;rft.pages=S147%26ndash%3BS149%3B+discussion+S195%26ndash%3BS196&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=59+Suppl+1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_Amphetamines_ADHD-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-Cochrane_Amphetamines_ADHD_53-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M (2011). "Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults". In Castells X. <i>Cochrane Database Syst. Rev.</i> (6): CD007813. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD007813.pub2">10.1002/14651858.CD007813.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21678370">21678370</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamines+for+Attention+Deficit+Hyperactivity+Disorder+%28ADHD%29+in+adults&amp;rft.au=Castells+X%2C+Ramos-Quiroga+JA%2C+Bosch+R%2C+Nogueira+M%2C+Casas+M&amp;rft.aulast=Castells+X%2C+Ramos-Quiroga+JA%2C+Bosch+R%2C+Nogueira+M%2C+Casas+M&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007813.pub2&amp;rft_id=info%3Apmid%2F21678370&amp;rft.issue=6&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD007813&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><span class="citation journal">Pringsheim T, Steeves T (April 2011). "Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders". In Pringsheim T. <i>Cochrane Database Syst. Rev.</i> (4): CD007990. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD007990.pub2">10.1002/14651858.CD007990.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21491404">21491404</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Pharmacological+treatment+for+Attention+Deficit+Hyperactivity+Disorder+%28ADHD%29+in+children+with+comorbid+tic+disorders&amp;rft.aulast=Pringsheim+T%2C+Steeves+T&amp;rft.au=Pringsheim+T%2C+Steeves+T&amp;rft.date=April+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD007990.pub2&amp;rft_id=info%3Apmid%2F21491404&amp;rft.issue=4&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD007990&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-55">^</a></b></span> <span class="reference-text"><span class="citation journal">Martinsson L, Hårdemark H, Eksborg S (January 2007). "Amphetamines for improving recovery after stroke". In Martinsson L. <i>Cochrane Database Syst. Rev.</i> (1): CD002090. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD002090.pub2">10.1002/14651858.CD002090.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17253474">17253474</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamines+for+improving+recovery+after+stroke&amp;rft.aulast=Martinsson+L%2C+H%C3%A5rdemark+H%2C+Eksborg+S&amp;rft.au=Martinsson+L%2C+H%C3%A5rdemark+H%2C+Eksborg+S&amp;rft.date=January+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD002090.pub2&amp;rft_id=info%3Apmid%2F17253474&amp;rft.issue=1&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD002090&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><span class="citation journal">Forsyth RJ, Jayamoni B, Paine TC (October 2006). "Monoaminergic agonists for acute traumatic brain injury". In Forsyth RJ. <i>Cochrane Database Syst. Rev.</i> (4): CD003984. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003984.pub2">10.1002/14651858.CD003984.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17054192">17054192</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Monoaminergic+agonists+for+acute+traumatic+brain+injury&amp;rft.au=Forsyth+RJ%2C+Jayamoni+B%2C+Paine+TC&amp;rft.aulast=Forsyth+RJ%2C+Jayamoni+B%2C+Paine+TC&amp;rft.date=October+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003984.pub2&amp;rft_id=info%3Apmid%2F17054192&amp;rft.issue=4&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003984&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-SpeedyRecovery-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-SpeedyRecovery_57-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Harbeck-Seu A, Brunk I, Platz T, Vajkoczy P, Endres M, Spies C (April 2011). "A speedy recovery: amphetamines and other therapeutics that might impact the recovery from brain injury". <i>Curr. Opin. Anaesthesiol.</i> <b>24</b> (2): 144–153. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1097%2FACO.0b013e328344587f">10.1097/ACO.0b013e328344587f</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21386667">21386667</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=A+speedy+recovery%3A+amphetamines+and+other+therapeutics+that+might+impact+the+recovery+from+brain+injury&amp;rft.au=Harbeck-Seu+A%2C+Brunk+I%2C+Platz+T%2C+Vajkoczy+P%2C+Endres+M%2C+Spies+C&amp;rft.aulast=Harbeck-Seu+A%2C+Brunk+I%2C+Platz+T%2C+Vajkoczy+P%2C+Endres+M%2C+Spies+C&amp;rft.date=April+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2FACO.0b013e328344587f&amp;rft_id=info%3Apmid%2F21386667&amp;rft.issue=2&amp;rft.jtitle=Curr.+Opin.+Anaesthesiol.&amp;rft.pages=144%26ndash%3B153&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><span class="citation web">Twohey M (26 March 2006). <a rel="nofollow" class="external text" href="http://web.archive.org/web/20070815200239/http://www.jsonline.com/story/index.aspx?id=410902">"Pills become an addictive study aid"</a>. <i>JS Online</i>. Archived from <a rel="nofollow" class="external text" href="http://www.jsonline.com/story/index.aspx?id=410902">the original</a> on 15 August 2007<span class="reference-accessdate">. Retrieved 2 December 2007</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Pills+become+an+addictive+study+aid&amp;rft.aulast=Twohey+M&amp;rft.au=Twohey+M&amp;rft.date=26+March+2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.jsonline.com%2Fstory%2Findex.aspx%3Fid%3D410902&amp;rft.jtitle=JS+Online&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16999660-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16999660_59-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223">"Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration"</a>. <i>Pharmacotherapy</i> <b>26</b> (10): 1501–1510. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1592%2Fphco.26.10.1501">10.1592/phco.26.10.1501</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1794223">1794223</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16999660">16999660</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Illicit+use+of+specific+prescription+stimulants+among+college+students%3A+prevalence%2C+motives%2C+and+routes+of+administration&amp;rft.aulast=Teter+CJ%2C+McCabe+SE%2C+LaGrange+K%2C+Cranford+JA%2C+Boyd+CJ&amp;rft.au=Teter+CJ%2C+McCabe+SE%2C+LaGrange+K%2C+Cranford+JA%2C+Boyd+CJ&amp;rft.date=October+2006&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1794223&amp;rft_id=info%3Adoi%2F10.1592%2Fphco.26.10.1501&amp;rft_id=info%3Apmc%2F1794223&amp;rft_id=info%3Apmid%2F16999660&amp;rft.issue=10&amp;rft.jtitle=Pharmacotherapy&amp;rft.pages=1501%26ndash%3B1510&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NCAA-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-NCAA_60-0">^</a></b></span> <span class="reference-text"><span class="citation web">Bracken NM (January 2012). <a rel="nofollow" class="external text" href="http://www.ncaapublications.com/productdownloads/SAHS09.pdf">"National Study of Substance Use Trends Among NCAA College Student-Athletes"</a>. <i>NCAA Publications</i>. National Collegiate Athletic Association<span class="reference-accessdate">. Retrieved 8 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=National+Study+of+Substance+Use+Trends+Among+NCAA+College+Student-Athletes&amp;rft.au=Bracken+NM&amp;rft.aulast=Bracken+NM&amp;rft.date=January+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.ncaapublications.com%2Fproductdownloads%2FSAHS09.pdf&amp;rft.jtitle=NCAA+Publications&amp;rft.pub=National+Collegiate+Athletic+Association&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Ergogenics2-61"><span class="mw-cite-backlink">^ <a href="#cite_ref-Ergogenics2_61-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Ergogenics2_61-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Ergogenics2_61-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Ergogenics2_61-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Parr JW (July 2011). "Attention-deficit hyperactivity disorder and the athlete: new advances and understanding". <i>Clin Sports Med</i> <b>30</b> (3): 591–610. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.csm.2011.03.007">10.1016/j.csm.2011.03.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21658550">21658550</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Attention-deficit+hyperactivity+disorder+and+the+athlete%3A+new+advances+and+understanding&amp;rft.aulast=Parr+JW&amp;rft.au=Parr+JW&amp;rft.date=July+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.csm.2011.03.007&amp;rft_id=info%3Apmid%2F21658550&amp;rft.issue=3&amp;rft.jtitle=Clin+Sports+Med&amp;rft.pages=591%26ndash%3B610&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Roelands_2013-62"><span class="mw-cite-backlink">^ <a href="#cite_ref-Roelands_2013_62-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Roelands_2013_62-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Roelands_2013_62-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). "Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing". <i>Sports Med.</i> <b>43</b> (5): 301–311. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs40279-013-0030-4">10.1007/s40279-013-0030-4</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23456493">23456493</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Neurophysiological+determinants+of+theoretical+concepts+and+mechanisms+involved+in+pacing&amp;rft.aulast=Roelands+B%2C+de+Koning+J%2C+Foster+C%2C+Hettinga+F%2C+Meeusen+R&amp;rft.au=Roelands+B%2C+de+Koning+J%2C+Foster+C%2C+Hettinga+F%2C+Meeusen+R&amp;rft.date=May+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs40279-013-0030-4&amp;rft_id=info%3Apmid%2F23456493&amp;rft.issue=5&amp;rft.jtitle=Sports+Med.&amp;rft.pages=301%26ndash%3B311&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=43" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Contra_Warnings-64"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Contra_Warnings_64-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Contra_Warnings_64-6"><sup><i><b>g</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;4–6<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=4%26ndash%3B6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-65"><span class="mw-cite-backlink"><b><a href="#cite_ref-65">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://depts.washington.edu/druginfo/Formulary/Pregnancy.pdf">"FDA Pregnancy Categories"</a>. <i>United States Food and Drug Administration</i>. 21 October 2004<span class="reference-accessdate">. Retrieved 31 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=FDA+Pregnancy+Categories&amp;rft.date=21+October+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fdepts.washington.edu%2Fdruginfo%2FFormulary%2FPregnancy.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-66">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/ndc/results.cfm?beginrow=1&amp;numberperpage=160&amp;searchfield=amphetamine&amp;searchtype=ActiveIngredient&amp;OrderBy=ProprietaryName">"National Drug Code Amphetamine Search Results"</a>. <i>National Drug Code Directory</i>. United States Food and Drug Administration<span class="reference-accessdate">. Retrieved 16 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=National+Drug+Code+Amphetamine+Search+Results&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fndc%2Fresults.cfm%3Fbeginrow%3D1%26numberperpage%3D160%26searchfield%3Damphetamine%26searchtype%3DActiveIngredient%26OrderBy%3DProprietaryName&amp;rft.jtitle=National+Drug+Code+Directory&amp;rft.pub=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18295156-67"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid18295156_67-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid18295156_67-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Vitiello B (April 2008). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826">"Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function"</a>. <i>Child Adolesc. Psychiatr. Clin. N. Am.</i> <b>17</b> (2): 459–474. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.chc.2007.11.010">10.1016/j.chc.2007.11.010</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2408826">2408826</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18295156">18295156</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Understanding+the+risk+of+using+medications+for+attention+deficit+hyperactivity+disorder+with+respect+to+physical+growth+and+cardiovascular+function&amp;rft.aulast=Vitiello+B&amp;rft.au=Vitiello+B&amp;rft.date=April+2008&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2408826&amp;rft_id=info%3Adoi%2F10.1016%2Fj.chc.2007.11.010&amp;rft_id=info%3Apmc%2F2408826&amp;rft_id=info%3Apmid%2F18295156&amp;rft.issue=2&amp;rft.jtitle=Child+Adolesc.+Psychiatr.+Clin.+N.+Am.&amp;rft.pages=459%26ndash%3B474&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-68">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/DrugSafety/ucm277770.htm">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults"</a>. <i>United States Food and Drug Administration</i>. 20 December 2011<span class="reference-accessdate">. Retrieved 4 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=FDA+Drug+Safety+Communication%3A+Safety+Review+Update+of+Medications+used+to+treat+Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29+in+children+and+young+adults&amp;rft.date=20+December+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm277770.htm&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22043968-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22043968_69-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (November 2011). "ADHD drugs and serious cardiovascular events in children and young adults". <i>N. Engl. J. Med.</i> <b>365</b> (20): 1896–1904. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1056%2FNEJMoa1110212">10.1056/NEJMoa1110212</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22043968">22043968</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=ADHD+drugs+and+serious+cardiovascular+events+in+children+and+young+adults&amp;rft.au=Cooper+WO%2C+Habel+LA%2C+Sox+CM%2C+Chan+KA%2C+Arbogast+PG%2C+Cheetham+TC%2C+Murray+KT%2C+Quinn+VP%2C+Stein+CM%2C+Callahan+ST%2C+Fireman+BH%2C+Fish+FA%2C+Kirshner+HS%2C+O%27Duffy+A%2C+Connell+FA%2C+Ray+WA&amp;rft.aulast=Cooper+WO%2C+Habel+LA%2C+Sox+CM%2C+Chan+KA%2C+Arbogast+PG%2C+Cheetham+TC%2C+Murray+KT%2C+Quinn+VP%2C+Stein+CM%2C+Callahan+ST%2C+Fireman+BH%2C+Fish+FA%2C+Kirshner+HS%2C+O%27Duffy+A%2C+Connell+FA%2C+Ray+WA&amp;rft.date=November+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa1110212&amp;rft_id=info%3Apmid%2F22043968&amp;rft.issue=20&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1896%26ndash%3B1904&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=365" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-70">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/Drugs/DrugSafety/ucm279858.htm">"FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults"</a>. <i>United States Food and Drug Administration</i>. 15 December 2011<span class="reference-accessdate">. Retrieved 4 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=FDA+Drug+Safety+Communication%3A+Safety+Review+Update+of+Medications+used+to+treat+Attention-Deficit%2FHyperactivity+Disorder+%28ADHD%29+in+adults&amp;rft.date=15+December+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FDrugSafety%2Fucm279858.htm&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22161946-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22161946_71-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (December 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308">"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults"</a>. <i>JAMA</i> <b>306</b> (24): 2673–2683. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1001%2Fjama.2011.1830">10.1001/jama.2011.1830</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3350308">3350308</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22161946">22161946</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=ADHD+medications+and+risk+of+serious+cardiovascular+events+in+young+and+middle-aged+adults&amp;rft.au=Habel+LA%2C+Cooper+WO%2C+Sox+CM%2C+Chan+KA%2C+Fireman+BH%2C+Arbogast+PG%2C+Cheetham+TC%2C+Quinn+VP%2C+Dublin+S%2C+Boudreau+DM%2C+Andrade+SE%2C+Pawloski+PA%2C+Raebel+MA%2C+Smith+DH%2C+Achacoso+N%2C+Uratsu+C%2C+Go+AS%2C+Sidney+S%2C+Nguyen-Huynh+MN%2C+Ray+WA%2C+Selby+JV&amp;rft.aulast=Habel+LA%2C+Cooper+WO%2C+Sox+CM%2C+Chan+KA%2C+Fireman+BH%2C+Arbogast+PG%2C+Cheetham+TC%2C+Quinn+VP%2C+Dublin+S%2C+Boudreau+DM%2C+Andrade+SE%2C+Pawloski+PA%2C+Raebel+MA%2C+Smith+DH%2C+Achacoso+N%2C+Uratsu+C%2C+Go+AS%2C+Sidney+S%2C+Nguyen-Huynh+MN%2C+Ray+WA%2C+Selby+JV&amp;rft.date=December+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3350308&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.2011.1830&amp;rft_id=info%3Apmc%2F3350308&amp;rft_id=info%3Apmid%2F22161946&amp;rft.issue=24&amp;rft.jtitle=JAMA&amp;rft.pages=2673%26ndash%3B2683&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=306" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Merck_Manual_Amphetamines-73"><span class="mw-cite-backlink">^ <a href="#cite_ref-Merck_Manual_Amphetamines_73-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Merck_Manual_Amphetamines_73-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web">O'Connor PG (February 2012). <a rel="nofollow" class="external text" href="http://www.merckmanuals.com/professional/special_subjects/drug_use_and_dependence/amphetamines.html">"Amphetamines"</a>. <i>Merck Manual for Health Care Professionals</i>. Merck<span class="reference-accessdate">. Retrieved 8 May 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamines&amp;rft.aulast=O%27Connor+PG&amp;rft.au=O%27Connor+PG&amp;rft.date=February+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fprofessional%2Fspecial_subjects%2Fdrug_use_and_dependence%2Famphetamines.html&amp;rft.jtitle=Merck+Manual+for+Health+Care+Professionals&amp;rft.pub=Merck&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amphetamine_toxidrome-75"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amphetamine_toxidrome_75-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amphetamine_toxidrome_75-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Spiller HA, Hays HL, Aleguas A (June 2013). "Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management". <i>CNS Drugs</i> <b>27</b> (7): 531–543. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs40263-013-0084-8">10.1007/s40263-013-0084-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23757186">23757186</a>. "Amphetamine, dextroamphetamine, and methylphenidate act as substrates for the cellular monoamine transporter, especially the dopamine transporter (DAT) and less so the norepinephrine (NET) and serotonin transporter. The mechanism of toxicity is primarily related to excessive extracellular dopamine, norepinephrine, and serotonin."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Overdose+of+drugs+for+attention-deficit+hyperactivity+disorder%3A+clinical+presentation%2C+mechanisms+of+toxicity%2C+and+management&amp;rft.aulast=Spiller+HA%2C+Hays+HL%2C+Aleguas+A&amp;rft.au=Spiller+HA%2C+Hays+HL%2C+Aleguas+A&amp;rft.date=June+2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs40263-013-0084-8&amp;rft_id=info%3Apmid%2F23757186&amp;rft.issue=7&amp;rft.jtitle=CNS+Drugs&amp;rft.pages=531%26ndash%3B543&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Albertson_2011-76"><span class="mw-cite-backlink"><b><a href="#cite_ref-Albertson_2011_76-0">^</a></b></span> <span class="reference-text"><span class="citation book">Albertson TE (2011). "Amphetamines". In Olson KR, Anderson IB, Benowitz NL, Blanc PD, Kearney TE, Kim-Katz SY, Wu AHB. <i>Poisoning &amp; Drug Overdose</i> (6th ed.). New York: McGraw-Hill Medical. pp.&#160;77–79. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071668330" title="Special:BookSources/9780071668330">9780071668330</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Poisoning+%26+Drug+Overdose&amp;rft.au=Albertson+TE&amp;rft.aulast=Albertson+TE&amp;rft.btitle=Amphetamines&amp;rft.date=2011&amp;rft.edition=6th&amp;rft.genre=bookitem&amp;rft.isbn=9780071668330&amp;rft.pages=77%26ndash%3B79&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph_OD-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-Amph_OD_77-0">^</a></b></span> <span class="reference-text"><span class="citation web">Oskie SM, Rhee JW (11 February 2011). <a rel="nofollow" class="external text" href="http://emergency.unboundmedicine.com/emergency/ub/view/5-Minute_Emergency_Consult/307063/all/Amphetamine_Poisoning">"Amphetamine Poisoning"</a>. <i>Emergency Central</i>. Unbound Medicine<span class="reference-accessdate">. Retrieved 11 June 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine+Poisoning&amp;rft.aulast=Oskie+SM%2C+Rhee+JW&amp;rft.au=Oskie+SM%2C+Rhee+JW&amp;rft.date=11+February+2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Femergency.unboundmedicine.com%2Femergency%2Fub%2Fview%2F5-Minute_Emergency_Consult%2F307063%2Fall%2FAmphetamine_Poisoning&amp;rft.jtitle=Emergency+Central&amp;rft.pub=Unbound+Medicine&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20070217053619/http://www.merck.com/mmhe/sec07/ch108/ch108g.html">"Amphetamines: Drug Use and Abuse"</a>. <i>Merck Manual Home Edition</i>. Merck. February 2003. Archived from <a rel="nofollow" class="external text" href="http://www.merckmanuals.com/home/special_subjects/drug_use_and_abuse/amphetamines.html">the original</a> on 17 February 2007<span class="reference-accessdate">. Retrieved 28 February 2007</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamines%3A+Drug+Use+and+Abuse&amp;rft.date=February+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.merckmanuals.com%2Fhome%2Fspecial_subjects%2Fdrug_use_and_abuse%2Famphetamines.html&amp;rft.jtitle=Merck+Manual+Home+Edition&amp;rft.pub=Merck&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><span class="citation journal">Pérez-Mañá C, Castells X, Torrens M, Capellà D, Farre M (2013). "Efficacy of psychostimulant drugs for amphetamine abuse or dependence". In Pérez-Mañá C. <i>Cochrane Database Syst. Rev.</i> <b>9</b>: CD009695. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD009695.pub2">10.1002/14651858.CD009695.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23996457">23996457</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Efficacy+of+psychostimulant+drugs+for+amphetamine+abuse+or+dependence&amp;rft.aulast=P%C3%A9rez-Ma%C3%B1%C3%A1+C%2C+Castells+X%2C+Torrens+M%2C+Capell%C3%A0+D%2C+Farre+M&amp;rft.au=P%C3%A9rez-Ma%C3%B1%C3%A1+C%2C+Castells+X%2C+Torrens+M%2C+Capell%C3%A0+D%2C+Farre+M&amp;rft.date=2013&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD009695.pub2&amp;rft_id=info%3Apmid%2F23996457&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD009695&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_Addiction-81"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_Addiction_81-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_Addiction_81-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cochrane_Addiction_81-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cochrane_Addiction_81-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Cochrane_Addiction_81-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P (2001). "Treatment for amphetamine dependence and abuse". In Srisurapanont M. <i>Cochrane Database Syst. Rev.</i> (4): CD003022. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003022">10.1002/14651858.CD003022</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11687171">11687171</a>. "Although there are a variety of amphetamines and amphetamine derivatives, the word “amphetamines” in this review stands for amphetamine, dextroamphetamine and methamphetamine only."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Treatment+for+amphetamine+dependence+and+abuse&amp;rft.aulast=Srisurapanont+M%2C+Jarusuraisin+N%2C+Kittirattanapaiboon+P&amp;rft.au=Srisurapanont+M%2C+Jarusuraisin+N%2C+Kittirattanapaiboon+P&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003022&amp;rft_id=info%3Apmid%2F11687171&amp;rft.issue=4&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003022&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Magnesium-84"><span class="mw-cite-backlink">^ <a href="#cite_ref-Magnesium_84-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Magnesium_84-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Magnesium_84-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Magnesium_84-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Magnesium_84-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Nechifor M (March 2008). "Magnesium in drug dependences". <i>Magnes. Res.</i> <b>21</b> (1): 5–15. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18557129">18557129</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Magnesium+in+drug+dependences&amp;rft.aulast=Nechifor+M&amp;rft.au=Nechifor+M&amp;rft.date=March+2008&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F18557129&amp;rft.issue=1&amp;rft.jtitle=Magnes.+Res.&amp;rft.pages=5%26ndash%3B15&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=21" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Cochrane_Withdrawal-86"><span class="mw-cite-backlink">^ <a href="#cite_ref-Cochrane_Withdrawal_86-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_86-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_86-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Cochrane_Withdrawal_86-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Shoptaw SJ, Kao U, Heinzerling K, Ling W (2009). "Treatment for amphetamine withdrawal". In Shoptaw SJ. <i>Cochrane Database Syst. Rev.</i> (2): CD003021. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F14651858.CD003021.pub2">10.1002/14651858.CD003021.pub2</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19370579">19370579</a>. "<br />
The prevalence of this withdrawal syndrome is extremely common (Cantwell 1998; Gossop 1982) with 87.6% of 647 individuals with amphetamine dependence reporting six or more signs of amphetamine withdrawal listed in the DSM when the drug is not available (Schuckit 1999)&#160;...&#160;Withdrawal symptoms typically present within 24 hours of the last use of amphetamine, with a withdrawal syndrome involving two general phases that can last 3 weeks or more. The first phase of this syndrome is the initial “crash” that resolves within about a week (Gossop 1982;McGregor 2005)&#160;..."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Treatment+for+amphetamine+withdrawal&amp;rft.aulast=Shoptaw+SJ%2C+Kao+U%2C+Heinzerling+K%2C+Ling+W&amp;rft.au=Shoptaw+SJ%2C+Kao+U%2C+Heinzerling+K%2C+Ling+W&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F14651858.CD003021.pub2&amp;rft_id=info%3Apmid%2F19370579&amp;rft.issue=2&amp;rft.jtitle=Cochrane+Database+Syst.+Rev.&amp;rft.pages=CD003021&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/011522s040lbl.pdf">"Adderall IR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. March 2007<span class="reference-accessdate">. Retrieved 4 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+IR+Prescribing+Information&amp;rft.date=March+2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F011522s040lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-88">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017078s046lbl.pdf">"Dexedrine Medication Guide"</a>. <i>United States Food and Drug Administration</i>. May 2013<span class="reference-accessdate">. Retrieved 4 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Dexedrine+Medication+Guide&amp;rft.date=May+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F017078s046lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler.2C_Hyman.2C_and_Malenka_2-90"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Nestler.2C_Hyman.2C_and_Malenka_2_90-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Hyman SE, Malenka RC, Nestler EJ (2006). "Neural mechanisms of addiction: the role of reward-related learning and memory". <i>Annu. Rev. Neurosci.</i> <b>29</b>: 565–598. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1146%2Fannurev.neuro.29.051605.113009">10.1146/annurev.neuro.29.051605.113009</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16776597">16776597</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Neural+mechanisms+of+addiction%3A+the+role+of+reward-related+learning+and+memory&amp;rft.au=Hyman+SE%2C+Malenka+RC%2C+Nestler+EJ&amp;rft.aulast=Hyman+SE%2C+Malenka+RC%2C+Nestler+EJ&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1146%2Fannurev.neuro.29.051605.113009&amp;rft_id=info%3Apmid%2F16776597&amp;rft.jtitle=Annu.+Rev.+Neurosci.&amp;rft.pages=565%26ndash%3B598&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Nestler-91"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nestler_91-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nestler_91-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Nestler_91-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Nestler_91-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Nestler_91-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Nestler_91-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Nestler_91-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Nestler_91-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Nestler_91-8"><sup><i><b>i</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Nestler EJ (December 2012). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166">"Transcriptional mechanisms of drug addiction"</a>. <i>Clin. Psychopharmacol. Neurosci.</i> <b>10</b> (3): 136–143. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.9758%2Fcpn.2012.10.3.136">10.9758/cpn.2012.10.3.136</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3569166">3569166</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23430970">23430970</a>. "ΔFosB has been linked directly to several addiction-related behaviors&#160;...&#160; Importantly, genetic or viral overexpression of ΔJunD, a dominant negative mutant of JunD which antagonizes ΔFosB- and other AP-1-mediated transcriptional activity, in the NAc or OFC blocks these key effects of drug exposure14,22–24. This indicates that ΔFosB is both necessary and sufficient for many of the changes wrought in the brain by chronic drug exposure. ΔFosB is also induced in D1-type NAc MSNs by chronic consumption of several natural rewards, including sucrose, high fat food, sex, wheel running, where it promotes that consumption14,26–30. This implicates ΔFosB in the regulation of natural rewards under normal conditions and perhaps during pathological addictive-like states."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Transcriptional+mechanisms+of+drug+addiction&amp;rft.aulast=Nestler+EJ&amp;rft.au=Nestler+EJ&amp;rft.date=December+2012&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3569166&amp;rft_id=info%3Adoi%2F10.9758%2Fcpn.2012.10.3.136&amp;rft_id=info%3Apmc%2F3569166&amp;rft_id=info%3Apmid%2F23430970&amp;rft.issue=3&amp;rft.jtitle=Clin.+Psychopharmacol.+Neurosci.&amp;rft.pages=136%26ndash%3B143&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Addiction_genetics-92"><span class="mw-cite-backlink">^ <a href="#cite_ref-Addiction_genetics_92-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_92-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_92-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Addiction_genetics_92-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Steiner H, Van Waes V (January 2013). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776">"Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants"</a>. <i>Prog. Neurobiol.</i> <b>100</b>: 60–80. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pneurobio.2012.10.001">10.1016/j.pneurobio.2012.10.001</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3525776">3525776</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/23085425">23085425</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Addiction-related+gene+regulation%3A+risks+of+exposure+to+cognitive+enhancers+vs.+other+psychostimulants&amp;rft.aulast=Steiner+H%2C+Van+Waes+V&amp;rft.au=Steiner+H%2C+Van+Waes+V&amp;rft.date=January+2013&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3525776&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pneurobio.2012.10.001&amp;rft_id=info%3Apmc%2F3525776&amp;rft_id=info%3Apmid%2F23085425&amp;rft.jtitle=Prog.+Neurobiol.&amp;rft.pages=60%26ndash%3B80&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=100" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Genetic_sex_addiction-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-Genetic_sex_addiction_93-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Pitchers KK, Frohmader KS, Vialou V, Mouzon E, Nestler EJ, Lehman MN, Coolen LM (October 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2970635">"ΔFosB in the nucleus accumbens is critical for reinforcing effects of sexual reward"</a>. <i>Genes Brain Behav.</i> <b>9</b> (7): 831–840. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1601-183X.2010.00621.x">10.1111/j.1601-183X.2010.00621.x</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2970635">2970635</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20618447">20618447</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=%CE%94FosB+in+the+nucleus+accumbens+is+critical+for+reinforcing+effects+of+sexual+reward&amp;rft.aulast=Pitchers+KK%2C+Frohmader+KS%2C+Vialou+V%2C+Mouzon+E%2C+Nestler+EJ%2C+Lehman+MN%2C+Coolen+LM&amp;rft.au=Pitchers+KK%2C+Frohmader+KS%2C+Vialou+V%2C+Mouzon+E%2C+Nestler+EJ%2C+Lehman+MN%2C+Coolen+LM&amp;rft.date=October+2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2970635&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1601-183X.2010.00621.x&amp;rft_id=info%3Apmc%2F2970635&amp;rft_id=info%3Apmid%2F20618447&amp;rft.issue=7&amp;rft.jtitle=Genes+Brain+Behav.&amp;rft.pages=831%26ndash%3B840&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=9" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009_04-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-Malenka_2009_04_94-0">^</a></b></span> <span class="reference-text"><span class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and addictive disorders". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. pp.&#160;384–385. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.aulast=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=Chapter+15%3A+Reinforcement+and+addictive+disorders&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=384%26ndash%3B385&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Hofmann-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-Hofmann_95-0">^</a></b></span> <span class="reference-text"><span class="citation book">Hofmann FG (1983). <i>A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects</i> (2nd ed.). New York: Oxford University Press. p.&#160;329. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780195030570" title="Special:BookSources/9780195030570">9780195030570</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.au=Hofmann+FG&amp;rft.aulast=Hofmann+FG&amp;rft.btitle=A+Handbook+on+Drug+and+Alcohol+Abuse%3A+The+Biomedical+Aspects&amp;rft.date=1983&amp;rft.edition=2nd&amp;rft.genre=book&amp;rft.isbn=9780195030570&amp;rft.pages=329&amp;rft.place=New+York&amp;rft.pub=Oxford+University+Press&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Humans.26Animals-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-Humans.26Animals_96-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Advokat C (2007). "Update on amphetamine neurotoxicity and its relevance to the treatment of ADHD". <i>J. Atten. Disord.</i> <b>11</b> (1): 8–16. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1177%2F1087054706295605">10.1177/1087054706295605</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17606768">17606768</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Update+on+amphetamine+neurotoxicity+and+its+relevance+to+the+treatment+of+ADHD&amp;rft.au=Advokat+C&amp;rft.aulast=Advokat+C&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1177%2F1087054706295605&amp;rft_id=info%3Apmid%2F17606768&amp;rft.issue=1&amp;rft.jtitle=J.+Atten.+Disord.&amp;rft.pages=8%26ndash%3B16&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=11" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9">"Amphetamine"</a>. <i>Hazardous Substances Data Bank</i>. National Library of Medicine<span class="reference-accessdate">. Retrieved 26 February 2014</span>. "Direct toxic damage to vessels seems unlikely because of the dilution that occurs before the drug reaches the cerebral circulation."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Ftoxnet.nlm.nih.gov%2Fcgi-bin%2Fsis%2Fsearch%2Fr%3Fdbs%2Bhsdb%3A%40term%2B%40rn%2B%40rel%2B300-62-9&amp;rft.jtitle=Hazardous+Substances+Data+Bank&amp;rft.pub=National+Library+of+Medicine&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Malenka_2009_02-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-Malenka_2009_02_98-0">^</a></b></span> <span class="reference-text"><span class="citation book">Malenka RC, Nestler EJ, Hyman SE (2009). "15". In Sydor A, Brown RY. <i>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience</i> (2nd ed.). New York: McGraw-Hill Medical. p.&#160;370. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780071481274" title="Special:BookSources/9780071481274">9780071481274</a>. "Unlike cocaine and amphetamine, methamphetamine is directly toxic to midbrain dopamine neurons."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Molecular+Neuropharmacology%3A+A+Foundation+for+Clinical+Neuroscience&amp;rft.aulast=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.au=Malenka+RC%2C+Nestler+EJ%2C+Hyman+SE&amp;rft.btitle=15&amp;rft.date=2009&amp;rft.edition=2nd&amp;rft.genre=bookitem&amp;rft.isbn=9780071481274&amp;rft.pages=370&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill+Medical&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Autoxidation1-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-Autoxidation1_99-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Sulzer D, Zecca L (February 2000). "Intraneuronal dopamine-quinone synthesis: a review". <i>Neurotox. Res.</i> <b>1</b> (3): 181–195. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2FBF03033289">10.1007/BF03033289</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12835101">12835101</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Intraneuronal+dopamine-quinone+synthesis%3A+a+review&amp;rft.aulast=Sulzer+D%2C+Zecca+L&amp;rft.au=Sulzer+D%2C+Zecca+L&amp;rft.date=February+2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2FBF03033289&amp;rft_id=info%3Apmid%2F12835101&amp;rft.issue=3&amp;rft.jtitle=Neurotox.+Res.&amp;rft.pages=181%26ndash%3B195&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Autoxidation2-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-Autoxidation2_100-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Miyazaki I, Asanuma M (June 2008). "Dopaminergic neuron-specific oxidative stress caused by dopamine itself". <i>Acta Med. Okayama</i> <b>62</b> (3): 141–150. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18596830">18596830</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Dopaminergic+neuron-specific+oxidative+stress+caused+by+dopamine+itself&amp;rft.aulast=Miyazaki+I%2C+Asanuma+M&amp;rft.au=Miyazaki+I%2C+Asanuma+M&amp;rft.date=June+2008&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F18596830&amp;rft.issue=3&amp;rft.jtitle=Acta+Med.+Okayama&amp;rft.pages=141%26ndash%3B150&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=62" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Interactions-101"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Interactions_101-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-FDA_Interactions_101-9"><sup><i><b>j</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf">"Adderall XR Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;8–10<span class="reference-accessdate">. Retrieved 30 December 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Adderall+XR+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021303s026lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=8%26ndash%3B10&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DrugBank_2-102"><span class="mw-cite-backlink">^ <a href="#cite_ref-DrugBank_2_102-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DrugBank_2_102-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-DrugBank_2_102-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-DrugBank_2_102-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-DrugBank_2_102-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-DrugBank_2_102-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#targets"><i>Targets</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Targets&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23targets&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><span class="citation web">Maguire JJ, Davenport AP (19 April 2013). <a rel="nofollow" class="external text" href="http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=364">"TA<sub>1</sub> receptor"</a>. <i>IUPHAR database</i>. International Union of Basic and Clinical Pharmacology<span class="reference-accessdate">. Retrieved 18 February 2014</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=TA%3Csub%3E1%3C%2Fsub%3E+receptor&amp;rft.aulast=Maguire+JJ%2C+Davenport+AP&amp;rft.au=Maguire+JJ%2C+Davenport+AP&amp;rft.date=19+April+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.iuphar-db.org%2FDATABASE%2FObjectDisplayForward%3FobjectId%3D364&amp;rft.jtitle=IUPHAR+database&amp;rft.pub=International+Union+of+Basic+and+Clinical+Pharmacology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid11459929-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11459929_104-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C (July 2001). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC55357">"Trace amines: identification of a family of mammalian G protein-coupled receptors"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>98</b> (16): 8966–8971. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1073%2Fpnas.151105198">10.1073/pnas.151105198</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC55357">55357</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11459929">11459929</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Trace+amines%3A+identification+of+a+family+of+mammalian+G+protein-coupled+receptors&amp;rft.au=Borowsky+B%2C+Adham+N%2C+Jones+KA%2C+Raddatz+R%2C+Artymyshyn+R%2C+Ogozalek+KL%2C+Durkin+MM%2C+Lakhlani+PP%2C+Bonini+JA%2C+Pathirana+S%2C+Boyle+N%2C+Pu+X%2C+Kouranova+E%2C+Lichtblau+H%2C+Ochoa+FY%2C+Branchek+TA%2C+Gerald+C&amp;rft.aulast=Borowsky+B%2C+Adham+N%2C+Jones+KA%2C+Raddatz+R%2C+Artymyshyn+R%2C+Ogozalek+KL%2C+Durkin+MM%2C+Lakhlani+PP%2C+Bonini+JA%2C+Pathirana+S%2C+Boyle+N%2C+Pu+X%2C+Kouranova+E%2C+Lichtblau+H%2C+Ochoa+FY%2C+Branchek+TA%2C+Gerald+C&amp;rft.date=July+2001&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC55357&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.151105198&amp;rft_id=info%3Apmc%2F55357&amp;rft_id=info%3Apmid%2F11459929&amp;rft.issue=16&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=8966%26ndash%3B8971&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=98" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-PubChem_Targets-105"><span class="mw-cite-backlink">^ <a href="#cite_ref-PubChem_Targets_105-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-PubChem_Targets_105-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-PubChem_Targets_105-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-PubChem_Targets_105-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x301"><i>Biomolecular Interactions and Pathways</i></a>. "Amphetamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Biomolecular+Interactions+and+Pathways&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23x301&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DrugBank_Transporters-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-DrugBank_Transporters_106-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#transporters"><i>Transporters</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Transporters&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23transporters&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid13677912-107"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid13677912_107-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Inazu M, Takeda H, Matsumiya T (August 2003). "[The role of glial monoamine transporters in the central nervous system]". <i>Nihon Shinkei Seishin Yakurigaku Zasshi</i> (in Japanese) <b>23</b> (4): 171–178. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/13677912">13677912</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=%5BThe+role+of+glial+monoamine+transporters+in+the+central+nervous+system%5D&amp;rft.au=Inazu+M%2C+Takeda+H%2C+Matsumiya+T&amp;rft.aulast=Inazu+M%2C+Takeda+H%2C+Matsumiya+T&amp;rft.date=August+2003&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F13677912&amp;rft.issue=4&amp;rft.jtitle=Nihon+Shinkei+Seishin+Yakurigaku+Zasshi&amp;rft.pages=171%26ndash%3B178&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=23" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-CART-108"><span class="mw-cite-backlink">^ <a href="#cite_ref-CART_108-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-CART_108-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Vicentic A, Lakatos A, Jones D (August 2006). "The CART receptors: background and recent advances". <i>Peptides</i> <b>27</b> (8): 1934–1937. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.peptides.2006.03.031">10.1016/j.peptides.2006.03.031</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16713658">16713658</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+CART+receptors%3A+background+and+recent+advances&amp;rft.aulast=Vicentic+A%2C+Lakatos+A%2C+Jones+D&amp;rft.au=Vicentic+A%2C+Lakatos+A%2C+Jones+D&amp;rft.date=August+2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.peptides.2006.03.031&amp;rft_id=info%3Apmid%2F16713658&amp;rft.issue=8&amp;rft.jtitle=Peptides&amp;rft.pages=1934%26ndash%3B1937&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=27" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21855138-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21855138_109-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lin Y, Hall RA, Kuhar MJ (October 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3170513">"CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist"</a>. <i>Neuropeptides</i> <b>45</b> (5): 351–358. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.npep.2011.07.006">10.1016/j.npep.2011.07.006</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3170513">3170513</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21855138">21855138</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=CART+peptide+stimulation+of+G+protein-mediated+signaling+in+differentiated+PC12+cells%3A+identification+of+PACAP+6-38+as+a+CART+receptor+antagonist&amp;rft.aulast=Lin+Y%2C+Hall+RA%2C+Kuhar+MJ&amp;rft.au=Lin+Y%2C+Hall+RA%2C+Kuhar+MJ&amp;rft.date=October+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3170513&amp;rft_id=info%3Adoi%2F10.1016%2Fj.npep.2011.07.006&amp;rft_id=info%3Apmc%2F3170513&amp;rft_id=info%3Apmid%2F21855138&amp;rft.issue=5&amp;rft.jtitle=Neuropeptides&amp;rft.pages=351%26ndash%3B358&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=45" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-E_Weihe-110"><span class="mw-cite-backlink">^ <a href="#cite_ref-E_Weihe_110-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-E_Weihe_110-10"><sup><i><b>k</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Eiden LE, Weihe E (January 2011). "VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse". <i>Ann. N. Y. Acad. Sci.</i> <b>1216</b>: 86–98. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1111%2Fj.1749-6632.2010.05906.x">10.1111/j.1749-6632.2010.05906.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21272013">21272013</a>. "VMAT2 is the CNS vesicular transporter for not only the biogenic amines <abbr title="dopamine">DA</abbr>, <abbr title="norepinephrine">NE</abbr>, <abbr title="epinephrine">EPI</abbr>, <abbr title="serotonin">5-HT</abbr>, and <abbr title="histamine">HIS</abbr>, but likely also for the trace amines <abbr title="tyramine">TYR</abbr>, <abbr title="phenethylamine">PEA</abbr>, and thyronamine (THYR)&#160;...&#160;[Trace aminergic] neurons in mammalian CNS would be identiﬁable as neurons expressing VMAT2 for storage, and the biosynthetic enzyme aromatic amino acid decarboxylase (AADC)."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=VMAT2%3A+a+dynamic+regulator+of+brain+monoaminergic+neuronal+function+interacting+with+drugs+of+abuse&amp;rft.au=Eiden+LE%2C+Weihe+E&amp;rft.aulast=Eiden+LE%2C+Weihe+E&amp;rft.date=January+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1749-6632.2010.05906.x&amp;rft_id=info%3Apmid%2F21272013&amp;rft.jtitle=Ann.+N.+Y.+Acad.+Sci.&amp;rft.pages=86%26ndash%3B98&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1216" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Acetylcholine-111"><span class="mw-cite-backlink">^ <a href="#cite_ref-Acetylcholine_111-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Acetylcholine_111-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Acetylcholine_111-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Imperato A, Obinu MC, Gessa GL (July 1993). "Effects of cocaine and amphetamine on acetylcholine release in the hippocampus and caudate nucleus". <i>Eur. J. Pharmacol.</i> <b>238</b> (2–3): 377–381. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2F0014-2999%2893%2990869-J">10.1016/0014-2999(93)90869-J</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8405105">8405105</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Effects+of+cocaine+and+amphetamine+on+acetylcholine+release+in+the+hippocampus+and+caudate+nucleus&amp;rft.au=Imperato+A%2C+Obinu+MC%2C+Gessa+GL&amp;rft.aulast=Imperato+A%2C+Obinu+MC%2C+Gessa+GL&amp;rft.date=July+1993&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0014-2999%2893%2990869-J&amp;rft_id=info%3Apmid%2F8405105&amp;rft.issue=2%26ndash%3B3&amp;rft.jtitle=Eur.+J.+Pharmacol.&amp;rft.pages=377%26ndash%3B381&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=238" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MEDRS-Cholinergic-112"><span class="mw-cite-backlink">^ <a href="#cite_ref-MEDRS-Cholinergic_112-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-MEDRS-Cholinergic_112-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-MEDRS-Cholinergic_112-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Dickson SL, Egecioglu E, Landgren S, Skibicka KP, Engel JA, Jerlhag E (June 2011). "The role of the central ghrelin system in reward from food and chemical drugs". <i>Mol. Cell. Endocrinol.</i> <b>340</b> (1): 80–87. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.mce.2011.02.017">10.1016/j.mce.2011.02.017</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21354264">21354264</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+role+of+the+central+ghrelin+system+in+reward+from+food+and+chemical+drugs&amp;rft.au=Dickson+SL%2C+Egecioglu+E%2C+Landgren+S%2C+Skibicka+KP%2C+Engel+JA%2C+Jerlhag+E&amp;rft.aulast=Dickson+SL%2C+Egecioglu+E%2C+Landgren+S%2C+Skibicka+KP%2C+Engel+JA%2C+Jerlhag+E&amp;rft.date=June+2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.mce.2011.02.017&amp;rft_id=info%3Apmid%2F21354264&amp;rft.issue=1&amp;rft.jtitle=Mol.+Cell.+Endocrinol.&amp;rft.pages=80%26ndash%3B87&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=340" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-glutamate1-113"><span class="mw-cite-backlink">^ <a href="#cite_ref-glutamate1_113-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-glutamate1_113-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-glutamate1_113-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Stuber GD, Hnasko TS, Britt JP, Edwards RH, Bonci A (June 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2918390">"Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate"</a>. <i>J. Neurosci.</i> <b>30</b> (24): 8229–8233. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1523%2FJNEUROSCI.1754-10.2010">10.1523/JNEUROSCI.1754-10.2010</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2918390">2918390</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20554874">20554874</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Dopaminergic+terminals+in+the+nucleus+accumbens+but+not+the+dorsal+striatum+corelease+glutamate&amp;rft.aulast=Stuber+GD%2C+Hnasko+TS%2C+Britt+JP%2C+Edwards+RH%2C+Bonci+A&amp;rft.au=Stuber+GD%2C+Hnasko+TS%2C+Britt+JP%2C+Edwards+RH%2C+Bonci+A&amp;rft.date=June+2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2918390&amp;rft_id=info%3Adoi%2F10.1523%2FJNEUROSCI.1754-10.2010&amp;rft_id=info%3Apmc%2F2918390&amp;rft_id=info%3Apmid%2F20554874&amp;rft.issue=24&amp;rft.jtitle=J.+Neurosci.&amp;rft.pages=8229%26ndash%3B8233&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-glutamate2-114"><span class="mw-cite-backlink">^ <a href="#cite_ref-glutamate2_114-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-glutamate2_114-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-glutamate2_114-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Gu XL (October 2010). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2974325">"Deciphering the corelease of glutamate from dopaminergic terminals derived from the ventral tegmental area"</a>. <i>J. Neurosci.</i> <b>30</b> (41): 13549–13551. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1523%2FJNEUROSCI.3802-10.2010">10.1523/JNEUROSCI.3802-10.2010</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2974325">2974325</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20943895">20943895</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Deciphering+the+corelease+of+glutamate+from+dopaminergic+terminals+derived+from+the+ventral+tegmental+area&amp;rft.au=Gu+XL&amp;rft.aulast=Gu+XL&amp;rft.date=October+2010&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2974325&amp;rft_id=info%3Adoi%2F10.1523%2FJNEUROSCI.3802-10.2010&amp;rft_id=info%3Apmc%2F2974325&amp;rft_id=info%3Apmid%2F20943895&amp;rft.issue=41&amp;rft.jtitle=J.+Neurosci.&amp;rft.pages=13549%26ndash%3B13551&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-cognition_enhancers-115"><span class="mw-cite-backlink">^ <a href="#cite_ref-cognition_enhancers_115-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-cognition_enhancers_115-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-cognition_enhancers_115-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-cognition_enhancers_115-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Bidwell LC, McClernon FJ, Kollins SH (August 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150">"Cognitive enhancers for the treatment of ADHD"</a>. <i>Pharmacol. Biochem. Behav.</i> <b>99</b> (2): 262–274. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pbb.2011.05.002">10.1016/j.pbb.2011.05.002</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3353150">3353150</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21596055">21596055</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Cognitive+enhancers+for+the+treatment+of+ADHD&amp;rft.au=Bidwell+LC%2C+McClernon+FJ%2C+Kollins+SH&amp;rft.aulast=Bidwell+LC%2C+McClernon+FJ%2C+Kollins+SH&amp;rft.date=August+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3353150&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pbb.2011.05.002&amp;rft_id=info%3Apmc%2F3353150&amp;rft_id=info%3Apmid%2F21596055&amp;rft.issue=2&amp;rft.jtitle=Pharmacol.+Biochem.+Behav.&amp;rft.pages=262%26ndash%3B274&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TAAR1_stereoselective-116"><span class="mw-cite-backlink">^ <a href="#cite_ref-TAAR1_stereoselective_116-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-TAAR1_stereoselective_116-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Lewin AH, Miller GM, Gilmour B (December 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3236098">"Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class"</a>. <i>Bioorg. Med. Chem.</i> <b>19</b> (23): 7044–7048. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.bmc.2011.10.007">10.1016/j.bmc.2011.10.007</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3236098">3236098</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22037049">22037049</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Trace+amine-associated+receptor+1+is+a+stereoselective+binding+site+for+compounds+in+the+amphetamine+class&amp;rft.aulast=Lewin+AH%2C+Miller+GM%2C+Gilmour+B&amp;rft.au=Lewin+AH%2C+Miller+GM%2C+Gilmour+B&amp;rft.date=December+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3236098&amp;rft_id=info%3Adoi%2F10.1016%2Fj.bmc.2011.10.007&amp;rft_id=info%3Apmc%2F3236098&amp;rft_id=info%3Apmid%2F22037049&amp;rft.issue=23&amp;rft.jtitle=Bioorg.+Med.+Chem.&amp;rft.pages=7044%26ndash%3B7048&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=19" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TAAR1-Paradoxical-117"><span class="mw-cite-backlink"><b><a href="#cite_ref-TAAR1-Paradoxical_117-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Revel FG, Moreau JL, Gainetdinov RR, <i>et al.</i> (May 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3101002">"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity"</a>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <b>108</b> (20): 8485–8490. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1073%2Fpnas.1103029108">10.1073/pnas.1103029108</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3101002">3101002</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21525407">21525407</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=TAAR1+activation+modulates+monoaminergic+neurotransmission%2C+preventing+hyperdopaminergic+and+hypoglutamatergic+activity&amp;rft.aulast=Revel+FG%2C+Moreau+JL%2C+Gainetdinov+RR%2C+%27%27et+al.%27%27&amp;rft.au=Revel+FG%2C+Moreau+JL%2C+Gainetdinov+RR%2C+%27%27et+al.%27%27&amp;rft.date=May+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3101002&amp;rft_id=info%3Adoi%2F10.1073%2Fpnas.1103029108&amp;rft_id=info%3Apmc%2F3101002&amp;rft_id=info%3Apmid%2F21525407&amp;rft.issue=20&amp;rft.jtitle=Proc.+Natl.+Acad.+Sci.+U.S.A.&amp;rft.pages=8485%26ndash%3B8490&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=108" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TAAR1_Review-118"><span class="mw-cite-backlink">^ <a href="#cite_ref-TAAR1_Review_118-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-TAAR1_Review_118-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Maguire JJ, Parker WA, Foord SM, Bonner TI, Neubig RR, Davenport AP (March 2009). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2830119">"International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature"</a>. <i>Pharmacol. Rev.</i> <b>61</b> (1): 1–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1124%2Fpr.109.001107">10.1124/pr.109.001107</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC2830119">2830119</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19325074">19325074</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=International+Union+of+Pharmacology.+LXXII.+Recommendations+for+trace+amine+receptor+nomenclature&amp;rft.aulast=Maguire+JJ%2C+Parker+WA%2C+Foord+SM%2C+Bonner+TI%2C+Neubig+RR%2C+Davenport+AP&amp;rft.au=Maguire+JJ%2C+Parker+WA%2C+Foord+SM%2C+Bonner+TI%2C+Neubig+RR%2C+Davenport+AP&amp;rft.date=March+2009&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2830119&amp;rft_id=info%3Adoi%2F10.1124%2Fpr.109.001107&amp;rft_id=info%3Apmc%2F2830119&amp;rft_id=info%3Apmid%2F19325074&amp;rft.issue=1&amp;rft.jtitle=Pharmacol.+Rev.&amp;rft.pages=1%26ndash%3B8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=61" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid21334367-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid21334367_119-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Levin ED, Bushnell PJ, Rezvani AH (August 2011). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3114188">"Attention-modulating effects of cognitive enhancers"</a>. <i>Pharmacol. Biochem. Behav.</i> <b>99</b> (2): 146–154. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pbb.2011.02.008">10.1016/j.pbb.2011.02.008</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC3114188">3114188</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/21334367">21334367</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Attention-modulating+effects+of+cognitive+enhancers&amp;rft.aulast=Levin+ED%2C+Bushnell+PJ%2C+Rezvani+AH&amp;rft.au=Levin+ED%2C+Bushnell+PJ%2C+Rezvani+AH&amp;rft.date=August+2011&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3114188&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pbb.2011.02.008&amp;rft_id=info%3Apmc%2F3114188&amp;rft_id=info%3Apmid%2F21334367&amp;rft.issue=2&amp;rft.jtitle=Pharmacol.+Biochem.+Behav.&amp;rft.pages=146%26ndash%3B154&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=99" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Pubchem_Kinetics-120"><span class="mw-cite-backlink">^ <a href="#cite_ref-Pubchem_Kinetics_120-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_120-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_120-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Pubchem_Kinetics_120-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x332"><i>Biomedical Effects and Toxicity</i></a>. "Amphetamine". <i>Pubchem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 12 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Biomedical+Effects+and+Toxicity&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23x332&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-121"><span class="mw-cite-backlink"><b><a href="#cite_ref-121">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+@rel+300-62-9"><i>Biological Half-Life</i></a>. "AMPHETAMINE". <i>United States National Library of Medicine - Toxnet</i>. Hazardous Substances Data Bank<span class="reference-accessdate">. Retrieved 5 January 2014</span>. "Concentrations of (14)C-amphetamine declined less rapidly in the plasma of human subjects maintained on an alkaline diet (urinary pH &gt; 7.5) than those on an acid diet (urinary pH &lt; 6). Plasma half-lives of amphetamine ranged between 16-31 hr &amp; 8-11 hr, respectively, &amp; the excretion of (14)C in 24 hr urine was 45 &amp; 70%."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=AMPHETAMINE&amp;rft.btitle=Biological+Half-Life&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Ftoxnet.nlm.nih.gov%2Fcgi-bin%2Fsis%2Fsearch%2Fr%3Fdbs%2Bhsdb%3A%40term%2B%40rn%2B%40rel%2B300-62-9&amp;rft.pub=Hazardous+Substances+Data+Bank&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Flomenbaum_2006-122"><span class="mw-cite-backlink"><b><a href="#cite_ref-Flomenbaum_2006_122-0">^</a></b></span> <span class="reference-text"><span class="citation web">Richard RA (1999). <a rel="nofollow" class="external text" href="http://www.ncbi.nlm.nih.gov/books/NBK64323/"><i>Route of Administration</i></a>. "Chapter 5—Medical Aspects of Stimulant Use Disorders". <i>National Center for Biotechnology Information Bookshelf</i>. Treatment Improvement Protocol 33. Substance Abuse and Mental Health Services Administration.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Chapter+5%26mdash%3BMedical+Aspects+of+Stimulant+Use+Disorders&amp;rft.aulast=Richard+RA&amp;rft.au=Richard+RA&amp;rft.btitle=Route+of+Administration&amp;rft.date=1999&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK64323%2F&amp;rft.pub=Substance+Abuse+and+Mental+Health+Services+Administration&amp;rft.series=Treatment+Improvement+Protocol+33&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-FDA_Vyvanse-123"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_Vyvanse_123-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_Vyvanse_123-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_Vyvanse_123-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021977s030lbl.pdf">"Vyvanse Prescribing Information"</a>. <i>United States Food and Drug Administration</i>. December 2013. pp.&#160;12–13<span class="reference-accessdate">. Retrieved 25 February 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Vyvanse+Prescribing+Information&amp;rft.date=December+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2013%2F021977s030lbl.pdf&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft.pages=12%26ndash%3B13&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DrugBank_Enzymes-124"><span class="mw-cite-backlink"><b><a href="#cite_ref-DrugBank_Enzymes_124-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182#enzymes"><i>Enzymes</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 30 September 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Enzymes&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182%23enzymes&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Metabolites-125"><span class="mw-cite-backlink">^ <a href="#cite_ref-Metabolites_125-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Metabolites_125-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Metabolites_125-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G (September 2002). "Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection". <i>J. Pharm. Biomed. Anal.</i> <b>30</b> (2): 247–255. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0731-7085%2802%2900330-8">10.1016/S0731-7085(02)00330-8</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12191709">12191709</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Simultaneous+determination+of+amphetamine+and+one+of+its+metabolites+by+HPLC+with+electrochemical+detection&amp;rft.aulast=Santagati+NA%2C+Ferrara+G%2C+Marrazzo+A%2C+Ronsisvalle+G&amp;rft.au=Santagati+NA%2C+Ferrara+G%2C+Marrazzo+A%2C+Ronsisvalle+G&amp;rft.date=September+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0731-7085%2802%2900330-8&amp;rft_id=info%3Apmid%2F12191709&amp;rft.issue=2&amp;rft.jtitle=J.+Pharm.+Biomed.+Anal.&amp;rft.pages=247%26ndash%3B255&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=30" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-126"><span class="mw-cite-backlink"><b><a href="#cite_ref-126">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3651"><i>Compound Summary</i></a>. "p-Hydroxyamphetamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 15 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=p-Hydroxyamphetamine&amp;rft.btitle=Compound+Summary&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3651&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-127"><span class="mw-cite-backlink"><b><a href="#cite_ref-127">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11099"><i>Compound Summary</i></a>. "p-Hydroxynorephedrine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 15 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=p-Hydroxynorephedrine&amp;rft.btitle=Compound+Summary&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D11099&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-128"><span class="mw-cite-backlink"><b><a href="#cite_ref-128">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=26934"><i>Compound Summary</i></a>. "Phenylpropanolamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 15 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Phenylpropanolamine&amp;rft.btitle=Compound+Summary&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D26934&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Renaissance_GPCR-129"><span class="mw-cite-backlink">^ <a href="#cite_ref-Renaissance_GPCR_129-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_129-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_129-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_129-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Renaissance_GPCR_129-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family". <i>Trends Pharmacol. Sci.</i> <b>26</b> (5): 274–281. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.tips.2005.03.007">10.1016/j.tips.2005.03.007</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15860375">15860375</a>. "In addition to the main metabolic pathway, TAs can also be converted by nonspecific N-methyltransferase (NMT) [22] and phenylethanolamine N-methyltransferase (PNMT) [23] to the corresponding secondary amines (e.g. synephrine [14], N-methylphenylethylamine and N-methyltyramine [15]), which display similar activities on TAAR1 (TA1) as their primary amine precursors."</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=A+renaissance+in+trace+amines+inspired+by+a+novel+GPCR+family&amp;rft.aulast=Lindemann+L%2C+Hoener+MC&amp;rft.au=Lindemann+L%2C+Hoener+MC&amp;rft.date=May+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.tips.2005.03.007&amp;rft_id=info%3Apmid%2F15860375&amp;rft.issue=5&amp;rft.jtitle=Trends+Pharmacol.+Sci.&amp;rft.pages=274%26ndash%3B281&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=26" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Properties-131"><span class="mw-cite-backlink"><b><a href="#cite_ref-Properties_131-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007#x27"><i>Chemical and Physical Properties</i></a>. "Amphetamine". <i>PubChem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Chemical+and+Physical+Properties&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D3007%23x27&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-132"><span class="mw-cite-backlink"><b><a href="#cite_ref-132">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=92939">"Amphetamine Hydrochloride"</a>. <i>Pubchem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 8 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine+Hydrochloride&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D92939&amp;rft.jtitle=Pubchem+Compound&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-133"><span class="mw-cite-backlink"><b><a href="#cite_ref-133">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=62885">"Amphetamine Phosphate"</a>. <i>Pubchem Compound</i>. National Center for Biotechnology Information<span class="reference-accessdate">. Retrieved 8 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine+Phosphate&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fpubchem.ncbi.nlm.nih.gov%2Fsummary%2Fsummary.cgi%3Fcid%3D62885&amp;rft.jtitle=Pubchem+Compound&amp;rft.pub=National+Center+for+Biotechnology+Information&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Chiral_Ligand-134"><span class="mw-cite-backlink"><b><a href="#cite_ref-Chiral_Ligand_134-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Brussee J, Jansen ACA (1983). "A highly stereoselective synthesis of s(-)-[1,1′-binaphthalene]-2,2′-diol". <i>Tetrahedron Lett.</i> <b>24</b> (31): 3261–3262. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0040-4039%2800%2988151-4">10.1016/S0040-4039(00)88151-4</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=A+highly+stereoselective+synthesis+of+s%28-%29-%5B1%2C1%E2%80%B2-binaphthalene%5D-2%2C2%E2%80%B2-diol&amp;rft.au=Brussee+J%2C+Jansen+ACA&amp;rft.aulast=Brussee+J%2C+Jansen+ACA&amp;rft.date=1983&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0040-4039%2800%2988151-4&amp;rft.issue=31&amp;rft.jtitle=Tetrahedron+Lett.&amp;rft.pages=3261%26ndash%3B3262&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-DrugBank_Header-135"><span class="mw-cite-backlink">^ <a href="#cite_ref-DrugBank_Header_135-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-DrugBank_Header_135-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB00182"><i>Compound Summary</i></a>. "Amphetamine". <i>DrugBank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 30 September 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine&amp;rft.btitle=Compound+Summary&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00182&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Schep-136"><span class="mw-cite-backlink">^ <a href="#cite_ref-Schep_136-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Schep_136-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Schep LJ, Slaughter RJ, Beasley DM (August 2010). "The clinical toxicology of metamfetamine". <i>Clin. Toxicol. (Phila.)</i> <b>48</b> (7): 675–694. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.3109%2F15563650.2010.516752">10.3109/15563650.2010.516752</a>. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/issn/1556-3650">1556-3650</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20849327">20849327</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+clinical+toxicology+of+metamfetamine&amp;rft.aulast=Schep+LJ%2C+Slaughter+RJ%2C+Beasley+DM&amp;rft.au=Schep+LJ%2C+Slaughter+RJ%2C+Beasley+DM&amp;rft.date=August+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.3109%2F15563650.2010.516752&amp;rft_id=info%3Apmid%2F20849327&amp;rft.issn=1556-3650&amp;rft.issue=7&amp;rft.jtitle=Clin.+Toxicol.+%28Phila.%29&amp;rft.pages=675%26ndash%3B694&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-137"><span class="mw-cite-backlink"><b><a href="#cite_ref-137">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cqld.ca/livre/en/en/07-amphetamine.htm">"Amphetamine, Methamphetamine, &amp; Cystal Meth"</a>. <i>Addiction Prevention Centre</i><span class="reference-accessdate">. Retrieved 10 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Amphetamine%2C+Methamphetamine%2C+%26+Cystal+Meth&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.cqld.ca%2Flivre%2Fen%2Fen%2F07-amphetamine.htm&amp;rft.jtitle=Addiction+Prevention+Centre&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Vermont-138"><span class="mw-cite-backlink">^ <a href="#cite_ref-Vermont_138-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Vermont_138-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Vermont_138-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Vermont_138-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://healthvermont.gov/adap/meth/brief_history.aspx">"Historical overview of methamphetamine"</a>. <i>Vermont Department of Health</i>. Government of Vermont<span class="reference-accessdate">. Retrieved 29 January 2012</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Historical+overview+of+methamphetamine&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fhealthvermont.gov%2Fadap%2Fmeth%2Fbrief_history.aspx&amp;rft.jtitle=Vermont+Department+of+Health&amp;rft.pub=Government+of+Vermont&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Allen_Cantrell_1989-139"><span class="mw-cite-backlink">^ <a href="#cite_ref-Allen_Cantrell_1989_139-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Allen_Cantrell_1989_139-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Allen A, Cantrell TS (August 1989). "Synthetic reductions in clandestine amphetamine and methamphetamine laboratories: A review". <i>Forensic Science International</i> <b>42</b> (3): 183–199. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2F0379-0738%2889%2990086-8">10.1016/0379-0738(89)90086-8</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Synthetic+reductions+in+clandestine+amphetamine+and+methamphetamine+laboratories%3A+A+review&amp;rft.au=Allen+A%2C+Cantrell+TS&amp;rft.aulast=Allen+A%2C+Cantrell+TS&amp;rft.date=August+1989&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0379-0738%2889%2990086-8&amp;rft.issue=3&amp;rft.jtitle=Forensic+Science+International&amp;rft.pages=183%26ndash%3B199&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Allen_Ely_2009-140"><span class="mw-cite-backlink">^ <a href="#cite_ref-Allen_Ely_2009_140-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Allen_Ely_2009_140-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Allen A, Ely R (2011). <a rel="nofollow" class="external text" href="http://www.nwafs.org/newsletters/2011_Spring.pdf">"Review: Synthetic Methods for Amphetamine"</a> (PDF). <i>Crime Scene</i> (Northwest Association of Forensic Scientists) <b>37</b> (2): 15–25.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Review%3A+Synthetic+Methods+for+Amphetamine&amp;rft.au=Allen+A%2C+Ely+R&amp;rft.aulast=Allen+A%2C+Ely+R&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.nwafs.org%2Fnewsletters%2F2011_Spring.pdf&amp;rft.issue=2&amp;rft.jtitle=Crime+Scene&amp;rft.pages=15%26ndash%3B25&amp;rft.pub=Northwest+Association+of+Forensic+Scientists&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=37" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid20985610-141"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid20985610_141-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Patrick TM, McBee ET, Hass HB (June 1946). "Synthesis of arylpropylamines; from allyl chloride". <i>J. Am. Chem. Soc.</i> <b>68</b>: 1009–1011. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1021%2Fja01210a032">10.1021/ja01210a032</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20985610">20985610</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Synthesis+of+arylpropylamines%3B+from+allyl+chloride&amp;rft.aulast=Patrick+TM%2C+McBee+ET%2C+Hass+HB&amp;rft.au=Patrick+TM%2C+McBee+ET%2C+Hass+HB&amp;rft.date=June+1946&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fja01210a032&amp;rft_id=info%3Apmid%2F20985610&amp;rft.jtitle=J.+Am.+Chem.+Soc.&amp;rft.pages=1009%26ndash%3B1011&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=68" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid18105933-142"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid18105933_142-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Ritter JJ, Kalish J (December 1948). "A new reaction of nitriles; synthesis of t-carbinamines". <i>J. Am. Chem. Soc.</i> <b>70</b> (12): 4048–4050. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1021%2Fja01192a023">10.1021/ja01192a023</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18105933">18105933</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=A+new+reaction+of+nitriles%3B+synthesis+of+t-carbinamines&amp;rft.aulast=Ritter+JJ%2C+Kalish+J&amp;rft.au=Ritter+JJ%2C+Kalish+J&amp;rft.date=December+1948&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fja01192a023&amp;rft_id=info%3Apmid%2F18105933&amp;rft.issue=12&amp;rft.jtitle=J.+Am.+Chem.+Soc.&amp;rft.pages=4048%26ndash%3B4050&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=70" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Krimen_Cota_1969-143"><span class="mw-cite-backlink"><b><a href="#cite_ref-Krimen_Cota_1969_143-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Krimen LI, Cota DJ (1969). <i>Organic Reactions</i> <b>17</b>: 216. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2F0471264180.or017.03">10.1002/0471264180.or017.03</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.au=Krimen+LI%2C+Cota+DJ&amp;rft.aulast=Krimen+LI%2C+Cota+DJ&amp;rft.date=1969&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2F0471264180.or017.03&amp;rft.jtitle=Organic+Reactions&amp;rft.pages=216&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-US2413493-144"><span class="mw-cite-backlink"><b><a href="#cite_ref-US2413493_144-0">^</a></b></span> <span class="reference-text"><span class="citation patent" id="CITEREFBitler_WP.2C_Flisik_AC.2C_Leonard_N2014"><a rel="nofollow" class="external text" href="http://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=US2413493">US patent 2413493</a>, Bitler WP, Flisik AC, Leonard N, "Synthesis of isomer-free benzyl methyl acetoacetic methyl ester", published 31 December 1946,  assigned to Kay Fries Chemicals Inc</span><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=2413493&amp;rft.cc=US&amp;rft.title=Synthesis+of+isomer-free+benzyl+methyl+acetoacetic+methyl+ester&amp;rft.inventor=Bitler+WP%2C+Flisik+AC%2C+Leonard+N&amp;rft.assignee=Kay+Fries+Chemicals+Inc&amp;rft.appldate=3 June 1943&amp;rft.pubdate=31 December 1946&amp;rft.prioritydate=3 June 1943"><span style="display: none;">&#160;</span></span></span></li>
<li id="cite_note-Delta_Isotope-145"><span class="mw-cite-backlink"><b><a href="#cite_ref-Delta_Isotope_145-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Collins M, Salouros H, Cawley AT, Robertson J, Heagney AC, Arenas-Queralt A (June 2010). "δ<sup>13</sup>C and δ<sup>2</sup>H isotope ratios in amphetamine synthesized from benzaldehyde and nitroethane". <i>Rapid Commun. Mass Spectrom.</i> <b>24</b> (11): 1653–1658. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Frcm.4563">10.1002/rcm.4563</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/20486262">20486262</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=%CE%B4%3Csup%3E13%3C%2Fsup%3EC+and+%CE%B4%3Csup%3E2%3C%2Fsup%3EH+isotope+ratios+in+amphetamine+synthesized+from+benzaldehyde+and+nitroethane&amp;rft.au=Collins+M%2C+Salouros+H%2C+Cawley+AT%2C+Robertson+J%2C+Heagney+AC%2C+Arenas-Queralt+A&amp;rft.aulast=Collins+M%2C+Salouros+H%2C+Cawley+AT%2C+Robertson+J%2C+Heagney+AC%2C+Arenas-Queralt+A&amp;rft.date=June+2010&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Frcm.4563&amp;rft_id=info%3Apmid%2F20486262&amp;rft.issue=11&amp;rft.jtitle=Rapid+Commun.+Mass+Spectrom.&amp;rft.pages=1653%26ndash%3B1658&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Amph_Synth-146"><span class="mw-cite-backlink">^ <a href="#cite_ref-Amph_Synth_146-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Amph_Synth_146-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Amph_Synth_146-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Amph_Synth_146-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Amph_Synth_146-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Amph_Synth_146-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.unodc.org/pdf/scientific/stnar34.pdf">"Recommended methods of the identification and analysis of amphetamine, methamphetamine, and their ring-substituted analogues in seized materials"</a>. <i>United Nations Office on Drugs and Crime</i>. United Nations. 2006. pp.&#160;9–12<span class="reference-accessdate">. Retrieved 14 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Recommended+methods+of+the+identification+and+analysis+of+amphetamine%2C+methamphetamine%2C+and+their+ring-substituted+analogues+in+seized+materials&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.unodc.org%2Fpdf%2Fscientific%2Fstnar34.pdf&amp;rft.jtitle=United+Nations+Office+on+Drugs+and+Crime&amp;rft.pages=9%26ndash%3B12&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-147"><span class="mw-cite-backlink"><b><a href="#cite_ref-147">^</a></b></span> <span class="reference-text"><span class="citation journal">Pollard CB, Young DC (May 1951). "The Mechanism of the Leuckart Reaction". <i>J. Org. Chem.</i> <b>16</b> (5): 661–672. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1021%2Fjo01145a001">10.1021/jo01145a001</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+Mechanism+of+the+Leuckart+Reaction&amp;rft.aulast=Pollard+CB%2C+Young+DC&amp;rft.au=Pollard+CB%2C+Young+DC&amp;rft.date=May+1951&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1021%2Fjo01145a001&amp;rft.issue=5&amp;rft.jtitle=J.+Org.+Chem.&amp;rft.pages=661%26ndash%3B672&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=16" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-US2276508-148"><span class="mw-cite-backlink"><b><a href="#cite_ref-US2276508_148-0">^</a></b></span> <span class="reference-text"><span class="citation patent" id="CITEREFNabenhauer_FP2014"><a rel="nofollow" class="external text" href="http://worldwide.espacenet.com/textdoc?DB=EPODOC&amp;IDX=US2276508">US patent 2276508</a>, Nabenhauer FP, "Method for the separation of optically active alpha-methylphenethylamine", published 17 March 1942,  assigned to Smith Kline French</span><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&amp;rft.number=2276508&amp;rft.cc=US&amp;rft.title=Method+for+the+separation+of+optically+active+alpha-methylphenethylamine&amp;rft.inventor=Nabenhauer+FP&amp;rft.assignee=Smith+Kline+French&amp;rft.appldate=3 November 1939&amp;rft.pubdate=17 March 1942&amp;rft.prioritydate=3 November 1939"><span style="display: none;">&#160;</span></span></span></li>
<li id="cite_note-Gray_2007-149"><span class="mw-cite-backlink">^ <a href="#cite_ref-Gray_2007_149-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Gray_2007_149-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation book">Gray DL (2007). <a rel="nofollow" class="external text" href="http://books.google.com/books?id=zvruBDAulWEC&amp;lpg=PP1&amp;dq=The%20Art%20of%20Drug%20Synthesis%20(Wiley%20Series%20on%20Drug%20Synthesis)&amp;pg=SA17-PA4#v=onepage&amp;q=amphetamine&amp;f=false">"Approved Treatments for Attention Deficit Hyperactivity Disorder: Amphetamine (Adderall), Methylphenidate (Ritalin), and Atomoxetine (Straterra)"</a>. In Johnson DS, Li JJ. <i>The Art of Drug Synthesis</i>. New York, NY: Wiley-Interscience. p.&#160;247. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780471752158" title="Special:BookSources/9780471752158">9780471752158</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=The+Art+of+Drug+Synthesis&amp;rft.au=Gray+DL&amp;rft.aulast=Gray+DL&amp;rft.btitle=Approved+Treatments+for+Attention+Deficit+Hyperactivity+Disorder%3A+Amphetamine+%28Adderall%29%2C+Methylphenidate+%28Ritalin%29%2C+and+Atomoxetine+%28Straterra%29&amp;rft.date=2007&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fbooks.google.com%2Fbooks%3Fid%3DzvruBDAulWEC%26lpg%3DPP1%26dq%3DThe%2520Art%2520of%2520Drug%2520Synthesis%2520%28Wiley%2520Series%2520on%2520Drug%2520Synthesis%29%26pg%3DSA17-PA4%23v%3Donepage%26q%3Damphetamine%26f%3Dfalse&amp;rft.isbn=9780471752158&amp;rft.pages=247&amp;rft.place=New+York%2C+NY&amp;rft.pub=Wiley-Interscience&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid9700558-150"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid9700558_150-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kraemer T, Maurer HH (August 1998). "Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine". <i>J. Chromatogr. B Biomed. Sci. Appl.</i> <b>713</b> (1): 163–187. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2FS0378-4347%2897%2900515-X">10.1016/S0378-4347(97)00515-X</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9700558">9700558</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Determination+of+amphetamine%2C+methamphetamine+and+amphetamine-derived+designer+drugs+or+medicaments+in+blood+and+urine&amp;rft.au=Kraemer+T%2C+Maurer+HH&amp;rft.aulast=Kraemer+T%2C+Maurer+HH&amp;rft.date=August+1998&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2FS0378-4347%2897%2900515-X&amp;rft_id=info%3Apmid%2F9700558&amp;rft.issue=1&amp;rft.jtitle=J.+Chromatogr.+B+Biomed.+Sci.+Appl.&amp;rft.pages=163%26ndash%3B187&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=713" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid17468860-151"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17468860_151-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kraemer T, Paul LD (August 2007). "Bioanalytical procedures for determination of drugs of abuse in blood". <i>Anal. Bioanal. Chem.</i> <b>388</b> (7): 1415–1435. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1007%2Fs00216-007-1271-6">10.1007/s00216-007-1271-6</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17468860">17468860</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Bioanalytical+procedures+for+determination+of+drugs+of+abuse+in+blood&amp;rft.au=Kraemer+T%2C+Paul+LD&amp;rft.aulast=Kraemer+T%2C+Paul+LD&amp;rft.date=August+2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs00216-007-1271-6&amp;rft_id=info%3Apmid%2F17468860&amp;rft.issue=7&amp;rft.jtitle=Anal.+Bioanal.+Chem.&amp;rft.pages=1415%26ndash%3B1435&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=388" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid8075776-152"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid8075776_152-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Goldberger BA, Cone EJ (July 1994). "Confirmatory tests for drugs in the workplace by gas chromatography-mass spectrometry". <i>J. Chromatogr. A</i> <b>674</b> (1–2): 73–86. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2F0021-9673%2894%2985218-9">10.1016/0021-9673(94)85218-9</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/8075776">8075776</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Confirmatory+tests+for+drugs+in+the+workplace+by+gas+chromatography-mass+spectrometry&amp;rft.au=Goldberger+BA%2C+Cone+EJ&amp;rft.aulast=Goldberger+BA%2C+Cone+EJ&amp;rft.date=July+1994&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2F0021-9673%2894%2985218-9&amp;rft_id=info%3Apmid%2F8075776&amp;rft.issue=1%26ndash%3B2&amp;rft.jtitle=J.+Chromatogr.+A&amp;rft.pages=73%26ndash%3B86&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=674" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-NAHMSA_testing-154"><span class="mw-cite-backlink">^ <a href="#cite_ref-NAHMSA_testing_154-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NAHMSA_testing_154-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://162.99.3.213/products/manuals/pdfs/TAP32.pdf">"Clinical Drug Testing in Primary Care"</a>. <i>Substance Abuse and Mental Health Services Administration</i>. Technical Assistance Publication Series 32. United States Department of Health and Human Services. 2012<span class="reference-accessdate">. Retrieved 31 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Clinical+Drug+Testing+in+Primary+Care&amp;rft.date=2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2F162.99.3.213%2Fproducts%2Fmanuals%2Fpdfs%2FTAP32.pdf&amp;rft.jtitle=Substance+Abuse+and+Mental+Health+Services+Administration&amp;rft.pub=United+States+Department+of+Health+and+Human+Services&amp;rft.series=Technical+Assistance+Publication+Series+32&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15516295-155"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid15516295_155-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid15516295_155-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid15516295_155-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid15516295_155-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-pmid15516295_155-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA (September 2004). "Enantiomeric separation and quantitation of (±)-amphetamine, (±)-methamphetamine, (±)-MDA, (±)-MDMA, and (±)-MDEA in urine specimens by GC-EI-MS after derivatization with (<i>R</i>)-(-)- or (<i>S</i>)-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride (MTPA)". <i>J. Anal. Toxicol.</i> <b>28</b> (6): 449–455. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1093%2Fjat%2F28.6.449">10.1093/jat/28.6.449</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15516295">15516295</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Enantiomeric+separation+and+quantitation+of+%28%C2%B1%29-amphetamine%2C+%28%C2%B1%29-methamphetamine%2C+%28%C2%B1%29-MDA%2C+%28%C2%B1%29-MDMA%2C+and+%28%C2%B1%29-MDEA+in+urine+specimens+by+GC-EI-MS+after+derivatization+with+%28%27%27R%27%27%29-%28-%29-+or+%28%27%27S%27%27%29-%28%2B%29-%CE%B1-methoxy-%CE%B1-%28trifluoromethyl%29phenylacetyl+chloride+%28MTPA%29&amp;rft.aulast=Paul+BD%2C+Jemionek+J%2C+Lesser+D%2C+Jacobs+A%2C+Searles+DA&amp;rft.au=Paul+BD%2C+Jemionek+J%2C+Lesser+D%2C+Jacobs+A%2C+Searles+DA&amp;rft.date=September+2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjat%2F28.6.449&amp;rft_id=info%3Apmid%2F15516295&amp;rft.issue=6&amp;rft.jtitle=J.+Anal.+Toxicol.&amp;rft.pages=449%26ndash%3B455&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=28" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16105261-156"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16105261_156-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16105261_156-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Verstraete AG, Heyden FV (2005). "Comparison of the sensitivity and specificity of six immunoassays for the detection of amphetamines in urine". <i>J. Anal. Toxicol.</i> <b>29</b> (5): 359–364. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1093%2Fjat%2F29.5.359">10.1093/jat/29.5.359</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16105261">16105261</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Comparison+of+the+sensitivity+and+specificity+of+six+immunoassays+for+the+detection+of+amphetamines+in+urine&amp;rft.aulast=Verstraete+AG%2C+Heyden+FV&amp;rft.au=Verstraete+AG%2C+Heyden+FV&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1093%2Fjat%2F29.5.359&amp;rft_id=info%3Apmid%2F16105261&amp;rft.issue=5&amp;rft.jtitle=J.+Anal.+Toxicol.&amp;rft.pages=359%26ndash%3B364&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Baselt_2011-157"><span class="mw-cite-backlink"><b><a href="#cite_ref-Baselt_2011_157-0">^</a></b></span> <span class="reference-text"><span class="citation book">Baselt RC (2011). <i>Disposition of Toxic Drugs and Chemicals in Man</i> (9th ed.). Seal Beach, CA: Biomedical Publications. pp.&#160;85–88. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780962652387" title="Special:BookSources/9780962652387">9780962652387</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.au=Baselt+RC&amp;rft.aulast=Baselt+RC&amp;rft.btitle=Disposition+of+Toxic+Drugs+and+Chemicals+in+Man&amp;rft.date=2011&amp;rft.edition=9th&amp;rft.genre=book&amp;rft.isbn=9780962652387&amp;rft.pages=85%26ndash%3B88&amp;rft.place=Seal+Beach%2C+CA&amp;rft.pub=Biomedical+Publications&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10711406-158"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid10711406_158-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid10711406_158-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Musshoff F (February 2000). "Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine". <i>Drug Metab. Rev.</i> <b>32</b> (1): 15–44. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1081%2FDMR-100100562">10.1081/DMR-100100562</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10711406">10711406</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Illegal+or+legitimate+use%3F+Precursor+compounds+to+amphetamine+and+methamphetamine&amp;rft.aulast=Musshoff+F&amp;rft.au=Musshoff+F&amp;rft.date=February+2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1081%2FDMR-100100562&amp;rft_id=info%3Apmid%2F10711406&amp;rft.issue=1&amp;rft.jtitle=Drug+Metab.+Rev.&amp;rft.pages=15%26ndash%3B44&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=32" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12024689-159"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12024689_159-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12024689_159-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Cody JT (May 2002). "Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results". <i>J. Occup. Environ. Med.</i> <b>44</b> (5): 435–450. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1097%2F00043764-200205000-00012">10.1097/00043764-200205000-00012</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12024689">12024689</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Precursor+medications+as+a+source+of+methamphetamine+and%2For+amphetamine+positive+drug+testing+results&amp;rft.au=Cody+JT&amp;rft.aulast=Cody+JT&amp;rft.date=May+2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1097%2F00043764-200205000-00012&amp;rft_id=info%3Apmid%2F12024689&amp;rft.issue=5&amp;rft.jtitle=J.+Occup.+Environ.+Med.&amp;rft.pages=435%26ndash%3B450&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=44" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Edeleanu-160"><span class="mw-cite-backlink"><b><a href="#cite_ref-Edeleanu_160-0">^</a></b></span> <span class="reference-text">Lazăr Edeleano: <i><a rel="nofollow" class="external text" href="http://gallica.bnf.fr/ark:/12148/bpt6k90709v/f619.image.langDE?pageNumber=616">Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure.</a></i> In: Berichte der Deutschen chemischen Gesellschaft zu Berlin; 20. Jg. (1887), Band 3, S. 616–622. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1002%2Fcber.188702001142">10.1002/cber.188702001142</a></span></li>
<li id="cite_note-161"><span class="mw-cite-backlink"><b><a href="#cite_ref-161">^</a></b></span> <span class="reference-text"><span class="citation book">Rassool GH (2009). <i>Alcohol and Drug Misuse: A Handbook for Students and Health Professionals</i>. London: Routledge. p.&#160;113. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9780203871171" title="Special:BookSources/9780203871171">9780203871171</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.aulast=Rassool+GH&amp;rft.au=Rassool+GH&amp;rft.btitle=Alcohol+and+Drug+Misuse%3A+A+Handbook+for+Students+and+Health+Professionals&amp;rft.date=2009&amp;rft.genre=book&amp;rft.isbn=9780203871171&amp;rft.pages=113&amp;rft.place=London&amp;rft.pub=Routledge&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-SynthHistory-162"><span class="mw-cite-backlink">^ <a href="#cite_ref-SynthHistory_162-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SynthHistory_162-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><span class="citation journal">Sulzer D, Sonders MS, Poulsen NW, Galli A (April 2005). "Mechanisms of neurotransmitter release by amphetamines: a review". <i>Prog. Neurobiol.</i> <b>75</b> (6): 406–433. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1016%2Fj.pneurobio.2005.04.003">10.1016/j.pneurobio.2005.04.003</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15955613">15955613</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Mechanisms+of+neurotransmitter+release+by+amphetamines%3A+a+review&amp;rft.aulast=Sulzer+D%2C+Sonders+MS%2C+Poulsen+NW%2C+Galli+A&amp;rft.au=Sulzer+D%2C+Sonders+MS%2C+Poulsen+NW%2C+Galli+A&amp;rft.date=April+2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1016%2Fj.pneurobio.2005.04.003&amp;rft_id=info%3Apmid%2F15955613&amp;rft.issue=6&amp;rft.jtitle=Prog.+Neurobiol.&amp;rft.pages=406%26ndash%3B433&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=75" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-163"><span class="mw-cite-backlink"><b><a href="#cite_ref-163">^</a></b></span> <span class="reference-text"><span class="citation journal">Rasmussen N (2011). "Medical science and the military: the Allies' use of amphetamine during World War II". <i>J. Interdiscip. Hist.</i> <b>42</b> (2): 205–233. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="http://dx.doi.org/10.1162%2FJINH_a_00212">10.1162/JINH_a_00212</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22073434">22073434</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Medical+science+and+the+military%3A+the+Allies%27+use+of+amphetamine+during+World+War+II&amp;rft.aulast=Rasmussen+N&amp;rft.au=Rasmussen+N&amp;rft.date=2011&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1162%2FJINH_a_00212&amp;rft_id=info%3Apmid%2F22073434&amp;rft.issue=2&amp;rft.jtitle=J.+Interdiscip.+Hist.&amp;rft.pages=205%26ndash%3B233&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=42" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid22849208-164"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid22849208_164-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Defalque RJ, Wright AJ (April 2011). "Methamphetamine for Hitler's Germany: 1937 to 1945". <i>Bull. Anesth. Hist.</i> <b>29</b> (2): 21–24, 32. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/22849208">22849208</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Methamphetamine+for+Hitler%27s+Germany%3A+1937+to+1945&amp;rft.au=Defalque+RJ%2C+Wright+AJ&amp;rft.aulast=Defalque+RJ%2C+Wright+AJ&amp;rft.date=April+2011&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F22849208&amp;rft.issue=2&amp;rft.jtitle=Bull.+Anesth.+Hist.&amp;rft.pages=21%26ndash%3B24%2C+32&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=29" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-165"><span class="mw-cite-backlink"><b><a href="#cite_ref-165">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.fda.gov/regulatoryinformation/legislation/ucm148726.htm">"Controlled Substances Act"</a>. <i>United States Food and Drug Administration</i>. 11 June 2009<span class="reference-accessdate">. Retrieved 4 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Controlled+Substances+Act&amp;rft.date=11+June+2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fregulatoryinformation%2Flegislation%2Fucm148726.htm&amp;rft.jtitle=United+States+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-166"><span class="mw-cite-backlink"><b><a href="#cite_ref-166">^</a></b></span> <span class="reference-text"><span class="citation web">Gyenis A. <a rel="nofollow" class="external text" href="http://web.archive.org/web/20080214171739/http://www.wordsareimportant.com/ontheroad.htm">"Forty Years of <i>On the Road</i> 1957–1997"</a>. <i>wordsareimportant.com</i>. DHARMA beat. Archived from <a rel="nofollow" class="external text" href="http://www.wordsareimportant.com/ontheroad.htm">the original</a> on 14 February 2008<span class="reference-accessdate">. Retrieved 18 March 2008</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Forty+Years+of+%27%27On+the+Road%27%27+1957%26ndash%3B1997&amp;rft.au=Gyenis+A&amp;rft.aulast=Gyenis+A&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.wordsareimportant.com%2Fontheroad.htm&amp;rft.jtitle=wordsareimportant.com&amp;rft.pub=DHARMA+beat&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-167"><span class="mw-cite-backlink"><b><a href="#cite_ref-167">^</a></b></span> <span class="reference-text"><span class="citation journal">Wilson A (2008). <a rel="nofollow" class="external text" href="http://www.internetjournalofcriminology.com/Wilson%20-%20Mixing%20the%20Medicine.pdf">"Mixing the Medicine: The unintended consequence of amphetamine control on the Northern Soul Scene"</a>. <i>Internet Journal of Criminology</i><span class="reference-accessdate">. Retrieved 25 May 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Mixing+the+Medicine%3A+The+unintended+consequence+of+amphetamine+control+on+the+Northern+Soul+Scene&amp;rft.aulast=Wilson+A&amp;rft.au=Wilson+A&amp;rft.date=2008&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.internetjournalofcriminology.com%2FWilson%2520-%2520Mixing%2520the%2520Medicine.pdf&amp;rft.jtitle=Internet+Journal+of+Criminology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-168"><span class="mw-cite-backlink"><b><a href="#cite_ref-168">^</a></b></span> <span class="reference-text"><span class="citation web">Hill J (4 June 2004). <a rel="nofollow" class="external text" href="http://www.untruth.org/~josh/math/Paul%20Erd%F6s%20bio-rev2.pdf">"Paul Erdos, Mathematical Genius, Human (In That Order)"</a>. <i>untruth.org</i><span class="reference-accessdate">. Retrieved 2 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Paul+Erdos%2C+Mathematical+Genius%2C+Human+%28In+That+Order%29&amp;rft.au=Hill+J&amp;rft.aulast=Hill+J&amp;rft.date=4+June+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.untruth.org%2F~josh%2Fmath%2FPaul%2520Erd%25F6s%2520bio-rev2.pdf&amp;rft.jtitle=untruth.org&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-isbn92-1-148223-2-169"><span class="mw-cite-backlink"><b><a href="#cite_ref-isbn92-1-148223-2_169-0">^</a></b></span> <span class="reference-text"><span class="citation book">United Nations Office on Drugs and Crime (2007). <a rel="nofollow" class="external text" href="http://www.unodc.org/pdf/youthnet/ATS.pdf"><i>Preventing Amphetamine-type Stimulant Use Among Young People: A Policy and Programming Guide</i></a>. New York: United Nations. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/9789211482232" title="Special:BookSources/9789211482232">9789211482232</a><span class="reference-accessdate">. Retrieved 11 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.aulast=United+Nations+Office+on+Drugs+and+Crime&amp;rft.au=United+Nations+Office+on+Drugs+and+Crime&amp;rft.btitle=Preventing+Amphetamine-type+Stimulant+Use+Among+Young+People%3A+A+Policy+and+Programming+Guide&amp;rft.date=2007&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.unodc.org%2Fpdf%2Fyouthnet%2FATS.pdf&amp;rft.isbn=9789211482232&amp;rft.place=New+York&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-170"><span class="mw-cite-backlink"><b><a href="#cite_ref-170">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20051205125434/http://www.incb.org/pdf/e/list/green.pdf">"List of psychotropic substances under international control"</a>. <i>International Narcotics Control Board</i>. United Nations. August 2003. Archived from <a rel="nofollow" class="external text" href="http://www.incb.org/pdf/e/list/green.pdf">the original</a> on 5 December 2005<span class="reference-accessdate">. Retrieved 19 November 2005</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=List+of+psychotropic+substances+under+international+control&amp;rft.date=August+2003&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.incb.org%2Fpdf%2Fe%2Flist%2Fgreen.pdf&amp;rft.jtitle=International+Narcotics+Control+Board&amp;rft.pub=United+Nations&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-urlMoving_to_Korea_brings_medical.2C_social_changes-171"><span class="mw-cite-backlink"><b><a href="#cite_ref-urlMoving_to_Korea_brings_medical.2C_social_changes_171-0">^</a></b></span> <span class="reference-text"><span class="citation web">Park Jin-seng (25 May 2012). <a rel="nofollow" class="external text" href="http://www.koreatimes.co.kr/www/news/nation/2012/10/319_111757.html">"Moving to Korea brings medical, social changes"</a>. <i>The Korean Times</i><span class="reference-accessdate">. Retrieved 14 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Moving+to+Korea+brings+medical%2C+social+changes&amp;rft.aulast=Park+Jin-seng&amp;rft.au=Park+Jin-seng&amp;rft.date=25+May+2012&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.koreatimes.co.kr%2Fwww%2Fnews%2Fnation%2F2012%2F10%2F319_111757.html&amp;rft.jtitle=The+Korean+Times&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-172"><span class="mw-cite-backlink"><b><a href="#cite_ref-172">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.mhlw.go.jp/english/topics/import/">"Importing or Bringing Medication into Japan for Personal Use"</a>. <i>Japanese Ministry of Health, Labour and Welfare</i>. 1 April 2004<span class="reference-accessdate">. Retrieved 3 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Importing+or+Bringing+Medication+into+Japan+for+Personal+Use&amp;rft.date=1+April+2004&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.mhlw.go.jp%2Fenglish%2Ftopics%2Fimport%2F&amp;rft.jtitle=Japanese+Ministry+of+Health%2C+Labour+and+Welfare&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Canada_Control-173"><span class="mw-cite-backlink"><b><a href="#cite_ref-Canada_Control_173-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-24.html#h-28">"Controlled Drugs and Substances Act"</a>. <i>Canadian Justice Laws Website</i>. Government of Canada. 11 November 2013<span class="reference-accessdate">. Retrieved 11 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Controlled+Drugs+and+Substances+Act&amp;rft.date=11+November+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Flaws-lois.justice.gc.ca%2Feng%2Facts%2FC-38.8%2Fpage-24.html%23h-28&amp;rft.jtitle=Canadian+Justice+Laws+Website&amp;rft.pub=Government+of+Canada&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-174"><span class="mw-cite-backlink"><b><a href="#cite_ref-174">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://narcotic.fda.moph.go.th/faq/upload/Thai%20Narcotic%20Act%202012.doc._37ef.pdf">"Table of controlled Narcotic Drugs under the Thai Narcotics Act"</a>. <i>Thailand Food and Drug Administration</i>. 22 May 2013<span class="reference-accessdate">. Retrieved 11 November 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Table+of+controlled+Narcotic+Drugs+under+the+Thai+Narcotics+Act&amp;rft.date=22+May+2013&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fnarcotic.fda.moph.go.th%2Ffaq%2Fupload%2FThai%2520Narcotic%2520Act%25202012.doc._37ef.pdf&amp;rft.jtitle=Thailand+Food+and+Drug+Administration&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-175"><span class="mw-cite-backlink"><b><a href="#cite_ref-175">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://web.archive.org/web/20070804233232/http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/">"Class A, B and C drugs"</a>. <i>Home Office, Government of the United Kingdom</i>. Archived from <a rel="nofollow" class="external text" href="http://www.homeoffice.gov.uk/drugs/drugs-law/Class-a-b-c/">the original</a> on 4 August 2007<span class="reference-accessdate">. Retrieved 23 July 2007</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Class+A%2C+B+and+C+drugs&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.homeoffice.gov.uk%2Fdrugs%2Fdrugs-law%2FClass-a-b-c%2F&amp;rft.jtitle=Home+Office%2C+Government+of+the+United+Kingdom&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-Vyvanse-176"><span class="mw-cite-backlink">^ <a href="#cite_ref-Vyvanse_176-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Vyvanse_176-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Vyvanse_176-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.drugbank.ca/drugs/DB01255#identification"><i>Identification</i></a>. "Lisdexamfetamine". <i>Drugbank</i>. University of Alberta. 8 February 2013<span class="reference-accessdate">. Retrieved 13 October 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AAmphetamine&amp;rft.atitle=Lisdexamfetamine&amp;rft.btitle=Identification&amp;rft.date=8+February+2013&amp;rft.genre=bookitem&amp;rft_id=http%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB01255%23identification&amp;rft.pub=University+of+Alberta&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span></h2>
<table class="metadata mbox-small plainlinks" style="border:1px solid #aaa; background-color:#f9f9f9;">
<tr>
<td class="mbox-image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png" width="30" height="40" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x" /></td>
<td class="mbox-text plainlist" style="">Wikimedia Commons has media related to <i><b><a href="//commons.wikimedia.org/wiki/amphetamine" class="extiw" title="commons:amphetamine">amphetamine</a></b></i>.</td>
</tr>
</table>
<table class="metadata mbox-small plainlinks" style="border:1px solid #aaa; background-color:#f9f9f9;">
<tr>
<td class="mbox-image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/f/ff/Wikidata-logo.svg/40px-Wikidata-logo.svg.png" width="40" height="22" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/ff/Wikidata-logo.svg/60px-Wikidata-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/ff/Wikidata-logo.svg/80px-Wikidata-logo.svg.png 2x" /></td>
<td class="mbox-text plainlist" style=""><a href="/wiki/Wikidata" title="Wikidata">Wikidata</a> has <a href="/wiki/Open_data" title="Open data">open data</a> related to: <i><b><a href="//www.wikidata.org/wiki/Special:ItemByTitle/enwiki/Amphetamine" class="extiw" title="d:Special:ItemByTitle/enwiki/Amphetamine">Amphetamine</a></b></i></td>
</tr>
</table>
<ul>
<li><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5826">CID 5826</a> from <a href="/wiki/PubChem" title="PubChem">PubChem</a> (dextroamphetamine)</li>
<li><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3007">CID 3007</a> from <a href="/wiki/PubChem" title="PubChem">PubChem</a> (racemic amphetamine)</li>
<li><a rel="nofollow" class="external text" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=32893">CID 32893</a> from <a href="/wiki/PubChem" title="PubChem">PubChem</a> (levoamphetamine)</li>
<li><a rel="nofollow" class="external text" href="http://ctdbase.org/query.go?type=ixn&amp;chemqt=equals&amp;chem=name%3AAmphetamine&amp;actionDegreeTypes=increases&amp;actionDegreeTypes=decreases&amp;actionDegreeTypes=affects&amp;actionTypes=ANY&amp;geneqt=equals&amp;gene=&amp;pathwayqt=equals&amp;pathway=&amp;taxonqt=equals&amp;taxon=TAXON%3A9606&amp;goqt=equals&amp;go=&amp;sort=chemNmSort&amp;perPage=500&amp;action=Search">Comparative Toxicogenomics Database entry: Amphetamine</a></li>
<li><a rel="nofollow" class="external text" href="http://ctdbase.org/detail.go?type=gene&amp;acc=9607&amp;qid=2119242">Comparative Toxicogenomics Database entry: CARTPT</a></li>
<li><a rel="nofollow" class="external text" href="http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Amphetamine">U.S. National Library of Medicine: Drug Information Portal - Amphetamine</a></li>
</ul>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible expanded navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Amphetamine" title="Template:Amphetamine"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Amphetamine" title="Template talk:Amphetamine"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Amphetamine&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;">Articles related to <strong class="selflink">Amphetamine</strong></div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Main articles<br />
and<br />
pharmaceuticals</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;"><strong class="selflink">Amphetamine</strong></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Adderall" title="Adderall">Adderall</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">N/A</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Dexedrine</i></li>
<li><i>ProCentra</i></li>
<li><i>Zenzedi</i></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Vyvanse</i></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Neuropharmacology</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Biomolecular_target" title="Biomolecular target" class="mw-redirect">Biomolecular targets</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/TAAR1" title="TAAR1">TAAR1</a> (<a href="/wiki/Full_agonist" title="Full agonist" class="mw-redirect">full agonist</a>)</li>
<li><a href="/wiki/Cocaine_and_amphetamine_regulated_transcript#CART_Receptor" title="Cocaine and amphetamine regulated transcript">CART</a> (<a href="/wiki/Messenger_RNA" title="Messenger RNA"><abbr title="messenger RNA">mRNA</abbr></a> inducer)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;">Inhibited <a href="/wiki/Membrane_transport_protein" title="Membrane transport protein">transporters</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Dopamine_transporter" title="Dopamine transporter">DAT</a></li>
<li><a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">NET</a></li>
<li><a href="/wiki/Serotonin_transporter" title="Serotonin transporter">SERT</a></li>
<li><a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">VMAT2</a></li>
<li><a href="/wiki/SLC22A3" title="SLC22A3">SLC22A3</a></li>
<li><a href="/wiki/SLC22A5" title="SLC22A5">SLC22A5</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Active Metabolites</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Hydroxyamfetamine" title="Hydroxyamfetamine">4-Hydroxyamphetamine</a></li>
<li><a href="/wiki/P-Hydroxynorephedrine" title="P-Hydroxynorephedrine">4-Hydroxynorephedrine</a></li>
<li><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Norephedrine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="text-align: center;">Related articles</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder_predominantly_inattentive" title="Attention deficit hyperactivity disorder predominantly inattentive">ADD</a></li>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder" title="Attention deficit hyperactivity disorder">ADHD</a></li>
<li><a href="/wiki/Attention_deficit_hyperactivity_disorder_management" title="Attention deficit hyperactivity disorder management">ADHD management</a></li>
<li><a href="/wiki/Stimulant_psychosis#Substituted_amphetamines" title="Stimulant psychosis">Amphetamine psychosis</a></li>
<li><a href="/wiki/Benzedrine" title="Benzedrine">Benzedrine</a></li>
<li><a href="/wiki/Doping_in_sport" title="Doping in sport">Doping in sport</a></li>
<li><a href="/wiki/Formetamide" title="Formetamide">Formetamide</a></li>
<li><a href="/wiki/FOSB#.CE.94FosB" title="FOSB">ΔFosB</a></li>
<li><a href="/wiki/History_and_culture_of_amphetamines" title="History and culture of amphetamines">History and culture of amphetamines</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/Narcolepsy" title="Narcolepsy">Narcolepsy</a></li>
<li><a href="/wiki/Nootropic" title="Nootropic">Nootropic</a></li>
<li><a href="/wiki/Performance-enhancing_drugs" title="Performance-enhancing drugs">Performance-enhancing drugs</a></li>
<li><a href="/wiki/Pharmaceutical_drug" title="Pharmaceutical drug">Pharmaceutical drug</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="/wiki/Phenylacetone" title="Phenylacetone">Phenylacetone</a></li>
<li><a href="/wiki/Recreational_drug_use" title="Recreational drug use">Recreational drug use</a></li>
<li><a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">Substituted amphetamine</a></li>
<li><a href="/wiki/Trace_amine" title="Trace amine">Trace amine</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Methamphetamine" title="Template:Methamphetamine"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Methamphetamine" title="Template talk:Methamphetamine"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Methamphetamine&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;">Articles related to <a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Neuropharmacology</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;">Binding sites</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/TAAR1" title="TAAR1">TAAR1</a> (agonist)</li>
<li><a href="/wiki/Sigma-1_receptor" title="Sigma-1 receptor">σ1R</a> (agonist)</li>
<li><a href="/wiki/Sigma-2_receptor" title="Sigma-2 receptor">σ2R</a> (agonist)</li>
<li><a href="/wiki/Alpha-2A_adrenergic_receptor" title="Alpha-2A adrenergic receptor">α<sub>2A</sub> adrenoceptor</a> (agonist)</li>
<li><a href="/wiki/Alpha-2B_adrenergic_receptor" title="Alpha-2B adrenergic receptor">α<sub>2B</sub> adrenoceptor</a> (agonist)</li>
<li><a href="/wiki/Alpha-2C_adrenergic_receptor" title="Alpha-2C adrenergic receptor">α<sub>2C</sub> adrenoceptor</a> (agonist)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:13em;padding-left:0em;padding-right:0em;;">
<div style="padding:0em 0.75em;">Inhibited transporters</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Dopamine_transporter" title="Dopamine transporter">DAT</a></li>
<li><a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">NET</a></li>
<li><a href="/wiki/Serotonin_transporter" title="Serotonin transporter">SERT</a></li>
<li><a href="/wiki/Vesicular_monoamine_transporter_1" title="Vesicular monoamine transporter 1">VMAT1</a></li>
<li><a href="/wiki/Vesicular_monoamine_transporter_2" title="Vesicular monoamine transporter 2">VMAT2</a></li>
<li><a href="/wiki/SLC22A3" title="SLC22A3">SLC22A3</a></li>
<li><a href="/wiki/SLC22A5" title="SLC22A5">SLC22A5</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Related articles</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><strong class="selflink">Amphetamine</strong></li>
<li><a href="/wiki/Amphetamine_dependence" title="Amphetamine dependence">Amphetamine dependence</a></li>
<li><i><a href="/wiki/Breaking_Bad" title="Breaking Bad">Breaking Bad</a></i></li>
<li><a href="/wiki/Combat_Methamphetamine_Epidemic_Act_of_2005" title="Combat Methamphetamine Epidemic Act of 2005">Combat Methamphetamine Epidemic Act of 2005</a></li>
<li><i><a href="/wiki/Crystal_Darkness" title="Crystal Darkness">Crystal Darkness</a></i></li>
<li><a href="/wiki/Comprehensive_Methamphetamine_Control_Act_of_1996" title="Comprehensive Methamphetamine Control Act of 1996">Comprehensive Methamphetamine Control Act of 1996</a></li>
<li><a href="/wiki/Crystal_Meth_Anonymous" title="Crystal Meth Anonymous">Crystal Meth Anonymous</a></li>
<li><a href="/wiki/Faces_of_Meth" title="Faces of Meth">Faces of Meth</a></li>
<li><a href="/wiki/History_and_culture_of_amphetamines" title="History and culture of amphetamines">History and culture of amphetamines</a></li>
<li><a href="/wiki/Illinois_Methamphetamine_Precursor_Control_Act" title="Illinois Methamphetamine Precursor Control Act">Illinois Methamphetamine Precursor Control Act</a></li>
<li><a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Levomethamphetamine</a></li>
<li><a href="/wiki/Meth_mouth" title="Meth mouth">Meth mouth</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Methamphetamine_in_the_United_States" title="Methamphetamine in the United States">Methamphetamine in the United States</a></li>
<li><a href="/wiki/Montana_Meth_Project" title="Montana Meth Project">Montana Meth Project</a></li>
<li><a href="/wiki/Party_and_play" title="Party and play">Party and play</a></li>
<li><a href="/wiki/Prenatal_methamphetamine_exposure" title="Prenatal methamphetamine exposure">Prenatal methamphetamine exposure</a></li>
<li><a href="/wiki/Rolling_meth_lab" title="Rolling meth lab">Rolling meth lab</a></li>
<li><a href="/wiki/Ya_ba" title="Ya ba">Ya ba</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Euphoriants" title="Template:Euphoriants"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Euphoriants" title="Template talk:Euphoriants"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Euphoriants&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Euphoriant" title="Euphoriant">Euphoriants</a></div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Cannabinoid" title="Cannabinoid">Cannabinoids</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/AM-2201" title="AM-2201">AM-2201</a></li>
<li><a href="/wiki/JWH-018" title="JWH-018">JWH-018</a></li>
<li><a href="/wiki/Tetrahydrocannabinol" title="Tetrahydrocannabinol">THC</a> (found in <a href="/wiki/Cannabis_(drug)" title="Cannabis (drug)">Cannabis</a>)</li>
<li><a href="/wiki/UR-144" title="UR-144">UR-144</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Depressants</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;">General</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Barbiturate" title="Barbiturate">Barbiturates</a></li>
<li><a href="/wiki/Benzodiazepine" title="Benzodiazepine">Benzodiazepines</a></li>
<li><a href="/wiki/Gamma-Hydroxybutyric_acid" title="Gamma-Hydroxybutyric acid">GHB</a></li>
<li><a href="/wiki/Methaqualone" title="Methaqualone">Methaqualone</a></li>
<li><a href="/wiki/Pregabalin" title="Pregabalin">Pregabalin</a></li>
<li><a href="/wiki/Z-drug" title="Z-drug">Z-drugs</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Alcohol" title="Alcohol">Alcohols</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Tert-Amyl_alcohol" title="Tert-Amyl alcohol">2M2B</a></li>
<li><a href="/wiki/Ethanol" title="Ethanol">Ethanol</a>
<ul>
<li><a href="/wiki/Alcoholic_beverage" title="Alcoholic beverage">drinking alcohol</a></li>
</ul>
</li>
<li><a href="/wiki/Ethchlorvynol" title="Ethchlorvynol">Ethchlorvynol</a></li>
<li><a href="/wiki/Methylpentynol" title="Methylpentynol">Methylpentynol</a></li>
<li><a href="/wiki/4-Hydroxy-4-methylpentanoic_acid" title="4-Hydroxy-4-methylpentanoic acid">UMB68</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Opioid" title="Opioid">Opioids</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/7-Hydroxymitragynine" title="7-Hydroxymitragynine">7-Hydroxymitragynine</a> (Kratom)</li>
<li><a href="/wiki/Buprenorphine" title="Buprenorphine">Buprenorphine</a></li>
<li><a href="/wiki/Codeine" title="Codeine">Codeine</a></li>
<li><a href="/wiki/Dipipanone" title="Dipipanone">Dipipanone</a></li>
<li><a href="/wiki/Fentanyl" title="Fentanyl">Fentanyl</a></li>
<li><a href="/wiki/Heroin" title="Heroin">Heroin</a></li>
<li><a href="/wiki/Heterocodeine" title="Heterocodeine">Heterocodeine</a></li>
<li><a href="/wiki/Hydromorphone" title="Hydromorphone">Hydromorphone</a></li>
<li><a href="/wiki/Methadone" title="Methadone">Methadone</a></li>
<li><a href="/wiki/Morphine" title="Morphine">Morphine</a></li>
<li><a href="/wiki/Opium" title="Opium">Opium</a></li>
<li><a href="/wiki/Oxycodone" title="Oxycodone">Oxycodone</a></li>
<li><a href="/wiki/Oxymorphone" title="Oxymorphone">Oxymorphone</a></li>
<li><a href="/wiki/Pethidine" title="Pethidine">Pethidine</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Drugs with mixed <a href="/wiki/Mechanism_of_action" title="Mechanism of action">mechanism of actions</a> (MoA)</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Cocaine" title="Cocaine">Cocaine</a></li>
<li><a href="/wiki/Dimethyltryptamine" title="Dimethyltryptamine">Dimethyltryptamine</a> (DMT)</li>
<li><a href="/wiki/Ibogaine" title="Ibogaine">Ibogaine</a></li>
<li><a href="/wiki/Methadone" title="Methadone">Methadone</a></li>
<li><a href="/wiki/Pentazocine" title="Pentazocine">Pentazocine</a></li>
<li><a href="/wiki/Tramadol" title="Tramadol">Tramadol</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Stimulants</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;">General</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;"><a href="/wiki/Nicotine" title="Nicotine">Nicotine</a> (found in <a href="/wiki/Tobacco" title="Tobacco">Tobacco</a>)</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;">Releasing agents (RA)</div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/4-Methylaminorex" title="4-Methylaminorex">4-Methylaminorex</a></li>
<li><strong class="selflink">Amphetamine</strong></li>
<li><a href="/wiki/MDMA" title="MDMA">MDMA</a></li>
<li><a href="/wiki/Mephedrone" title="Mephedrone">Mephedrone</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/Methylone" title="Methylone">Methylone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Reuptake_inhibitor" title="Reuptake inhibitor">Reuptake inhibitors</a> (RI)</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Cocaine" title="Cocaine">Cocaine</a></li>
<li><a href="/wiki/Ethylphenidate" title="Ethylphenidate">Ethylphenidate</a></li>
<li><a href="/wiki/Methylphenidate" title="Methylphenidate">Methylphenidate</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Hallucinogens</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Deliriant" title="Deliriant">Deliriants</a></div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Atropine" title="Atropine">Atropine</a></li>
<li><a href="/wiki/Cyclizine" title="Cyclizine">Cyclizine</a></li>
<li><a href="/wiki/Diphenhydramine" title="Diphenhydramine">Diphenhydramine</a></li>
<li><a href="/wiki/Orphenadrine" title="Orphenadrine">Orphenadrine</a></li>
<li><a href="/wiki/Scopolamine" title="Scopolamine">Scopolamine</a></li>
<li><a href="/wiki/Trihexyphenidyl" title="Trihexyphenidyl">Trihexyphenidyl</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dissociative" title="Dissociative">Dissociatives</a></div>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Dextromethorphan" title="Dextromethorphan">Dextromethorphan</a> (DXM)</li>
<li><a href="/wiki/Ketamine" title="Ketamine">Ketamine</a> (K)</li>
<li><a href="/wiki/Methoxetamine" title="Methoxetamine">Methoxetamine</a> (MXE)</li>
<li><a href="/wiki/Nitrous_oxide" title="Nitrous oxide">Nitrous oxide</a> (N<sub>2</sub>O)</li>
<li><a href="/wiki/Phencyclidine" title="Phencyclidine">Phencyclidine</a> (PCP)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="padding-left:0em;padding-right:0em;width:13em;;">
<div style="padding:0em 0.75em;">Psychedelics</div>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;width:auto;;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/2C-B" title="2C-B">2C-B</a></li>
<li><a href="/wiki/2C-I" title="2C-I">2C-I</a></li>
<li><a href="/wiki/Dimethyltryptamine" title="Dimethyltryptamine">DMT</a></li>
<li><a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">LSD</a></li>
<li><a href="/wiki/Mescaline" title="Mescaline">Mescaline</a></li>
<li><a href="/wiki/Psilocybin" title="Psilocybin">Psilocybin</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Phenethylamines" title="Template:Phenethylamines"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Phenethylamines" title="Template talk:Phenethylamines"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Phenethylamines&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Substituted_phenethylamines" title="Substituted phenethylamines" class="mw-redirect">Phenethylamines</a></div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_phenethylamine" title="Substituted phenethylamine">Phenethylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Psychedelics:</i> <a href="/wiki/25B-NBOMe" title="25B-NBOMe">25B-NBOMe</a></li>
<li><a href="/wiki/25C-NBOMe" title="25C-NBOMe">25C-NBOMe</a></li>
<li><a href="/wiki/25D-NBOMe" title="25D-NBOMe">25D-NBOMe</a></li>
<li><a href="/wiki/25I-NBOMe" title="25I-NBOMe">25I-NBOMe</a></li>
<li><a href="/wiki/25N-NBOMe" title="25N-NBOMe">25N-NBOMe</a></li>
<li><a href="/wiki/2C-B" title="2C-B">2C-B</a></li>
<li><a href="/wiki/2C-B-FLY" title="2C-B-FLY">2C-B-FLY</a></li>
<li><a href="/wiki/%CE%92k-2C-B" title="Βk-2C-B" class="mw-redirect">βk-2C-B</a></li>
<li><a href="/wiki/2C-C" title="2C-C">2C-C</a></li>
<li><a href="/wiki/2C-D" title="2C-D">2C-D</a></li>
<li><a href="/wiki/2C-E" title="2C-E">2C-E</a></li>
<li><a href="/wiki/2C-EF" title="2C-EF">2C-EF</a></li>
<li><a href="/wiki/2C-F" title="2C-F">2C-F</a></li>
<li><a href="/wiki/2C-G" title="2C-G">2C-G</a></li>
<li><a href="/wiki/2C-I" title="2C-I">2C-I</a></li>
<li><a href="/wiki/2C-N" title="2C-N">2C-N</a></li>
<li><a href="/wiki/2C-P" title="2C-P">2C-P</a></li>
<li><a href="/wiki/2C-SE" title="2C-SE">2C-SE</a></li>
<li><a href="/wiki/2C-T" title="2C-T">2C-T</a></li>
<li><a href="/wiki/2C-T-2" title="2C-T-2">2C-T-2</a></li>
<li><a href="/wiki/2C-T-4" title="2C-T-4">2C-T-4</a></li>
<li><a href="/wiki/2C-T-7" title="2C-T-7">2C-T-7</a></li>
<li><a href="/wiki/2C-T-8" title="2C-T-8">2C-T-8</a></li>
<li><a href="/wiki/2C-T-9" title="2C-T-9" class="mw-redirect">2C-T-9</a></li>
<li><a href="/wiki/2C-T-13" title="2C-T-13">2C-T-13</a></li>
<li><a href="/wiki/2C-T-15" title="2C-T-15">2C-T-15</a></li>
<li><a href="/wiki/2C-T-17" title="2C-T-17">2C-T-17</a></li>
<li><a href="/wiki/2C-T-21" title="2C-T-21">2C-T-21</a></li>
<li><a href="/wiki/2C-TFM" title="2C-TFM">2C-TFM</a></li>
<li><a href="/wiki/2C-YN" title="2C-YN">2C-YN</a></li>
<li><a href="/wiki/Allylescaline" title="Allylescaline">Allylescaline</a></li>
<li><a href="/wiki/DESOXY" title="DESOXY">DESOXY</a></li>
<li><a href="/wiki/Escaline" title="Escaline">Escaline</a></li>
<li><a href="/wiki/Isoproscaline" title="Isoproscaline">Isoproscaline</a></li>
<li><a href="/wiki/Jimscaline" title="Jimscaline">Jimscaline</a></li>
<li><a href="/wiki/Macromerine" title="Macromerine">Macromerine</a></li>
<li><a href="/wiki/3-Methoxy-4-ethoxyphenethylamine" title="3-Methoxy-4-ethoxyphenethylamine">MEPEA</a></li>
<li><a href="/wiki/Mescaline" title="Mescaline">Mescaline</a></li>
<li><a href="/wiki/Metaescaline" title="Metaescaline">Metaescaline</a></li>
<li><a href="/wiki/Methallylescaline" title="Methallylescaline">Methallylescaline</a></li>
<li><a href="/wiki/Proscaline" title="Proscaline">Proscaline</a></li>
<li><a href="/wiki/Psi-2C-T-4" title="Psi-2C-T-4" class="mw-redirect">Psi-2C-T-4</a></li>
<li><a href="/wiki/TCB-2" title="TCB-2">TCB-2</a><br />
<i>Stimulants:</i> <a href="/wiki/Phenylethanolamine" title="Phenylethanolamine">Phenylethanolamine</a></li>
<li><a href="/wiki/Hordenine" title="Hordenine">Hordenine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><strong class="selflink">α-Methylphenethylamine</strong> (amphetamine)</li>
<li><a href="/wiki/%CE%92-Methylphenethylamine" title="Β-Methylphenethylamine">β-Methylphenethylamine</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/w/index.php?title=O-Methylphenethylamine&amp;action=edit&amp;redlink=1" class="new" title="O-Methylphenethylamine (page does not exist)">o-Methylphenethylamine</a></li>
<li><a href="/w/index.php?title=P-Methylphenethylamine&amp;action=edit&amp;redlink=1" class="new" title="P-Methylphenethylamine (page does not exist)">p-Methylphenethylamine</a></li>
</ul>
<p><i>Entactogens:</i> <a href="/wiki/Lophophine" title="Lophophine">Lophophine</a></p>
<ul>
<li><a href="/wiki/Methylenedioxyphenethylamine" title="Methylenedioxyphenethylamine">MDPEA</a></li>
<li><a href="/wiki/Methylenedioxymethylphenethylamine" title="Methylenedioxymethylphenethylamine">MDMPEA</a><br />
<i>Others:</i> <a href="/wiki/Benzodioxolylhydroxybutanamine" title="Benzodioxolylhydroxybutanamine" class="mw-redirect">BOH</a></li>
<li><a href="/wiki/3,4-Dimethoxyphenethylamine" title="3,4-Dimethoxyphenethylamine">DMPEA</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_amphetamine" title="Substituted amphetamine">Amphetamines</a><br /></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Psychedelics:</i> <a href="/wiki/3C-BZ" title="3C-BZ">3C-BZ</a></li>
<li><a href="/wiki/3C-E" title="3C-E">3C-E</a></li>
<li><a href="/wiki/3C-P" title="3C-P">3C-P</a></li>
<li><a href="/wiki/Aleph_(psychedelic)" title="Aleph (psychedelic)">Aleph</a></li>
<li><a href="/wiki/Beatrice_(psychedelic)" title="Beatrice (psychedelic)">Beatrice</a></li>
<li><a href="/wiki/Bromo-DragonFLY" title="Bromo-DragonFLY">Bromo-DragonFLY</a></li>
<li><a href="/wiki/D-Deprenyl" title="D-Deprenyl">D-Deprenyl</a></li>
<li><a href="/wiki/Dimethoxyamphetamine" title="Dimethoxyamphetamine">DMA</a></li>
<li><a href="/w/index.php?title=4-Methyl-2,5-methoxycyclopropylamine&amp;action=edit&amp;redlink=1" class="new" title="4-Methyl-2,5-methoxycyclopropylamine (page does not exist)">DMCPA</a></li>
<li><a href="/wiki/DMMDA" title="DMMDA">DMMDA</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-bromoamphetamine" title="2,5-Dimethoxy-4-bromoamphetamine">DOB</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-chloroamphetamine" title="2,5-Dimethoxy-4-chloroamphetamine">DOC</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-fluoroethylamphetamine" title="2,5-Dimethoxy-4-fluoroethylamphetamine" class="mw-redirect">DOEF</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-ethylamphetamine" title="2,5-Dimethoxy-4-ethylamphetamine">DOET</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-iodoamphetamine" title="2,5-Dimethoxy-4-iodoamphetamine">DOI</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-methylamphetamine" title="2,5-Dimethoxy-4-methylamphetamine">DOM</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-nitroamphetamine" title="2,5-Dimethoxy-4-nitroamphetamine">DON</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-propylamphetamine" title="2,5-Dimethoxy-4-propylamphetamine">DOPR</a></li>
<li><a href="/wiki/2,5-Dimethoxy-4-trifluoromethylamphetamine" title="2,5-Dimethoxy-4-trifluoromethylamphetamine">DOTFM</a></li>
<li><a href="/wiki/Ganesha_(psychedelic)" title="Ganesha (psychedelic)">Ganesha</a></li>
<li><a href="/wiki/MMDA_(drug)" title="MMDA (drug)">MMDA</a></li>
<li><a href="/wiki/MMDA-2" title="MMDA-2">MMDA-2</a></li>
<li><a href="/wiki/Psi-DOM" title="Psi-DOM">Psi-DOM</a></li>
<li><a href="/wiki/Trimethoxyamphetamine" title="Trimethoxyamphetamine">TMA</a></li>
<li><a href="/wiki/Tetramethoxyamphetamine" title="Tetramethoxyamphetamine" class="mw-redirect">TeMA</a><br />
<i>Stimulants:</i> <a href="/wiki/3-Fluoromethamphetamine" title="3-Fluoromethamphetamine">3-FMA</a></li>
<li><a href="/wiki/4-Methamphetamine" title="4-Methamphetamine" class="mw-redirect">4-MA</a></li>
<li><a href="/wiki/4-Methylmethamphetamine" title="4-Methylmethamphetamine">4-MMA</a></li>
<li><a href="/wiki/4-Methylthioamphetamine" title="4-Methylthioamphetamine">4-MTA</a></li>
<li><a href="/wiki/5-(2-Aminopropyl)indole" title="5-(2-Aminopropyl)indole">5-IT</a></li>
<li><a href="/wiki/Alfetamine" title="Alfetamine">Alfetamine</a></li>
<li><a href="/wiki/Amfecloral" title="Amfecloral">Amfecloral</a></li>
<li><a href="/wiki/Amfepentorex" title="Amfepentorex">Amfepentorex</a></li>
<li><strong class="selflink">Amphetamine</strong> (<a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a>, <a href="/wiki/Levoamphetamine" title="Levoamphetamine">Levoamphetamine</a>)</li>
<li><a href="/wiki/Amphetaminil" title="Amphetaminil">Amphetaminil</a></li>
<li><a href="/wiki/Benfluorex" title="Benfluorex">Benfluorex</a></li>
<li><a href="/wiki/Benzphetamine" title="Benzphetamine">Benzphetamine</a></li>
<li><a href="/wiki/Cathine" title="Cathine">Cathine</a></li>
<li><a href="/wiki/Clobenzorex" title="Clobenzorex">Clobenzorex</a></li>
<li><a href="/wiki/Dimethylamphetamine" title="Dimethylamphetamine">Dimethylamphetamine</a></li>
<li><a href="/wiki/Ephedrine" title="Ephedrine">Ephedrine</a></li>
<li><a href="/wiki/Etilamfetamine" title="Etilamfetamine">Etilamfetamine</a></li>
<li><a href="/wiki/Fencamfamine" title="Fencamfamine">Fencamfamine</a></li>
<li><a href="/wiki/Fencamine" title="Fencamine">Fencamine</a></li>
<li><a href="/wiki/Fenethylline" title="Fenethylline">Fenethylline</a></li>
<li><a href="/wiki/Fenfluramine" title="Fenfluramine">Fenfluramine</a> (<a href="/wiki/Dexfenfluramine" title="Dexfenfluramine">Dexfenfluramine</a>, <a href="/wiki/Levofenfluramine" title="Levofenfluramine">Levofenfluramine</a>)</li>
<li><a href="/wiki/Fenproporex" title="Fenproporex">Fenproporex</a></li>
<li><a href="/wiki/Fludorex" title="Fludorex">Fludorex</a></li>
<li><a href="/wiki/Furfenorex" title="Furfenorex">Furfenorex</a></li>
<li><a href="/wiki/Gepefrine" title="Gepefrine">Gepefrine</a></li>
<li><a href="/wiki/Hydroxyamphetamine" title="Hydroxyamphetamine">Hydroxyamphetamine</a></li>
<li><a href="/wiki/Iofetamine" title="Iofetamine" class="mw-redirect">Iofetamine</a></li>
<li><a href="/wiki/Isopropylamphetamine" title="Isopropylamphetamine">Isopropylamphetamine</a></li>
<li><a href="/wiki/Lefetamine" title="Lefetamine">Lefetamine</a></li>
<li><a href="/wiki/Lisdexamfetamine" title="Lisdexamfetamine">Lisdexamfetamine</a></li>
<li><a href="/wiki/Mefenorex" title="Mefenorex">Mefenorex</a></li>
<li><a href="/wiki/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a> (Dextromethamphetamine, <a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Levomethamphetamine</a>)</li>
<li><a href="/wiki/Methoxyphenamine" title="Methoxyphenamine">Methoxyphenamine</a></li>
<li><a href="/wiki/3-Methoxy-4-methylamphetamine" title="3-Methoxy-4-methylamphetamine">MMA</a></li>
<li><a href="/wiki/Norfenfluramine" title="Norfenfluramine">Norfenfluramine</a></li>
<li><a href="/wiki/L-Norpseudoephedrine" title="L-Norpseudoephedrine"><small>L</small>-Norpseudoephedrine</a></li>
<li><a href="/wiki/Oxilofrine" title="Oxilofrine">Oxilofrine</a></li>
<li><a href="/wiki/Ortetamine" title="Ortetamine">Ortetamine</a></li>
<li><a href="/wiki/Parabromoamphetamine" title="Parabromoamphetamine" class="mw-redirect">PBA</a></li>
<li><a href="/wiki/Parachloroamphetamine" title="Parachloroamphetamine" class="mw-redirect">PCA</a></li>
<li><a href="/wiki/Phenpromethamine" title="Phenpromethamine">Phenpromethamine</a></li>
<li><a href="/wiki/4-Fluoroamphetamine" title="4-Fluoroamphetamine">PFA</a></li>
<li><a href="/wiki/4-Fluoromethamphetamine" title="4-Fluoromethamphetamine">PFMA</a></li>
<li><a href="/wiki/Paraiodoamphetamine" title="Paraiodoamphetamine" class="mw-redirect">PIA</a></li>
<li><a href="/wiki/Para-Methoxyamphetamine" title="Para-Methoxyamphetamine">PMA</a></li>
<li><a href="/wiki/Para-Methoxyethylamphetamine" title="Para-Methoxyethylamphetamine" class="mw-redirect">PMEA</a></li>
<li><a href="/wiki/Paramethoxymethamphetamine" title="Paramethoxymethamphetamine" class="mw-redirect">PMMA</a></li>
<li><a href="/wiki/Phenylpropanolamine" title="Phenylpropanolamine">Phenylpropanolamine</a></li>
<li><a href="/wiki/Pholedrine" title="Pholedrine">Pholedrine</a></li>
<li><a href="/wiki/Prenylamine" title="Prenylamine">Prenylamine</a></li>
<li><a href="/wiki/Propylamphetamine" title="Propylamphetamine">Propylamphetamine</a></li>
<li><a href="/wiki/Pseudoephedrine" title="Pseudoephedrine">Pseudoephedrine</a></li>
<li><a href="/wiki/Sibutramine" title="Sibutramine">Sibutramine</a></li>
<li><a href="/wiki/Tiflorex" title="Tiflorex">Tiflorex</a></li>
<li><a href="/wiki/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a></li>
<li><a href="/wiki/Xylopropamine" title="Xylopropamine">Xylopropamine</a></li>
<li><a href="/wiki/Zylofuramine" title="Zylofuramine">Zylofuramine</a><br />
<i>Entactogens:</i> <a href="/wiki/5-APB" title="5-APB">5-APB</a></li>
<li><a href="/wiki/5-APDB" title="5-APDB">5-APDB</a></li>
<li><a href="/wiki/5-MAPB" title="5-MAPB">5-MAPB</a></li>
<li><a href="/wiki/6-APB" title="6-APB">6-APB</a></li>
<li><a href="/wiki/6-APDB" title="6-APDB">6-APDB</a></li>
<li><a href="/wiki/6-MAPB" title="6-MAPB">6-MAPB</a></li>
<li><a href="/wiki/Ethylidenedioxyamphetamine" title="Ethylidenedioxyamphetamine" class="mw-redirect">EDA</a></li>
<li><a href="/wiki/Indanylaminopropane" title="Indanylaminopropane" class="mw-redirect">IAP</a></li>
<li><a href="/wiki/Methylenedioxyamphetamine" title="Methylenedioxyamphetamine" class="mw-redirect">MDA</a></li>
<li><a href="/wiki/Methylenedioxyethylamphetamine" title="Methylenedioxyethylamphetamine">MDEA</a></li>
<li><a href="/wiki/Methylenedioxyhydroxylmethamphetamine" title="Methylenedioxyhydroxylmethamphetamine" class="mw-redirect">MDHMA</a></li>
<li><a href="/wiki/Methylenedioxymethamphetamine" title="Methylenedioxymethamphetamine" class="mw-redirect">MDMA</a></li>
<li><a href="/wiki/Methylenedioxyhydroxyamphetamine" title="Methylenedioxyhydroxyamphetamine">MDOH</a></li>
<li><a href="/wiki/Methoxymethylenedioxymethamphetamine" title="Methoxymethylenedioxymethamphetamine" class="mw-redirect">MMDMA</a></li>
<li><a href="/wiki/Naphthylaminopropane" title="Naphthylaminopropane">NAP</a></li>
<li><a href="/wiki/Tetralinylaminopropane" title="Tetralinylaminopropane" class="mw-redirect">TAP</a><br />
<i>Others:</i> <a href="/wiki/Amiflamine" title="Amiflamine">Amiflamine</a></li>
<li><a href="/wiki/Difluoromethylenedioxyamphetamine" title="Difluoromethylenedioxyamphetamine" class="mw-redirect">DFMDA</a></li>
<li><a href="/wiki/Selegiline" title="Selegiline">Selegiline</a> (also <a href="/wiki/D-Deprenyl" title="D-Deprenyl"><small>D</small>-Deprenyl</a>)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phentermine" title="Phentermine">Phentermines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/Chlorphentermine" title="Chlorphentermine">Chlorphentermine</a></li>
<li><a href="/wiki/Cloforex" title="Cloforex">Cloforex</a></li>
<li><a href="/wiki/Clortermine" title="Clortermine">Clortermine</a></li>
<li><a href="/wiki/Etolorex" title="Etolorex">Etolorex</a></li>
<li><a href="/wiki/Mephentermine" title="Mephentermine">Mephentermine</a></li>
<li><a href="/wiki/Pentorex" title="Pentorex">Pentorex</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a><br />
<i>Entactogens:</i> <a href="/wiki/Methylenedioxyphentermine" title="Methylenedioxyphentermine">MDPH</a></li>
<li><a href="/wiki/Methylenedioxymethylphentermine" title="Methylenedioxymethylphentermine" class="mw-redirect">MDMPH</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Substituted_cathinone" title="Substituted cathinone">Cathinones</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/Amfepramone" title="Amfepramone">Amfepramone</a></li>
<li><a href="/wiki/Brephedrone" title="Brephedrone" class="mw-redirect">Brephedrone</a></li>
<li><a href="/wiki/Buphedrone" title="Buphedrone">Buphedrone</a></li>
<li><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a></li>
<li><a href="/wiki/Cathinone" title="Cathinone">Cathinone</a></li>
<li><a href="/wiki/Dimethylcathinone" title="Dimethylcathinone" class="mw-redirect">Dimethylcathinone</a></li>
<li><a href="/wiki/Ethcathinone" title="Ethcathinone">Ethcathinone</a></li>
<li><a href="/wiki/Flephedrone" title="Flephedrone">Flephedrone</a></li>
<li><a href="/wiki/Methcathinone" title="Methcathinone">Methcathinone</a></li>
<li><a href="/wiki/Mephedrone" title="Mephedrone">Mephedrone</a></li>
<li><a href="/wiki/Methedrone" title="Methedrone">Methedrone</a><br />
<i>Entactogens:</i> <a href="/wiki/Ethylone" title="Ethylone">Ethylone</a></li>
<li><a href="/wiki/Methylone" title="Methylone">Methylone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phenylisobutylamine" title="Phenylisobutylamine">Phenylisobutylamines</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Entactogens:</i> <a href="/wiki/4-Chlorophenylisobutylamine" title="4-Chlorophenylisobutylamine">4-CAB</a></li>
<li><a href="/wiki/4-Methylphenylisobutylamine" title="4-Methylphenylisobutylamine">4-MAB</a></li>
<li><a href="/wiki/Ariadne_(psychedelic)" title="Ariadne (psychedelic)">Ariadne</a></li>
<li><a href="/wiki/Benzodioxolylbutanamine" title="Benzodioxolylbutanamine" class="mw-redirect">BDB</a></li>
<li><a href="/wiki/Butylone" title="Butylone">Butylone</a></li>
<li><a href="/wiki/Ethylbenzodioxolylbutanamine" title="Ethylbenzodioxolylbutanamine" class="mw-redirect">EBDB</a></li>
<li><a href="/wiki/Eutylone" title="Eutylone">Eutylone</a></li>
<li><a href="/wiki/Methylbenzodioxolylbutanamine" title="Methylbenzodioxolylbutanamine" class="mw-redirect">MBDB</a><br />
<i>Stimulants:</i> <a href="/wiki/Phenylisobutylamine" title="Phenylisobutylamine">Phenylisobutylamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Phenylethylpyrrolidine" title="Phenylethylpyrrolidine">Phenylalkylpyrrolidines</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><i>Stimulants:</i> <a href="/wiki/Alpha-Pyrrolidinobutiophenone" title="Alpha-Pyrrolidinobutiophenone">a-PBP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopropiophenone" title="Alpha-Pyrrolidinopropiophenone">a-PPP</a></li>
<li><a href="/wiki/Alpha-Pyrrolidinopentiophenone" title="Alpha-Pyrrolidinopentiophenone">a-PVP</a></li>
<li><a href="/w/index.php?title=3%27,4%27-Methylenedioxy-a-pyrrolidinobutiophenone&amp;action=edit&amp;redlink=1" class="new" title="3',4'-Methylenedioxy-a-pyrrolidinobutiophenone (page does not exist)">MDPBP</a></li>
<li><a href="/w/index.php?title=3%27,4%27-Methylenedioxy-a-pyrrolidinopropiophenone&amp;action=edit&amp;redlink=1" class="new" title="3',4'-Methylenedioxy-a-pyrrolidinopropiophenone (page does not exist)">MDPPP</a></li>
<li><a href="/wiki/3,4-Methylenedioxypyrovalerone" title="3,4-Methylenedioxypyrovalerone" class="mw-redirect">MDPV</a></li>
<li><a href="/w/index.php?title=4%27-Methoxy-a-pyrrolidinopropiophenone&amp;action=edit&amp;redlink=1" class="new" title="4'-Methoxy-a-pyrrolidinopropiophenone (page does not exist)">MOPPP</a></li>
<li><a href="/w/index.php?title=4%27-Methyl-a-pyrrolidinobutiophenone&amp;action=edit&amp;redlink=1" class="new" title="4'-Methyl-a-pyrrolidinobutiophenone (page does not exist)">MPBP</a></li>
<li><a href="/w/index.php?title=4%27-Methyl-a-pyrrolidinohexiophenone&amp;action=edit&amp;redlink=1" class="new" title="4'-Methyl-a-pyrrolidinohexiophenone (page does not exist)">MPHP</a></li>
<li><a href="/w/index.php?title=4%27-Methyl-a-pyrrolidinopropiophenone&amp;action=edit&amp;redlink=1" class="new" title="4'-Methyl-a-pyrrolidinopropiophenone (page does not exist)">MPPP</a></li>
<li><a href="/wiki/Naphyrone" title="Naphyrone">Naphyrone</a></li>
<li><a href="/wiki/Phenylethylpyrrolidine" title="Phenylethylpyrrolidine">PEP</a></li>
<li><a href="/wiki/Prolintane" title="Prolintane">Prolintane</a></li>
<li><a href="/wiki/Pyrovalerone" title="Pyrovalerone">Pyrovalerone</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Catecholamine" title="Catecholamine">Catecholamines</a><br />
<small>(and close relatives)</small></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/6-Fluoronorepinephrine" title="6-Fluoronorepinephrine">6-FNE</a></li>
<li><a href="/wiki/6-Hydroxydopamine" title="6-Hydroxydopamine" class="mw-redirect">6-OHDA</a></li>
<li><a href="/wiki/Alpha-Methyldopamine" title="Alpha-Methyldopamine">a-Me-DA</a></li>
<li><a href="/wiki/Alpha-Methyltyramine" title="Alpha-Methyltyramine" class="mw-redirect">a-Me-TRA</a></li>
<li><a href="/wiki/Adrenochrome" title="Adrenochrome">Adrenochrome</a></li>
<li><a href="/wiki/Ciladopa" title="Ciladopa">Ciladopa</a></li>
<li><a href="/wiki/D-DOPA" title="D-DOPA"><small>D</small>-DOPA</a> (Dextrodopa)</li>
<li><a href="/wiki/Dimetofrine" title="Dimetofrine">Dimetofrine</a></li>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/Epinephrine" title="Epinephrine">Epinephrine</a></li>
<li><a href="/wiki/Epinine" title="Epinine" class="mw-redirect">Epinine</a></li>
<li><a href="/wiki/Etilefrine" title="Etilefrine">Etilefrine</a></li>
<li><a href="/wiki/Ethylnorepinephrine" title="Ethylnorepinephrine">Ethylnorepinephrine</a></li>
<li><a href="/wiki/Fenclonine" title="Fenclonine">Fenclonine</a></li>
<li><a href="/wiki/Ibopamine" title="Ibopamine">Ibopamine</a></li>
<li><a href="/wiki/Isoprenaline" title="Isoprenaline">Isoprenaline</a></li>
<li><a href="/wiki/Isoetarine" title="Isoetarine">Isoetarine</a></li>
<li><a href="/wiki/L-DOPA" title="L-DOPA"><small>L</small>-DOPA</a> (Levodopa)</li>
<li><a href="/wiki/L-DOPS" title="L-DOPS" class="mw-redirect"><small>L</small>-DOPS</a> (Droxidopa)</li>
<li><a href="/wiki/L-Phenylalanine" title="L-Phenylalanine" class="mw-redirect"><small>L</small>-Phenylalanine</a></li>
<li><a href="/wiki/L-Tyrosine" title="L-Tyrosine" class="mw-redirect"><small>L</small>-Tyrosine</a></li>
<li><a href="/wiki/Meta-Tyramine" title="Meta-Tyramine"><i>m</i>-Tyramine</a></li>
<li><a href="/wiki/Metanephrine" title="Metanephrine">Metanephrine</a></li>
<li><a href="/wiki/Metaraminol" title="Metaraminol">Metaraminol</a></li>
<li><a href="/wiki/Metaterol" title="Metaterol">Metaterol</a></li>
<li><a href="/wiki/Metirosine" title="Metirosine">Metirosine</a></li>
<li><a href="/wiki/Methyldopa" title="Methyldopa">Methyldopa</a></li>
<li><a href="/wiki/N,N-Dimethyldopamine" title="N,N-Dimethyldopamine">N,N-Dimethyldopamine</a></li>
<li><a href="/wiki/Nordefrin" title="Nordefrin" class="mw-redirect">Nordefrin</a> (<a href="/wiki/Levonordefrin" title="Levonordefrin">Levonordefrin</a>)</li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Norfenefrine" title="Norfenefrine">Norfenefrine</a> (<i>m</i>-Octopamine)</li>
<li><a href="/wiki/Normetanephrine" title="Normetanephrine">Normetanephrine</a></li>
<li><a href="/wiki/Orciprenaline" title="Orciprenaline">Orciprenaline</a></li>
<li><a href="/wiki/Octopamine" title="Octopamine"><i>p</i>-Octopamine</a></li>
<li><a href="/wiki/Tyramine" title="Tyramine"><i>p</i>-Tyramine</a></li>
<li><a href="/wiki/Phenylephrine" title="Phenylephrine">Phenylephrine</a></li>
<li><a href="/wiki/Synephrine" title="Synephrine">Synephrine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Miscellaneous</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/Amidephrine" title="Amidephrine">Amidephrine</a></li>
<li><a href="/wiki/Arbutamine" title="Arbutamine">Arbutamine</a></li>
<li><a href="/wiki/Cafedrine" title="Cafedrine">Cafedrine</a></li>
<li><a href="/wiki/Denopamine" title="Denopamine">Denopamine</a></li>
<li><a href="/wiki/Dobutamine" title="Dobutamine">Dobutamine</a></li>
<li><a href="/wiki/Dopexamine" title="Dopexamine">Dopexamine</a></li>
<li><a href="/wiki/Etafedrine" title="Etafedrine">Etafedrine</a></li>
<li><a href="/wiki/Famprofazone" title="Famprofazone">Famprofazone</a></li>
<li><a href="/wiki/Hexapradol" title="Hexapradol">Hexapradol</a></li>
<li><a href="/wiki/Methoxamine" title="Methoxamine">Methoxamine</a></li>
<li><a href="/wiki/Pronethalol" title="Pronethalol">Pronethalol</a></li>
<li><a href="/wiki/Salbutamol" title="Salbutamol">Salbutamol</a> (<a href="/wiki/Levosalbutamol" title="Levosalbutamol">Levosalbutamol</a>)</li>
<li><a href="/wiki/Theodrenaline" title="Theodrenaline">Theodrenaline</a></li>
<li><a href="/wiki/UWA-101" title="UWA-101">UWA-101</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table cellspacing="0" class="navbox" style="border-spacing:0;">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks hlist collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit;">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:TAAR_ligands" title="Template:TAAR ligands"><span title="View this template" style=";;background:none transparent;border:none;;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:TAAR_ligands" title="Template talk:TAAR ligands"><span title="Discuss this template" style=";;background:none transparent;border:none;;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:TAAR_ligands&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%;"><a href="/wiki/Trace_amine-associated_receptor" title="Trace amine-associated receptor">Trace amine-associated receptor</a> (human TAAR) <a href="/wiki/Ligand" title="Ligand">ligands</a></div>
</th>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/TAAR1" title="TAAR1">TAAR1</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><a href="/wiki/Agonist" title="Agonist">Agonists</a><sup>†</sup></center>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><strong class="selflink">Amphetamine</strong></li>
<li><a href="/wiki/N,N-Dimethyltryptamine" title="N,N-Dimethyltryptamine" class="mw-redirect">DMT</a></li>
<li><a href="/wiki/Dopamine" title="Dopamine">Dopamine</a></li>
<li><a href="/wiki/2-Fluoroamphetamine" title="2-Fluoroamphetamine">2-Fluoroamphetamine</a></li>
<li><a href="/wiki/3-Iodothyronamine" title="3-Iodothyronamine">3-Iodothyronamine</a></li>
<li><a href="/wiki/Lysergic_acid_diethylamide" title="Lysergic acid diethylamide">LSD</a></li>
<li><a href="/wiki/3,4-Methylenedioxy-N-methylamphetamine" title="3,4-Methylenedioxy-N-methylamphetamine" class="mw-redirect">MDMA</a></li>
<li><a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a></li>
<li><a href="/wiki/3-Methoxytyramine" title="3-Methoxytyramine">3-Methoxytyramine</a></li>
<li><a href="/wiki/N-Methylphenethylamine" title="N-Methylphenethylamine"><i>N</i>-Methylphenethylamine</a></li>
<li><a href="/wiki/N-Methyltryptamine" title="N-Methyltryptamine"><i>N</i>-Methyltryptamine</a></li>
<li><a href="/wiki/N-Methyltyramine" title="N-Methyltyramine"><i>N</i>-Methyltyramine</a></li>
<li><a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a></li>
<li><a href="/wiki/Meta-Octopamine" title="Meta-Octopamine" class="mw-redirect"><i>m</i>-Octopamine</a></li>
<li><a href="/wiki/Para-Octopamine" title="Para-Octopamine" class="mw-redirect"><i>p</i>-Octopamine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Phentermine" title="Phentermine">Phentermine</a></li>
<li><a href="/wiki/O-Phenyl-3-iodotyramine" title="O-Phenyl-3-iodotyramine">O-Phenyl-3-iodotyramine</a></li>
<li><a href="/wiki/Propylhexedrine" title="Propylhexedrine">Propylhexedrine</a></li>
<li><a href="/wiki/RO5166017" title="RO5166017">RO5166017</a></li>
<li><a href="/wiki/Serotonin" title="Serotonin">Serotonin</a></li>
<li><a href="/wiki/Synephrine" title="Synephrine">Synephrine</a></li>
<li><a href="/wiki/Tryptamine" title="Tryptamine">Tryptamine</a></li>
<li><a href="/wiki/Meta-Tyramine" title="Meta-Tyramine"><i>m</i>-Tyramine</a></li>
<li><a href="/wiki/Para-Tyramine" title="Para-Tyramine" class="mw-redirect"><i>p</i>-Tyramine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><a href="/wiki/Receptor_antagonist" title="Receptor antagonist">Antagonists</a></center>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/EPPTB" title="EPPTB">EPPTB</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/TAAR2" title="TAAR2">TAAR2</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><b>Agonists</b></center>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/wiki/3-Iodothyronamine" title="3-Iodothyronamine">3-Iodothyronamine</a></li>
<li><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamine</a></li>
<li><a href="/wiki/Tyramine" title="Tyramine">Tyramine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><b>Antagonists</b></center>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li>&#160;</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/TAAR5" title="TAAR5">TAAR5</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;">
<div style="padding:0em 0.25em;"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="border-spacing:0;">
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><b>Agonists</b></center>
</th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li><a href="/w/index.php?title=Dimethylethylamine&amp;action=edit&amp;redlink=1" class="new" title="Dimethylethylamine (page does not exist)">Dimethylethylamine</a></li>
<li><a href="/wiki/Trimethylamine" title="Trimethylamine">Trimethylamine</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="width:6em;">
<center><b>Antagonists</b></center>
</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px;">
<div style="padding:0em 0.25em;">
<ul>
<li>&#160;</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px;">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2">
<div>
<ul>
<li><sup>†</sup>Other <a href="/wiki/Phenethylamine" title="Phenethylamine">phenethylamines</a>, <a href="/wiki/Tryptamine" title="Tryptamine">tryptamines</a>, <a href="/wiki/Ergoline" title="Ergoline">ergolines</a>, and <a href="/wiki/Thyronamine" title="Thyronamine">thyronamines</a> are either known to or are likely to be TAAR1 agonists as well.</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1031
CPU time usage: 10.785 seconds
Real time usage: 11.042 seconds
Preprocessor visited node count: 23097/1000000
Preprocessor generated node count: 90695/1500000
Post‐expand include size: 540121/2048000 bytes
Template argument size: 36213/2048000 bytes
Highest expansion depth: 19/40
Expensive parser function count: 12/500
Lua time usage: 0.527/10.000 seconds
Lua memory usage: 3.17 MB/50 MB
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:2504-0!*!0!!en!4!* and timestamp 20140330015436
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>								<div class="printfooter">
				Retrieved from "<a href="http://en.wikipedia.org/w/index.php?title=Amphetamine&amp;oldid=601362017">http://en.wikipedia.org/w/index.php?title=Amphetamine&amp;oldid=601362017</a>"				</div>
												<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Amphetamine" title="Category:Amphetamine">Amphetamine</a></li><li><a href="/wiki/Category:Amphetamines" title="Category:Amphetamines">Amphetamines</a></li><li><a href="/wiki/Category:Anorectics" title="Category:Anorectics">Anorectics</a></li><li><a href="/wiki/Category:Attention_deficit_hyperactivity_disorder" title="Category:Attention deficit hyperactivity disorder">Attention deficit hyperactivity disorder</a></li><li><a href="/wiki/Category:Drugs_acting_on_the_cardiovascular_system" title="Category:Drugs acting on the cardiovascular system">Drugs acting on the cardiovascular system</a></li><li><a href="/wiki/Category:Drugs_acting_on_the_nervous_system" title="Category:Drugs acting on the nervous system">Drugs acting on the nervous system</a></li><li><a href="/wiki/Category:Drugs_in_sport" title="Category:Drugs in sport">Drugs in sport</a></li><li><a href="/wiki/Category:Euphoriants" title="Category:Euphoriants">Euphoriants</a></li><li><a href="/wiki/Category:German_inventions" title="Category:German inventions">German inventions</a></li><li><a href="/wiki/Category:Monoamine_reuptake_inhibitors" title="Category:Monoamine reuptake inhibitors">Monoamine reuptake inhibitors</a></li><li><a href="/wiki/Category:Nootropics" title="Category:Nootropics">Nootropics</a></li><li><a href="/wiki/Category:Phenethylamines" title="Category:Phenethylamines">Phenethylamines</a></li><li><a href="/wiki/Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors" title="Category:Serotonin-norepinephrine-dopamine reuptake inhibitors">Serotonin-norepinephrine-dopamine reuptake inhibitors</a></li><li><a href="/wiki/Category:Stimulants" title="Category:Stimulants">Stimulants</a></li><li><a href="/wiki/Category:TAAR1_agonists" title="Category:TAAR1 agonists">TAAR1 agonists</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Good_articles" title="Category:Good articles">Good articles</a></li><li><a href="/wiki/Category:Wikipedia_indefinitely_semi-protected_pages" title="Category:Wikipedia indefinitely semi-protected pages">Wikipedia indefinitely semi-protected pages</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_March_2014" title="Category:Use dmy dates from March 2014">Use dmy dates from March 2014</a></li><li><a href="/wiki/Category:Articles_including_recorded_pronunciations" title="Category:Articles including recorded pronunciations">Articles including recorded pronunciations</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_March_2014" title="Category:Articles containing potentially dated statements from March 2014">Articles containing potentially dated statements from March 2014</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="/wiki/Category:Articles_using_fixed_number_of_columns_in_reflist" title="Category:Articles using fixed number of columns in reflist">Articles using fixed number of columns in reflist</a></li></ul></div></div>												<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>
			<div id="mw-head">
				<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
	<h3 id="p-personal-label">Personal tools</h3>
	<ul>
<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Amphetamine&amp;type=signup">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Amphetamine" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>	</ul>
</div>
				<div id="left-navigation">
					<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
	<h3 id="p-namespaces-label">Namespaces</h3>
	<ul>
					<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Amphetamine"  title="View the content page [c]" accesskey="c">Article</a></span></li>
					<li  id="ca-talk"><span><a href="/wiki/Talk:Amphetamine"  title="Discussion about the content page [t]" accesskey="t">Talk</a></span></li>
			</ul>
</div>
<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
	<h3 id="mw-vector-current-variant">
		</h3>
	<h3 id="p-variants-label"><span>Variants</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
				</div>
				<div id="right-navigation">
					<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
	<h3 id="p-views-label">Views</h3>
	<ul>
					<li id="ca-view" class="selected"><span><a href="/wiki/Amphetamine" >Read</a></span></li>
					<li id="ca-viewsource"><span><a href="/w/index.php?title=Amphetamine&amp;action=edit"  title="This page is protected.&#10;You can view its source [e]" accesskey="e">View source</a></span></li>
					<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Amphetamine&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
			</ul>
</div>
<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
	<h3 id="p-cactions-label"><span>Actions</span><a href="#"></a></h3>
	<div class="menu">
		<ul>
					</ul>
	</div>
</div>
<div id="p-search" role="search">
	<h3><label for="searchInput">Search</label></h3>
	<form action="/w/index.php" id="searchform">
					<div id="simpleSearch">
					<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />		</div>
	</form>
</div>
				</div>
			</div>
			<div id="mw-panel">
					<div id="p-logo" role="banner"><a style="background-image: url(//upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
				<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
	<h3 id='p-navigation-label'>Navigation</h3>
	<div class="body">
		<ul>
			<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
			<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
			<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li>
			<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
			<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			<li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li>
			<li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikimedia Shop</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
	<h3 id='p-interaction-label'>Interaction</h3>
	<div class="body">
		<ul>
			<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
			<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
			<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
			<li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
	<h3 id='p-tb-label'>Tools</h3>
	<div class="body">
		<ul>
			<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Amphetamine" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
			<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Amphetamine" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
			<li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li>
			<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li>
			<li id="t-permalink"><a href="/w/index.php?title=Amphetamine&amp;oldid=601362017" title="Permanent link to this revision of the page">Permanent link</a></li>
			<li id="t-info"><a href="/w/index.php?title=Amphetamine&amp;action=info">Page information</a></li>
			<li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q179452" title="Link to connected data repository item [g]" accesskey="g">Data item</a></li>
<li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Amphetamine&amp;id=601362017" title="Information on how to cite this page">Cite this page</a></li>		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
	<h3 id='p-coll-print_export-label'>Print/export</h3>
	<div class="body">
		<ul>
			<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Amphetamine">Create a book</a></li>
			<li id="coll-download-as-rl"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Amphetamine&amp;oldid=601362017&amp;writer=rl">Download as PDF</a></li>
			<li id="t-print"><a href="/w/index.php?title=Amphetamine&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>
		</ul>
	</div>
</div>
<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
	<h3 id='p-lang-label'>Languages</h3>
	<div class="body">
		<ul>
			<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D8%A3%D9%85%D9%81%D9%8A%D8%AA%D8%A7%D9%85%D9%8A%D9%86" title="أمفيتامين – Arabic" lang="ar" hreflang="ar">العربية</a></li>
			<li class="interlanguage-link interwiki-zh-min-nan"><a href="//zh-min-nan.wikipedia.org/wiki/Amphetamin" title="Amphetamin – Chinese (Min Nan)" lang="zh-min-nan" hreflang="zh-min-nan">Bân-lâm-gú</a></li>
			<li class="interlanguage-link interwiki-bg"><a href="//bg.wikipedia.org/wiki/%D0%90%D0%BC%D1%84%D0%B5%D1%82%D0%B0%D0%BC%D0%B8%D0%BD" title="Амфетамин – Bulgarian" lang="bg" hreflang="bg">Български</a></li>
			<li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/Amfetamina" title="Amfetamina – Catalan" lang="ca" hreflang="ca">Català</a></li>
			<li class="interlanguage-link interwiki-cs"><a href="//cs.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Czech" lang="cs" hreflang="cs">Čeština</a></li>
			<li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Danish" lang="da" hreflang="da">Dansk</a></li>
			<li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Amphetamin" title="Amphetamin – German" lang="de" hreflang="de">Deutsch</a></li>
			<li class="interlanguage-link interwiki-et"><a href="//et.wikipedia.org/wiki/Amfetamiin" title="Amfetamiin – Estonian" lang="et" hreflang="et">Eesti</a></li>
			<li class="interlanguage-link interwiki-el"><a href="//el.wikipedia.org/wiki/%CE%91%CE%BC%CF%86%CE%B5%CF%84%CE%B1%CE%BC%CE%AF%CE%BD%CE%B7" title="Αμφεταμίνη – Greek" lang="el" hreflang="el">Ελληνικά</a></li>
			<li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/Anfetamina" title="Anfetamina – Spanish" lang="es" hreflang="es">Español</a></li>
			<li class="interlanguage-link interwiki-eu"><a href="//eu.wikipedia.org/wiki/Anfetamina" title="Anfetamina – Basque" lang="eu" hreflang="eu">Euskara</a></li>
			<li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D8%A2%D9%85%D9%81%D8%AA%D8%A7%D9%85%DB%8C%D9%86" title="آمفتامین – Persian" lang="fa" hreflang="fa">فارسی</a></li>
			<li class="interlanguage-link interwiki-fo"><a href="//fo.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Faroese" lang="fo" hreflang="fo">Føroyskt</a></li>
			<li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Amph%C3%A9tamine" title="Amphétamine – French" lang="fr" hreflang="fr">Français</a></li>
			<li class="interlanguage-link interwiki-ga"><a href="//ga.wikipedia.org/wiki/Amfataim%C3%ADn" title="Amfataimín – Irish" lang="ga" hreflang="ga">Gaeilge</a></li>
			<li class="interlanguage-link interwiki-gl"><a href="//gl.wikipedia.org/wiki/Anfetamina" title="Anfetamina – Galician" lang="gl" hreflang="gl">Galego</a></li>
			<li class="interlanguage-link interwiki-ko"><a href="//ko.wikipedia.org/wiki/%EC%95%94%ED%8E%98%ED%83%80%EB%AF%BC" title="암페타민 – Korean" lang="ko" hreflang="ko">한국어</a></li>
			<li class="interlanguage-link interwiki-hr"><a href="//hr.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Croatian" lang="hr" hreflang="hr">Hrvatski</a></li>
			<li class="interlanguage-link interwiki-id"><a href="//id.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Indonesian" lang="id" hreflang="id">Bahasa Indonesia</a></li>
			<li class="interlanguage-link interwiki-is"><a href="//is.wikipedia.org/wiki/Amfetam%C3%ADn" title="Amfetamín – Icelandic" lang="is" hreflang="is">Íslenska</a></li>
			<li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Anfetamina" title="Anfetamina – Italian" lang="it" hreflang="it">Italiano</a></li>
			<li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%90%D7%9E%D7%A4%D7%98%D7%9E%D7%99%D7%9F" title="אמפטמין – Hebrew" lang="he" hreflang="he">עברית</a></li>
			<li class="interlanguage-link interwiki-sw"><a href="//sw.wikipedia.org/wiki/Amfetamini" title="Amfetamini – Swahili" lang="sw" hreflang="sw">Kiswahili</a></li>
			<li class="interlanguage-link interwiki-lv"><a href="//lv.wikipedia.org/wiki/Amfetam%C4%ABns" title="Amfetamīns – Latvian" lang="lv" hreflang="lv">Latviešu</a></li>
			<li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/Amfetaminas" title="Amfetaminas – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li>
			<li class="interlanguage-link interwiki-hu"><a href="//hu.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Hungarian" lang="hu" hreflang="hu">Magyar</a></li>
			<li class="interlanguage-link interwiki-ms"><a href="//ms.wikipedia.org/wiki/Amfetamina" title="Amfetamina – Malay" lang="ms" hreflang="ms">Bahasa Melayu</a></li>
			<li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Amfetamine" title="Amfetamine – Dutch" lang="nl" hreflang="nl">Nederlands</a></li>
			<li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E3%82%A2%E3%83%B3%E3%83%95%E3%82%A7%E3%82%BF%E3%83%9F%E3%83%B3" title="アンフェタミン – Japanese" lang="ja" hreflang="ja">日本語</a></li>
			<li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Norwegian (bokmål)" lang="no" hreflang="no">Norsk bokmål</a></li>
			<li class="interlanguage-link interwiki-nn"><a href="//nn.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Norwegian Nynorsk" lang="nn" hreflang="nn">Norsk nynorsk</a></li>
			<li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Amfetamina" title="Amfetamina – Polish" lang="pl" hreflang="pl">Polski</a></li>
			<li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/Anfetamina" title="Anfetamina – Portuguese" lang="pt" hreflang="pt">Português</a></li>
			<li class="interlanguage-link interwiki-ro"><a href="//ro.wikipedia.org/wiki/Amfetamin%C4%83" title="Amfetamină – Romanian" lang="ro" hreflang="ro">Română</a></li>
			<li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%90%D0%BC%D1%84%D0%B5%D1%82%D0%B0%D0%BC%D0%B8%D0%BD" title="Амфетамин – Russian" lang="ru" hreflang="ru">Русский</a></li>
			<li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Amphetamine" title="Amphetamine – Simple English" lang="simple" hreflang="simple">Simple English</a></li>
			<li class="interlanguage-link interwiki-sl"><a href="//sl.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Slovenian" lang="sl" hreflang="sl">Slovenščina</a></li>
			<li class="interlanguage-link interwiki-sr"><a href="//sr.wikipedia.org/wiki/%D0%90%D0%BC%D1%84%D0%B5%D1%82%D0%B0%D0%BC%D0%B8%D0%BD" title="Амфетамин – Serbian" lang="sr" hreflang="sr">Српски / srpski</a></li>
			<li class="interlanguage-link interwiki-sh"><a href="//sh.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Serbo-Croatian" lang="sh" hreflang="sh">Srpskohrvatski / српскохрватски</a></li>
			<li class="interlanguage-link interwiki-fi"><a href="//fi.wikipedia.org/wiki/Amfetamiini" title="Amfetamiini – Finnish" lang="fi" hreflang="fi">Suomi</a></li>
			<li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Swedish" lang="sv" hreflang="sv">Svenska</a></li>
			<li class="interlanguage-link interwiki-th"><a href="//th.wikipedia.org/wiki/%E0%B9%81%E0%B8%AD%E0%B8%A1%E0%B9%80%E0%B8%9F%E0%B8%95%E0%B8%B2%E0%B8%A1%E0%B8%B5%E0%B8%99" title="แอมเฟตามีน – Thai" lang="th" hreflang="th">ไทย</a></li>
			<li class="interlanguage-link interwiki-tr"><a href="//tr.wikipedia.org/wiki/Amfetamin" title="Amfetamin – Turkish" lang="tr" hreflang="tr">Türkçe</a></li>
			<li class="interlanguage-link interwiki-uk"><a href="//uk.wikipedia.org/wiki/%D0%90%D0%BC%D1%84%D0%B5%D1%82%D0%B0%D0%BC%D1%96%D0%BD" title="Амфетамін – Ukrainian" lang="uk" hreflang="uk">Українська</a></li>
			<li class="interlanguage-link interwiki-vi"><a href="//vi.wikipedia.org/wiki/Amphetamin" title="Amphetamin – Vietnamese" lang="vi" hreflang="vi">Tiếng Việt</a></li>
			<li class="interlanguage-link interwiki-zh-yue"><a href="//zh-yue.wikipedia.org/wiki/%E5%AE%89%E9%9D%9E%E4%BB%96%E5%91%BD" title="安非他命 – Cantonese" lang="zh-yue" hreflang="zh-yue">粵語</a></li>
			<li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E8%8B%AF%E4%B8%99%E8%83%BA" title="苯丙胺 – Chinese" lang="zh" hreflang="zh">中文</a></li>
			<li class="uls-p-lang-dummy"><a href="#"></a></li>
			<li class="wbc-editpage"><a href="//www.wikidata.org/wiki/Q179452#sitelinks-wikipedia" title="Edit interlanguage links">Edit links</a></li>
		</ul>
	</div>
</div>
			</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 26 March 2014 at 15:13.<br /></li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy.</a> <br/>
Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a class="external" href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/wiki/Amphetamine" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
					<li id="footer-copyrightico">
						<a href="//wikimediafoundation.org/"><img src="//bits.wikimedia.org/images/wikimedia-button.png" width="88" height="31" alt="Wikimedia Foundation"/></a>
					</li>
					<li id="footer-poweredbyico">
						<a href="//www.mediawiki.org/"><img src="//bits.wikimedia.org/static-1.23wmf19/skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" width="88" height="31" /></a>
					</li>
				</ul>
						<div style="clear:both"></div>
		</div>
		<script>/*<![CDATA[*/window.jQuery && jQuery.ready();/*]]>*/</script><script>if(window.mw){
mw.loader.state({"site":"loading","user":"ready","user.groups":"ready"});
}</script>
<script>if(window.mw){
mw.loader.load(["ext.cite","mediawiki.action.view.postEdit","mobile.desktop","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.DRN-wizard","ext.gadget.charinsert","mw.MwEmbedSupport.style","ext.navigationTiming","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage","skins.vector.collapsibleNav"],null,true);
}</script>
<script src="//bits.wikimedia.org/en.wikipedia.org/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=scripts&amp;skin=vector&amp;*"></script>
<!-- Served by mw1031 in 11.464 secs. -->
	</body>
</html>
